

CURRICULUM VITAE: MELETIOS A. DIMOPOULOS

Athens, 10 February 2020

1. PERSONAL DATA

- Specialty: Professor of Hematology/Oncology
- Date of birth: 24 July 1961
- Place of birth: Paris, France
- Nationality: Greek
- Work Address: Department of Clinical Therapeutics,
National and Kapodistrian University of Athens,
School of Medicine, Alexandra General Hospital,
80 Vas. Sofias Avenue, 11528, Athens, Greece;
Tel: +30-213-2162541
Fax: +30-213-2162511
e-mail: mdimop@med.uoa.gr

2. SENIORITY AND CURRENT RESPONSABILITY POSITIONS

- Seniority in clinical research: Investigator in more than 130 clinical trials in the field of cancer and especially of multiple myeloma and other plasma cell dyscrasias; active in clinical cancer research for the last 25 years
- Current Hospital position: Chair of the Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Alexandra General Hospital, Athens, Greece (since 9/2005)
- Current University position: Professor of Hematology and Oncology, National and Kapodistrian University of Athens (since 12/2002) & Rector of the National and Kapodistrian University of Athens, Athens, Greece (since 2/2015)

3. PREVIOUS RELEVANT POSITIONS/APPOINTMENTS

- 1985 to 1987: Registrar in Internal Medicine, 251 General Air-Force Hospital, Athens, Greece
- 1987 to 1989: Resident, Royal Victoria Hospital, McGill University, Montreal, Canada
- 1989 to 1992: Fellow, the University of Texas M.D. Anderson Cancer Center, Houston, USA
- 1/1993 to 6/1993: Junior Faculty Associate, the University of Texas M.D. Anderson Cancer Center, Houston, USA
- 7/1993 to 8/1994: Assistant Internist and Assistant Professor, Department of Hematology, the University of Texas M.D. Anderson Cancer Center, Houston, USA
- 8/1994 to 8/1999: Assistant Professor of Hematology/Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece & Adjunct Assistant Professor of Medicine, the University of Texas M.D. Anderson Cancer Center, Houston, USA
- 8/1999 to 12/2002: Associate Professor of Hematology/Oncology, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece

4. CORPORATIVE ACTIVITIES

I. In the National and Kapodistrian University of Athens

- 1994 to-date: Chair of the Hematology/Oncology Unit of the Department of Clinical Therapeutics
- 9/2004-8/2007: Director of the Academic Department of Medicine
- 9/2005 to-date: Chair of the Department of Clinical Therapeutics
- 9/2007-8/2011: Vice-Dean of the School of Medicine
- 9/2007-8/2011: President of the University Hospitals "Aretaieio" and "Aiginiteio"
- 9/2011-6/2013: Dean of the School of Medicine
- 2/2015 to-date: Rector of the University

II. Other Administrative Positions

- Minister of Health in the transitional government of the Prime Minister Vassiliki Thanou (July and August 2015)
- Chair of the Board of the Foundation of "Julia and Alexander N. Diomedes Botanic Garden" (February 2015 to-date)
- Member of the Board of the National Greek Committee for UNESCO (February 2015 to-date)

III. Member of the Boards of Scientific Societies or Organizations

- International Myeloma Foundation
- Multiple Myeloma Research Foundation
- International Waldenstrom's Macroglobulinemia Foundation
- European Myeloma Network
- The Institute of Cancer Research
- European School of Oncology (member of the scientific board for Balkan and Middle East Area)
- European Consortium for WM (member of the Steering Committee)
- Greek Myeloma Study Group (president since 2008)

IV. Member of Scientific Societies

- American Medical Association
- American College of Physicians
- American Society of Hematology
- American Society of Clinical Oncology
- American Society of Blood and Bone Marrow Transplantation
- European Society for Medical Oncology
- European Hematology Association
- Greek Society of Hematology
- Greek Society of Medical Oncology
- International Myeloma Society
- International Waldenstrom's Macroglobulinemia (WM) Foundation
- European Myeloma Network

V. Advisor of Scientific Societies or Organizations

- WHO Lymphoid Clinical Advisor Board
- European Hematology Association Fellowships and Grants Panel Committee
- Swiss National Science Foundation
- Multiple Myeloma Research Foundation
- Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
- European Calcified Tissue Society, International Myeloma Foundation

VI. Member of Editorial Boards/Reviewer of International Journals

- Associate Editor of the European Journal of Internal Medicine (2001-2007)
- Associate Editor of the Balkan Medical Journal (2000 to date)

- Associate Editor of the Current Hematologic Malignancy Reports
- Member of the Editorial Board of Journal of Clinical Oncology (2005-2008)
 - Haematologica
 - Leukemia & Lymphoma
 - Expert Review of Hematology
 - Clinical Lymphoma Myeloma and Leukemia and
 - Turkish Journal of Hematology.
- Reviewer of papers submitted in more than 50 international journals, including New England Journal of Medicine, Lancet Oncology, Journal of Clinical Oncology, Blood, Leukemia etc.

5. HONORS AND PRIZES

- Recipient of the “Robert A. Kyle Award for outstanding contributions in Waldenstrom’s Macroglobulinemia” (May 2003)
- “Lifetime Achievement Award” for contributions in Waldenstrom’s Macroglobulinemia (October 2008)
- Silver Award of the Mediterranean Multidisciplinary Oncology Forum (September 2009)
- Twelve National Awards for the best oral or poster presentations in Hematology and Oncology Meetings.
- Recipient of Waldenstrom's Award for Myeloma Research of the International Myeloma Society (March 2017)
- Recipient of the CoMy Excellence Award (International Myeloma Award-May 2017)
- Officier dans l'Ordre des Palmes academiques (August 2017)
- Membre associe etranger of the National Academy of Medicine of France (May 2018)
- Robert Kyle Life Achievement Award (June 2019)
- Visiting Professor at Dana-Farber Cancer Institute and Harvard Medical School (September 2019)
- Hippocratic Orator Award from The Hellenic Medical Society of United Kingdom (October 2019)
- 2020 Distinguished Alumnus Award from the MD Anderson Cancer Centre, Houston, TX, USA (January 2020)

6. INTERNATIONAL EVENT ORGANIZATION

- Chair of the Organizing Committee of the XIth International Myeloma Workshop and the IVth International Workshop on Waldenstrom’s Macroglobulinemia (Kos, June 2007).
- Chair of the ESH Myeloma Conference (Athens, November 2014).
- Chair of the IMS Educational Workshop (Athens, October 2018).

7. TEACHING AND TRAINING

- Teaching in undergraduate and postgraduate courses of the School of Medicine of the National and Kapodistrian University of Athens;
- Teaching in seminars for residents of Hematology and Oncology in all major Greek institutes;
- Responsible for more than 80 doctoral theses in the School of Medicine of the National and Kapodistrian University of Athens.
- Invited speaker in more than 150 international events including the Annual Meetings of the
 - a. American Society of Hematology,
 - b. European Hematology Association,
 - c. European Society of Medical Oncology and also the
 - d. International Myeloma Workshops
 - e. International Workshops on Waldenstrom’s Macroglobulinemia.
- Invited speaker in more than 25 educational events (international seminars, master classes) of the Medical Schools of highly ranked universities including
 - a. the Dana-Farber Cancer Institute of Harvard University,
 - b. the Medical School of Johns Hopkins University,
 - c. the MD Anderson Cancer Center of Texas University,

- d. the Princess Margaret Hospital of the University of Toronto,
 - e. the Medical School of the McGill University (Montreal, Canada),
 - f. the Medical School of the Keio University of Tokyo, Japan and
 - g. the Sydney Medical School, Sydney, Australia.
- Reviewer of abstracts of more than 25 International Conferences, including the annual meetings of the
 - a. American Society of Hematology,
 - b. American Society for Clinical Oncology,
 - c. European Hematology Association,
 - d. European Blood and Marrow Transplantation Group
 - e. European Society of Medical Oncology and also the
 - f. International Myeloma Workshops
 - g. International Workshops on Waldenstrom's Macroglobulinemia
 - h. European School of Hematology Courses

 - Chair of sessions in 40 International Conferences and presenter of more than 800 abstracts in international events, including the annual meetings of the
 - a. American Society of Hematology,
 - b. American Society for Clinical Oncology,
 - c. European Hematology Association,
 - d. European Society of Medical Oncology
 - e. European Blood and Marrow Transplantation Group and also the
 - f. International Myeloma Workshops
 - g. International Workshops on Waldenstrom's Macroglobulinemia.

8. RESEARCH

I. Major Scientific Contributions

My research interest is mainly focused in the field of plasma cell dyscrasias (multiple myeloma, Waldenstrom's Macroglobulinemia and systemic AL amyloidosis). My major contributions in the field of these disorders include:

1. Identification of prognostic factors in plasma cell dyscrasias and contribution to new definition criteria:
 - i. asymptomatic myeloma (role of MRI, bone marrow plasma cells, FLC ratio)
 - ii. solitary bone plasmacytoma (potential of curability, role of MRI)
 - iii. multiple myeloma (first report on the role of LDH, 1991; prognostic significance of MRI)
2. Major role in diagnosis and management of bone disease in multiple myeloma
 - i. Establishment of MRI in the imaging of myeloma.
 - ii. Biology of myeloma-related bone disease (RANKL/OPG, sclerostin, dickkopf-1, periostin)
 - iii. Management of bone disease (bisphosphonates, osteonecrosis of the jaw, denosumab).
3. Major role in the evaluation and management of renal impairment (RI) in myeloma patients: prognostic factors for reversibility of RI, criteria for renal response, role of novel agents in RI myeloma (first author of the respective guidelines of the International Myeloma Working Group published in *Journal of Clinical Oncology* in 2010 and 2016).
4. Principal investigator (PI) or Co-PI of trials that led to drug approval for myeloma patients:
 - i. MM-010, which led to approval of lenalidomide and dexamethasone for relapsed/refractory myeloma (RRMM) by FDA and EMEA;
 - ii. NIMBUS, which led to approval of pomalidomide and low dose dexamethasone for relapsed/refractory myeloma by EMEA;
 - iii. ENDEAVOR, which led to the approval of carfilzomib/dexamethasone combination by FDA for RRMM patients who have received 1-3 prior lines of therapy;
 - iv. POLLUX, which led to the approval of daratumumab/lenalidomide/dexamethasone combination for RRMM patients who have received 1-3 prior lines of therapy.
5. Establishment of the use of nucleoside analogues, thalidomide and rituximab for the treatment of Waldenstrom's Macroglobulinemia (WM); the combination of dexamethasone, rituximab and

cyclophosphamide (DRC regimen), firstly described by my group, is considered to-date as the standard of care for the treatment of symptomatic WM.

6. Establishment of the use of ibrutinib alone or in combination with rituximab (approval by FDA) for the treatment of Waldenstrom's Macroglobulinemia.

II. Current More Important Funded Research in the field of Multiple Myeloma

- Role of Indirubins in Myeloma Cell Growth and Survival: an *in vitro* Study.
- Exploitation of Drosophila as an *in vivo* platform to screen for the physiological and/or cytotoxic effect(s) of novel proteasome inhibitors-cross verification with parallel studies in human cells.
- Study of TLR4 function in myeloma cell lines through the PERR/ATF4/CHOP signaling; the role of intercellular stress and proteasome inhibition.
- Study of the *in vitro* mechanism of action of JQ1, a BRD4 inhibitor, in myeloma cell lines.
- Genetic and epidemiological factors of bone disease in patients with multiple myeloma
- Immunophenotypic study of MRD in myeloma patients who have achieved CR after frontline anti-myeloma therapy.
- Prospective evaluation of the effect of Carfilzomib therapy in cardiovascular and endothelial function and atherosclerosis and correlations with proteasome inhibition in patients with relapsed or refractory myeloma.
- Genetic and acquired factors for the development of thromboembolism in myeloma patients; a prospective validation of the 4TS Risk Assessment Model for the prevention of venous thromboembolism in patients with multiple myeloma.

III. Publications & Recognitions

- Chapters in 55 books (both international and national).
- 1021 papers in peer-reviewed journals (PubMed).
- Citation metrics (as of January 2020):
 - >53,000 citations (Web of Science)
 - >63,000 citations (Scopus)
 - h-index of 105 (Web of Science)
 - h-index of 114 (Scopus)
- "Thomson Reuters Highly Cited Researcher" in the field of Clinical Medicine for 2013, 2014, 2015, 2016 and 2017.
- First in the rank of "Expertscape" International Ranking of the more important physicians in the field of Paraproteinemias. Second in the same Ranking for Multiple Myeloma and fourth for Waldenstrom's Macroglobulinemia.

IV. My 15 Top Publications

1. Alexanian R, **Dimopoulos MA**. The treatment of multiple myeloma. N Engl J Med 1994;330:484-9.
2. **Dimopoulos MA**, et al. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol 1994;12:2694-8.
3. **Dimopoulos MA**, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-33.
4. **Dimopoulos MA**, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32.
5. **Dimopoulos MA**, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344-9.

6. **Dimopoulos MA**, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. *J Clin Oncol* 2010;28:4976-84.
7. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, **Dimopoulos MA**. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med* 2012;366:1759-69.
8. **Dimopoulos MA**, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. *Lancet Oncol* 2013;14:1129-40.
9. **Dimopoulos MA**, et al. Role of Magnetic Resonance Imaging in the management of patients with Multiple Myeloma: a consensus statement. *J Clin Oncol* 2015;33:657-64.
10. Lonial S*, **Dimopoulos MA*** (*equal contribution), et al. Elotuzumb therapy for relapsed or refractory multiple myeloma. *N Engl J Med* 2015;373:621-31.
11. **Dimopoulos MA**, et al: Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomized, phase 3, open-label, multicenter study. *Lancet Oncol* 2016;17:27-38.
12. **Dimopoulos MA**, et al. Daratumumab, lenalidomide, and dexamethasone for Multiple Myeloma. *N Engl J Med* 2016;375:1319-31.
13. **Dimopoulos MA**, et al. Single-agent Ibrutinib in Rituximab-refractory patients with Waldenström's Macroglobulinemia: results from a multicenter, open-label phase 3 substudy (iINNOVATE™). *Lancet Oncol* 2017;18:241-50.
14. **Dimopoulos MA**, et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. *N Engl J Med* 2018;378:2399-410.
15. **Dimopoulos MA**, et al. Elotuzumab, pomalidomide, and dexamethasone for Multiple Myeloma. *N Engl J Med* 2018;379:1811-1822.

V. Full publication list in peer-reviewed journals (PubMed)

1. Germenis A, Savides P, **Dimopoulos MA**, Becopoulos T, Fertakis A, Dimopoulos C. [Genetic markers in benign hypertrophy of the prostate]. *Presse Med* 1983;12:751-2.
2. **Dimopoulos MA**, Germenis A, Savides P, Karayannis A, Fertakis A, Dimopoulos C. [Genetic markers in papillary cancer of the bladder]. *J Urol (Paris)* 1983;89:693-4.
3. Germenis A, **Dimopoulos MA**, Fertakis A, Dimopoulos C. Genetic markers in renal adenocarcinoma. *J Urol* 1984;132:173-4.
4. **Dimopoulos MA**, Germenis A, Savides P, Karayannis A, Fertakis A, Dimopoulos C. Genetic markers in carcinoma of the prostate. *Eur Urol* 1984;10:315-6.

5. Germenis A, Kolitsopoulos A, **Dimopoulos MA**, Fertakis A. C3 polymorphism in Greece. *Hum Hered* 1985;35:123-5.
6. Fertakis A, Theodorakopoylos J, Germenis A, Chatzis G, **Dimopoulos MA**. Qualitative study of proteinuria in renal cell carcinoma. *Acta Urol Belg* 1988;56:464-70.
7. Dimopoulou I, **Dimopoulos MA**, Tassopoulos N, Kalafatas P. [A new case of Hodgkin's disease in a patient with human immunodeficiency virus seropositivity]. *Presse Med* 1988;17:2037-8.
8. Kostakopoulos A, Delakas D, Deliveliotis C, **Dimopoulos MA**, Sofras F. Rhabdomyosarcoma of the testis. *Acta Urol Belg* 1989;57:863-5.
9. Giannopoulos A, Mitropoulos D, Davaris P, Alivizatos G, **Dimopoulos MA**. Squamous cell carcinoma of the renal pelvis presenting with a loin sinus. *Eur Urol* 1989;16:466-8.
10. Baltopoulos G, Zakynthinos S, **Dimopoulos MA**, Roussos C. Effects of furosemide on pulmonary shunts. *Chest* 1989;96:494-8.
11. Denault A, **Dimopoulos MA**, Fitzcharles MA. Meningoencephalitis and peripheral neuropathy complicating adult Still's disease. *J Rheumatol* 1990;17:698-700.
12. Likourinas M, Conidaris D, Alivizatos G, **Dimopoulos MA**. Complete testicular feminisation syndrome in three sisters. *Br J Urol* 1990;65:298-9.
13. Kostakopoulos A, Deliveliotis C, Mavromanolakis E, Aravantinos G, **Dimopoulos MA**. Intravesical interferon alfa-2b administration in the treatment of superficial bladder tumors. *Eur Urol* 1990;18:201-3.
14. Spandidos DA, Zakynthinos S, Petraki C, Sotsiou F, Yiagnisis M, **Dimopoulos MA**, Roussos C, Field JK. Expression of ras p21 and myc p62 oncoproteins in small cell and non small cell carcinoma of the lung. *Anticancer Res* 1990;10:1105-14.
15. **Dimopoulos MA**, Dimopoulou I, Bitsaktis A, Andriopoulos N. [Perception hypoacusis, an initial and isolated symptom of Wegener's disease]. *Presse Med* 1990;19:1195.
16. **Dimopoulos MA**, Barlogie B, Smith TL, Alexanian R. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. *Ann Intern Med* 1991;115:931-5.
17. Voravud N, **Dimopoulos MA**, Hortobagyi G, Ross M, Theriault R. Breast cancer and second primary ovarian cancer in dermatomyositis. *Gynecol Oncol* 1991;43:286-90.
18. Yau JC, **Dimopoulos MA**, Huan SD, Spencer V, Woo SY, Spitzer G, Brunner LJ, Wallerstein RO, Deisseroth AB, Andersson BS, et al. An effective acute graft-vs.-host disease prophylaxis with minidose methotrexate, cyclosporine, and single-dose methylprednisolone. *Am J Hematol* 1991;38:288-92.
19. Yau JC, **Dimopoulos MA**, Huan SD, Tarrand JJ, Spencer V, Spitzer G, Meneghetti CM, Wallerstein RO, Andersson BS, LeMaistre CF. Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. *Eur J Haematol* 1991;47:371-6.

20. **Dimopoulos MA**, Amato RJ, Logothetis CJ. Predictive factors for effective salvage therapy of nonseminomatous germ cell tumors of testis. *Urology* 1991;38:351-4.
21. Mouloupoulos A, DuBrow R, David C, **Dimopoulos MA**. Primary renal carcinoid: computed tomography, ultrasound, and angiographic findings. *J Comput Assist Tomogr* 1991;15:323-5.
22. Giannopoulos A, Alivizatos G, Kyriakou V, Mitropoulos D, **Dimopoulos MA**. Carcinosarcoma of the bladder. *Br J Urol* 1991;67:106-7.
23. Alivizatos G, Dimopoulou I, Mitropoulos D, **Dimopoulos MA**, Koufakis I, Lykourinas M. Bladder cancer in a young girl with systemic lupus erythematosus treated with cyclophosphamide. *Acta Urol Belg* 1991;59:133-7.
24. Mouloupoulos LA, Varma DG, **Dimopoulos MA**, Leeds NE, Kim EE, Johnston DA, Alexanian R, Libshitz HI. Multiple myeloma: spinal MR imaging in patients with untreated newly diagnosed disease. *Radiology* 1992;185:833-40.
25. **Dimopoulos MA**, Kantarjian HM, Estey EH, Alexanian R. 2-Chlorodeoxyadenosine in the treatment of multiple myeloma. *Blood* 1992;80:1626.
26. Alexanian R, **Dimopoulos MA**, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. *Blood* 1992;80:887-90.
27. **Dimopoulos MA**, Alexanian R. Irreversibility of drug resistance in VAD-refractory myeloma. *Am J Hematol* 1992;40:154-5.
28. **Dimopoulos MA**, Mouloupoulos A, Delasalle K, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. *Hematol Oncol Clin North Am* 1992;6:359-69.
29. **Dimopoulos MA**, Goldstein J, Fuller L, Delasalle K, Alexanian R. Curability of solitary bone plasmacytoma. *J Clin Oncol* 1992;10:587-90.
30. **Dimopoulos MA**, Fernandez JF, Samaan NA, Holoye PY, Vassilopoulou-Sellin R. Paraneoplastic Cushing's syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer. *Cancer* 1992;69:66-71.
31. Alivizatos G, **Dimopoulos MA**, Mitropoulos D, Alevizou K, Bougas D, Pantazopoulos D. Efficacy of eight serially measured markers for diagnosis of prostatic carcinoma. *Arch Esp Urol* 1992;45:269-72.
32. **Dimopoulos MA**, Weber D, Delasalle KB, Alexanian R. Combination therapy with interferon-dexamethasone for newly diagnosed patients with multiple myeloma. *Cancer* 1993;72:2589-92.
33. Mouloupoulos LA, Granfield CA, **Dimopoulos MA**, Kim EE, Alexanian R, Libshitz HI. Extrasosseous multiple myeloma: imaging features. *AJR Am J Roentgenol* 1993;161:1083-7.
34. **Dimopoulos MA**, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading C, et al. Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. *Blood* 1993;82:2324-8.

35. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, **Dimopoulos MA**, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. *Semin Oncol* 1993;20:13-20.
36. Mouloupoulos LA, **Dimopoulos MA**, Varma DG, Manning JT, Johnston DA, Leeds NE, Libshitz HI. Waldenstrom macroglobulinemia: MR imaging of the spine and CT of the abdomen and pelvis. *Radiology* 1993;188:669-73.
37. Davidson BS, Lee JE, Dodd LG, **Dimopoulos MA**, Evans DB. Extramedullary plasmacytoma of the pancreas. *Am J Clin Oncol* 1993;16:363-8.
38. **Dimopoulos MA**, Weber DM, Estey EE, Alexanian R. Primary treatment with 2-chlorodeoxyadenosine of low grade lymphomas that produce IgG or IgA immunoglobulin. *Am J Hematol* 1993;43:326-7.
39. **Dimopoulos MA**, O'Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B, Alexanian R, Keating MJ. Fludarabine therapy in Waldenstrom's macroglobulinemia. *Am J Med* 1993;95:49-52.
40. Mouloupoulos LA, **Dimopoulos MA**, Weber D, Fuller L, Libshitz HI, Alexanian R. Magnetic resonance imaging in the staging of solitary plasmacytoma of bone. *J Clin Oncol* 1993;11:1311-5.
41. **Dimopoulos MA**, Cabanillas F, Lee JJ, Swan F, Fuller L, Allen PK, Hagemester FB. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. *J Clin Oncol* 1993;11:1108-11.
42. **Dimopoulos MA**, Logothetis CJ, Markowitz A, Sella A, Amato R, Ro J. Collecting duct carcinoma of the kidney. *Br J Urol* 1993;71:388-91.
43. Weber DM, **Dimopoulos MA**, Alexanian R. Increased neurotoxicity with VAD-cyclosporin in multiple myeloma. *Lancet* 1993;341:558-9.
44. **Dimopoulos MA**, Delasalle KB, Champlin R, Alexanian R. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. *Br J Haematol* 1993;83:240-4.
45. **Dimopoulos MA**, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. *Ann Intern Med* 1993;118:195-8.
46. **Dimopoulos MA**, Mouloupoulos A, Smith T, Delasalle KB, Alexanian R. Risk of disease progression in asymptomatic multiple myeloma. *Am J Med* 1993;94:57-61.
47. **Dimopoulos MA**, O'Brien S, Kantarjian H, Estey EE, Keating MJ, Alexanian R. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues. *Leuk Lymphoma* 1993;11 Suppl 2:105-8.
48. Alexanian R, **Dimopoulos MA**, Hester J, Delasalle K, Champlin R. Early myeloablative therapy for multiple myeloma. *Blood* 1994;84:4278-82.

49. **Dimopoulos MA**, Kantarjian H, Weber D, O'Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxyadenosine. *J Clin Oncol* 1994;12:2694-8.
50. Weber DM, **Dimopoulos MA**, Anandu DP, Pugh WC, Steinbach G. Regression of gastric lymphoma of mucosa-associated lymphoid tissue with antibiotic therapy for *Helicobacter pylori*. *Gastroenterology* 1994;107:1835-8.
51. **Dimopoulos MA**, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. *Br J Haematol* 1994;88:754-9.
52. Mouloupoulos LA, **Dimopoulos MA**, Alexanian R, Leeds NE, Libshitz HI. Multiple myeloma: MR patterns of response to treatment. *Radiology* 1994;193:441-6.
53. Seymour JF, Gagel RF, Hagemester FB, **Dimopoulos MA**, Cabanillas F. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. *Ann Intern Med* 1994;121:633-40.
54. Mitropoulos D, **Dimopoulos MA**, Kiroudi-Voulgari A, Zervas A, Dimopoulos C, Logothetis CJ. Neoadjuvant cisplatin and interferon-alpha 2B in the treatment and organ preservation of penile carcinoma. *J Urol* 1994;152:1124-6.
55. **Dimopoulos MA**, Arbusk S, Huber M, Weber D, LUCKETT R, Delasalle K, Alexanian R. Primary therapy of multiple myeloma with paclitaxel (taxol). *Ann Oncol* 1994;5:757-9.
56. Giralt SA, LeMaistre CF, Vriesendorp HM, Andersson BS, **Dimopoulos MA**, Gajewski J, Van Besien K, Mehra R, Przepiorka D, Khouri I, et al. Etoposide, cyclophosphamide, total-body irradiation, and allogeneic bone marrow transplantation for hematologic malignancies. *J Clin Oncol* 1994;12:1923-30.
57. **Dimopoulos MA**, LUCKETT R, Alexanian R. Primary therapy of Waldenstrom's macroglobulinemia with paclitaxel. *J Clin Oncol* 1994;12:1998.
58. **Dimopoulos MA**, Hester J, Huh Y, Champlin R, Alexanian R. Intensive chemotherapy with blood progenitor transplantation for primary resistant multiple myeloma. *Br J Haematol* 1994;87:730-4.
59. **Dimopoulos MA**, Yau JC, Huan SD, Jagannath S, Spitzer G, Spinolo JA, Zagars GK, LeMaistre CF, Dicke KA, Zander AR. Allogeneic bone marrow transplantation for leukemia following piperazinedione and fractionated total body irradiation. *Am J Hematol* 1994;46:82-6.
60. **Dimopoulos MA**, Weber DM, Hester J, Delasalle K, Champlin R, Alexanian R. Intensive sequential therapy for VAD-resistant multiple myeloma. *Leuk Lymphoma* 1994;13:479-84.
61. Przepiorka D, **Dimopoulos MA**, Smith T, Ippoliti C, Diener K, Luna M, Champlin RE. Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. *Ann Hematol* 1994;68:183-8.
62. **Dimopoulos MA**, Alexanian R. Waldenstrom's macroglobulinemia. *Blood* 1994;83:1452-9.

63. **Dimopoulos MA**, Finn L, Logothetis CJ. Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. *J Urol* 1994;151:598-600; discussion -1.
64. **Dimopoulos MA**, Weber DM, Kantarjian H, Keating M, Alexanian R. 2Chlorodeoxyadenosine therapy of patients with Waldenstrom macroglobulinemia previously treated with fludarabine. *Ann Oncol* 1994;5:288-9.
65. Alexanian R, **Dimopoulos MA**. The treatment of multiple myeloma. *N Engl J Med* 1994;330:484-9.
66. Alexanian R, **Dimopoulos MA**, Smith T, Delasalle K, Barlogie B, Champlin R. Limited value of myeloablative therapy for late multiple myeloma. *Blood* 1994;83:512-6.
67. Keating MJ, O'Brien S, Robertson LE, Kantarjian H, **Dimopoulos MA**, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V, et al. The expanding role of fludarabine in hematologic malignancies. *Leuk Lymphoma* 1994;14 Suppl 2:11-6.
68. Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, **Dimopoulos MA**, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. *Semin Hematol* 1994;31:28-39.
69. **Dimopoulos MA**, Papadimitriou C, Sakarellou N, Athanassiades P. Complications and supportive therapy of multiple myeloma. *Baillieres Clin Haematol* 1995;8:845-52.
70. Weber D, **Dimopoulos MA**, Sinicrope F, Alexanian R. VAD-cyclosporine therapy for VAD-resistant multiple myeloma. *Leuk Lymphoma* 1995;19:159-63.
71. Alexanian R, **Dimopoulos MA**, Delasalle KB, Hester J, Champlin R. Myeloablative therapy for primary resistant multiple myeloma. *Stem Cells* 1995;13 Suppl 2:118-21.
72. Sarris A, **Dimopoulos MA**, Pugh W, Cabanillas F. Primary lymphoma of the prostate: good outcome with doxorubicin-based combination chemotherapy. *J Urol* 1995;153:1852-4.
73. Touroutoglou N, **Dimopoulos MA**, Younes A, Hess M, Pugh W, Cox J, Cabanillas F, Sarris AH. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. *J Clin Oncol* 1995;13:1361-7.
74. Bayouth JE, Macey DJ, Kasi LP, Garlich JR, McMillan K, **Dimopoulos MA**, Champlin RE. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. *J Nucl Med* 1995;36:730-7.
75. Sarris AH, Majlis A, **Dimopoulos MA**, Younes A, Swann F, Rodriguez MA, McLaughlin P, Cabanillas F. Rising serum lactate dehydrogenase often caused by granulocyte-or Granulocyte-macrophage colony stimulating factor and not tumor progression in patients with lymphoma or myeloma. *Leuk Lymphoma* 1995;17:473-7.
76. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemester F, Diener K, **Dimopoulos MA**, Giralt S, Khouri I, Samuels B, et al. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. *Leuk Lymphoma* 1995;17:427-33.

77. Deliveliotis C, Alivizatos G, Karayiannis A, Kontothanasis D, Makrychoritis K, Lysiotis P, **Dimopoulos MA**. The value of prostatic specific antigen in the early diagnosis of prostatic cancer: a Greek view. *Br J Urol* 1995;75:637-41.
78. Moore DF, Jr., Mouloupoulos LA, **Dimopoulos MA**. Waldenstrom macroglobulinemia presenting as a renal or perirenal mass: clinical and radiographic features. *Leuk Lymphoma* 1995;17:331-4.
79. van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, **Dimopoulos MA**, Giralt S, Suki S, Khouri I, et al. High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen-related toxicity. *Bone Marrow Transplant* 1995;15:549-55.
80. Alexanian R, **Dimopoulos MA**. Management of multiple myeloma. *Semin Hematol* 1995;32:20-30.
81. Mouloupoulos LA, **Dimopoulos MA**, Smith TL, Weber DM, Delasalle KB, Libshitz HI, Alexanian R. Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. *J Clin Oncol* 1995;13:251-6.
82. **Dimopoulos MA**, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom's macroglobulinemia resistant to standard therapy with 2-chlorodeoxyadenosine: identification of prognostic factors. *Ann Oncol* 1995;6:49-52.
83. Przepiorka D, Madden T, Ippoliti C, Estrov Z, **Dimopoulos MA**. Dosing of thioTEPA for myeloablative therapy. *Cancer Chemother Pharmacol* 1995;37:155-60.
84. Keating MJ, O'Brien S, McLaughlin P, **Dimopoulos MA**, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E. Clinical experience with fludarabine in hemato-oncology. *Hematol Cell Ther* 1996;38 Suppl 2:S83-91.
85. Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, **Dimopoulos MA**, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. *Blood* 1996;88:1771-9.
86. **Dimopoulos MA**, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HyperCVAD for VAD-resistant multiple myeloma. *Am J Hematol* 1996;52:77-81.
87. **Dimopoulos MA**, Mouloupoulos LA, Costantinides C, Deliveliotis C, Pantazopoulos D, Dimopoulos C. Primary renal lymphoma: a clinical and radiological study. *J Urol* 1996;155:1865-7.
88. Berenson JR, Lichtenstein A, Porter L, **Dimopoulos MA**, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs MJ, Blacklock HA, Bell R, Simeone J, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. *N Engl J Med* 1996;334:488-93.

89. Mavrikakis M, Vaiopoulos G, Athanassiades P, Antoniadis L, Papamichael C, **Dimopoulos MA**. Pseudohyperphosphatemia in multiple myeloma. *Am J Hematol* 1996;51:178-9.
90. Alivizatos G, Deliveliotis C, Mitropoulos D, Raptides G, Louras G, Karayiannis A, Becopoulos T, **Dimopoulos MA**. Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy? *Urology* 1996;48:71-5.
91. **Dimopoulos MA**, Kostis E, Anagnostopoulos A, Dalezios M, Papadimitris C, Papadimitriou C. Very late relapse of Hodgkin's disease after 24 years of complete remission. *Leuk Lymphoma* 1997;28:215-7.
92. **Dimopoulos MA**, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, Constantinidis C, Kostakopoulos A, Kastriotis I, Zervas A, Aravantinos G, Dimopoulos C. Oral estramustine and oral etoposide for hormone-refractory prostate cancer. *Urology* 1997;50:754-8.
93. Lekakis J, **Dimopoulos MA**, Nanas J, Prassopoulos V, Agapitos N, Alexopoulos G, Palazis L, Kostamis P, Stamatiopoulos S, Mouloupoulos S. Antimyosin scintigraphy for detection of cardiac amyloidosis. *Am J Cardiol* 1997;80:963-5.
94. Mouloupoulos LA, **Dimopoulos MA**. Magnetic resonance imaging of the bone marrow in hematologic malignancies. *Blood* 1997;90:2127-47.
95. Georgoulas V, Kourousis C, Androulakis N, Kakolyris S, **Dimopoulos MA**, Bouros D, Papadimitriou C, Hatzakis K, Heras P, Kalbakis K, Kotsakis T, Vardakis N, Meramveliotakis N, Hatzidaki D. Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results. *Semin Oncol* 1997;24:S14-22-S14-25.
96. Georgoulas V, Kourousis C, Kakolyris S, Androulakis N, **Dimopoulos MA**, Papadakis E, Kotsakis T, Vardakis N, Kalbakis K, Merambeliotakis N, Hatzidaki D. Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen. *Semin Oncol* 1997;24:S12-61-S12-66.
97. Kyriakakis Z, **Dimopoulos MA**, Kostakopoulos A, Karayiannis A, Sofras F, Zervas A, Giannopoulos A, Dimopoulos C. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer. *J Urol* 1997;158:408-11.
98. Papadimitriou CA, **Dimopoulos MA**, Giannakoulis N, Sarris K, Vassilakopoulos G, Akrivos T, Voulgaris Z, Vlahos G, Diakomanolis E, Michalas S. A phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of metastatic carcinoma of the uterine cervix. *Cancer* 1997;79:2391-5.
99. Sarris AH, Papadimitrakopoulou V, **Dimopoulos MA**, Smith T, Pugh W, Ha CS, McLaughlin P, Callender D, Cox J, Cabanillas F. Primary parotid lymphoma: the effect of International Prognostic Index on outcome. *Leuk Lymphoma* 1997;26:49-56.
100. Weber DM, **Dimopoulos MA**, Mouloupoulos LA, Delasalle KB, Smith T, Alexanian R. Prognostic features of asymptomatic multiple myeloma. *Br J Haematol* 1997;97:810-4.

101. **Dimopoulos MA**, Theodorakis M, Kostis E, Papadimitris C, Mouloupoulos LA, Anastasiou-Nana M. Treatment of Langerhans cell histiocytosis with 2 chlorodeoxyadenosine. *Leuk Lymphoma* 1997;25:187-9.
102. Papadimitris C, Papadimitriou C, Kokolakis N, Athanassiades P, **Dimopoulos MA**. Late relapse of nonseminomatous germ cell tumor of the testis: successful treatment with salvage chemotherapy alone. *Urology* 1997;49:469-70.
103. **Dimopoulos MA**, Daliani D, Pugh W, Gershenson D, Cabanillas F, Sarris AH. Primary ovarian non-Hodgkin's lymphoma: outcome after treatment with combination chemotherapy. *Gynecol Oncol* 1997;64:446-50.
104. **Dimopoulos MA**, Papadimitriou C, Gennatas C, Akrivos T, Vlahos G, Voulgaris Z, Diacomanolis E, Athanassiades P, Mihalas S. Ifosfamide and paclitaxel salvage chemotherapy for advanced epithelial ovarian cancer. *Ann Oncol* 1997;8:195-7.
105. Giralt S, Weber D, Colome M, **Dimopoulos MA**, Mehra R, Van Besien K, Gajewski J, Andersson B, Khouri I, Przepiorka D, von Wolff B, Delasalle K, Korbling M, Seong D, Alexanian R, Champlin R. Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue. *J Clin Oncol* 1997;15:667-73.
106. Sarris AH, Luthra R, Papadimitracopoulou V, Waasdorp M, **Dimopoulos MA**, McBride JA, Cabanillas F, Duvic M, Deisseroth A, Morris SW, Pugh WC. Long-range amplification of genomic DNA detects the t(2;5)(p23;q35) in anaplastic large-cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis. *Ann Oncol* 1997;8 Suppl 2:59-63.
107. Kostis E, Zaphiris E, Mouloupoulos LA, **Dimopoulos MA**. Acute lobar nephronia as the presenting manifestation of hyperparathyroidism. *Br J Urol* 1997;79:144-5.
108. Papadimitriou CA, **Dimopoulos MA**, Ampela C, Louvrou-Fertaki A, Anagnostopoulos A, Athanassiades P, Stamatelopoulos S, Keramopoulos A. Sequential administration of doxorubicin and paclitaxel followed by cyclophosphamide, methotrexate and 5-fluorouracil combination (CMF) in women with metastatic breast cancer. *Oncology* 1998;55:533-7.
109. **Dimopoulos MA**, Papadopoulou M, Andreopoulou E, Papadimitriou C, Pavlidis N, Aravantinos G, Aspropotamitis A, Anagnostopoulos A, Fountzilias G, Michalas S, Pectacides D. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study. *Gynecol Oncol* 1998;70:70-4.
110. **Dimopoulos MA**, Deliveliotis C, Mouloupoulos LA, Papadimitriou C, Mitropoulos D, Anagnostopoulos A, Athanassiades P, Dimopoulos C. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. *Urology* 1998;52:56-60.
111. Pantazopoulos D, Karakitsos P, Pouliakis A, Iokim-Liossi A, **Dimopoulos MA**. Static cytometry and neural networks in the discrimination of lower urinary system lesions. *Urology* 1998;51:946-50.

112. Seong C, Delasalle K, Hayes K, Weber D, **Dimopoulos MA**, Swantkowski J, Huh Y, Glassman A, Champlin R, Alexanian R. Prognostic value of cytogenetics in multiple myeloma. *Br J Haematol* 1998;101:189-94.
113. **Dimopoulos MA**, Mouloupoulos LA. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. *J Clin Oncol* 1998;16:1601-12.
114. Sfrikakis PP, **Dimopoulos MA**, Souliotis VL, Charalambopoulos D, Mavrikakis M, Panayiotidis P. Effects of 2-chlorodeoxyadenosine and gold sodium thiomalate on human bcl-2 gene expression. *Immunopharmacol Immunotoxicol* 1998;20:63-77.
115. Fountzilias G, Athanassiades A, Papadimitriou V, **Dimopoulos MA**, Bafaloukos D, Aravantinos G, Nicolaides C, Kalofonos H, Papakostas P, Xiros N, Razi E. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. *Oncology (Williston Park)* 1998;12:45-8.
116. Nakopoulou L, Vourlakou C, Zervas A, Tzonou A, Gakiopoulou H, **Dimopoulos MA**. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates. *Hum Pathol* 1998;29:146-54.
117. Berenson JR, Lichtenstein A, Porter L, **Dimopoulos MA**, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. *J Clin Oncol* 1998;16:593-602.
118. Fountzilias G, **Dimopoulos MA**, Papadimitriou C, Kalogera-Fountzila A, Aravantinos G, Bafaloukos D, Athanassiades A, Nicolaides C, Keramopoulos A, Pavlidis N, Kosmidis P, Skarlos D. First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology Group. *Ann Oncol* 1998;9:1031-4.
119. Georgoulas V, Androulakis N, **Dimopoulos MA**, Kourousis C, Kakolyris S, Papadakis E, Apostolopoulou F, Papadimitriou C, Vossos A, Agelidou M, Heras P, Tzannes S, Vlachonicolis J, Mavromanolakis E, Hatzidaki D. First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study. *Ann Oncol* 1998;9:331-4.
120. **Dimopoulos MA**, Bakoyannis C, Georgoulas V, Papadimitriou C, Mouloupoulos LA, Deliveliotis C, Karayannis A, Varkarakis I, Aravantinos G, Zervas A, Pantazopoulos D, Fountzilias G, Bamias A, Kyriakakis Z, Anagnostopoulos A, Giannopoulos A, Kosmidis P. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative Oncology Group. *Ann Oncol* 1999;10:1385-8.
121. **Dimopoulos MA**, Galani E, Matsouka C. Waldenstrom's macroglobulinemia. *Hematol Oncol Clin North Am* 1999;13:1351-66.
122. **Dimopoulos MA**, Kiamouris C, Mouloupoulos LA. Solitary plasmacytoma of bone and extramedullary plasmacytoma. *Hematol Oncol Clin North Am* 1999;13:1249-57.
123. Androulakis N, Kourousis C, **Dimopoulos MA**, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP, Georgoulas V. Treatment

- of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. *J Clin Oncol* 1999;17:1779-85.
124. Papadimitris C, **Dimopoulos MA**, Kostis E, Papadimitriou C, Anagnostopoulos A, Alexopoulos G, Papamichael C, Gika D, Mitsibounas D, Stamatelopoulos S. Outpatient treatment of neutropenic fever with oral antibiotics and granulocyte colony-stimulating factor. *Oncology* 1999;57:127-30.
125. Mouloupoulos LA, **Dimopoulos MA**, Vourtsi A, Gouliamos A, Vlahos L. Bone lesions with soft-tissue mass: magnetic resonance imaging diagnosis of lymphomatous involvement of the bone marrow versus multiple myeloma and bone metastases. *Leuk Lymphoma* 1999;34:179-84.
126. Georgoulis V, Kouroussis C, Androulakis N, Kakolyris S, **Dimopoulos MA**, Papadakis E, Bouros D, Apostolopoulou F, Papadimitriou C, Agelidou A, Hatzakis K, Kalbakis K, Kotsakis A, Vardakis N, Vlachonicolis J. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. *J Clin Oncol* 1999;17:914-20.
127. Papadimitriou CA, Sarris K, Mouloupoulos LA, Fountzilias G, Anagnostopoulos A, Voulgaris Z, Gika D, Giannakoulis N, Diakomanolis E, **Dimopoulos MA**. Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix. *J Clin Oncol* 1999;17:761-6.
128. Mouloupoulos LA, Karvouni E, Kehagias D, **Dimopoulos MA**, Gouliamos A, Vlahos L. MR imaging of complex tail-gut cysts. *Clin Radiol* 1999;54:118-22.
129. Ha CS, Kavadi V, **Dimopoulos MA**, Hagemester FB, Osborne BM, Fuller LM, Smith TL, Hess MA, McLaughlin PW, Cabanillas FF, Cox JD. Hodgkin's disease with lymphocyte predominance: long-term results based on current histopathologic criteria. *Int J Radiat Oncol Biol Phys* 1999;43:329-34.
130. Athanassiadou P, Petrakakou E, Liossi A, Nakopoulou L, Zerva C, **Dimopoulos MA**, Athanassiades P. Prognostic significance of p53, bcl-2 and EGFR in carcinoma of the endometrium. *Acta Cytol* 1999;43:1039-44.
131. Mandrekas DP, **Dimopoulos MA**, Mouloupoulou D, Papamichalis G, Gougoulakis AG. Distant cutaneous metastasis from carcinoma of the uterus. A case report. *Eur J Gynaecol Oncol* 1999;20:212-3.
132. **Dimopoulos MA**, Mouloupoulos LA, Datseris I, Weber D, Delasalle K, Gika D, Alexanian R. Imaging of myeloma bone disease--implications for staging, prognosis and follow-up. *Acta Oncol* 2000;39:823-7.
133. Papadimitriou CA, **Dimopoulos MA**, Kouvelis V, Kostis E, Kapsimali V, Contoyannis D, Anagnostopoulos A, Papadimitris C, Kiamouris C, Gika D, Nanas J, Athanassiades P, Stamatelopoulos S. Non-cryopreserved peripheral blood progenitor cells collected by a single very large-volume leukapheresis: a simplified and effective procedure for support of high-dose chemotherapy. *J Clin Apher* 2000;15:236-41.
134. Kastrinakis NG, Gorgoulis VG, Foukas PG, **Dimopoulos MA**, Kittas C. Molecular aspects of multiple myeloma. *Ann Oncol* 2000;11:1217-28.

135. Economopoulos T, **Dimopoulos MA**, Foudoulakis A, Nikolaidis C, Tsatalas C, Pectacides D, Rontogianni D, Papageorgiou E, Fountzilas G. Burkitt's lymphoma in Greek adults. A study of the Hellenic co-operative oncology group. *Leuk Res* 2000;24:993-8.
136. Alexanian R, Weber D, **Dimopoulos MA**, Delasalle K, Smith TL. Randomized trial of alpha-interferon or dexamethasone as maintenance treatment for multiple myeloma. *Am J Hematol* 2000;65:204-9.
137. Papadimitriou CA, Mouloupoulos LA, Vlahos G, Voulgaris Z, Kiosses E, Georgoulas N, Gika D, Diakomanolis E, Michalas S, **Dimopoulos MA**. Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study. *Cancer* 2000;89:1547-54.
138. Nicolaides C, **Dimopoulos MA**, Samantas E, Bafaloukos D, Kalofonos C, Fountzilas G, Razi E, Kosmidis P, Pavlidis N. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group. *Ann Oncol* 2000;11:873-5.
139. Kosmidis P, Mylonakis N, Skarlos D, Samantas E, **Dimopoulos MA**, Papadimitriou C, Kalophonos C, Pavlidis N, Nikolaidis C, Papaconstantinou C, Fountzilas G. Paclitaxel (175 mg/m²) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m²) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). *Ann Oncol* 2000;11:799-805.
140. **Dimopoulos MA**, Mouloupoulos LA, Maniatis A, Alexanian R. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. *Blood* 2000;96:2037-44.
141. Aravantinos G, **Dimopoulos MA**, Kosmidis P, Bafaloukos D, Papadimitriou C, Kiamouris C, Pavlidis N, Sikiotis K, Papakostas P, Skarlos DV. Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer. *Ann Oncol* 2000;11:607-12.
142. **Dimopoulos MA**, Papadimitriou CA, Georgoulas V, Mouloupoulos LA, Aravantinos G, Gika D, Karpathios S, Stamatelopoulos S. Paclitaxel and cisplatin in advanced or recurrent carcinoma of the endometrium: long-term results of a phase II multicenter study. *Gynecol Oncol* 2000;78:52-7.
143. Zomas A, Anagnostopoulos N, **Dimopoulos MA**. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. *Bone Marrow Transplant* 2000;25:1319-20.
144. Papadimitris C, Alevizaki M, Pantazopoulos D, Nakopoulou L, Athanassiades P, **Dimopoulos MA**. Cushing syndrome as the presenting feature of metastatic Leydig cell tumor of the testis. *Urology* 2000;56:153.
145. Kouroussis C, Samonis G, Androulakis N, Souglakos J, Voloudaki A, **Dimopoulos MA**, Kotsakis T, Kakolyris S, Kalbakis K, Georgoulas V. Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases. *Am J Clin Oncol* 2000;23:309-13.

146. Pectasides D, Economopoulos T, Kouvatses G, Antoniou A, Zoumbos Z, Aravantinos G, Tsatalas C, Halikia A, Nikolaidis C, Kiamouris C, Pappa E, Pavlidis N, Skarlos D, Fountzilas G, **Dimopoulos MA**. Anthracycline-based chemotherapy of primary non-Hodgkin's lymphoma of the testis: the hellenic cooperative oncology group experience. *Oncology* 2000;58:286-92.
147. **Dimopoulos MA**, Panayiotidis P, Mouloupoulos LA, Sfrikakis P, Dalakas M. Waldenstrom's macroglobulinemia: clinical features, complications, and management. *J Clin Oncol* 2000;18:214-26.
148. Kosmidis P, Mylonakis N, **Dimopoulos MA**, Pavlidis N, Fountzilas G, Samantas E, Dimitriadis K, Kalophonos C, Tsavdaridis D, Skarlos D. Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group. *Semin Oncol* 2000;27:3-8.
149. Pectasides D, **Dimopoulos MA**, Aravantinos G, Kalophonos HP, Papacostas P, Briasoulis E, Cogas E, Papadimitriou C, Skarlos D, Kosmidis P, Fountzilas G. First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study. *Anticancer Res* 2001;21:3575-80.
150. Pectasides D, Aravantinos G, Kalophonos H, Kiamouris C, Bafaloukos D, Xiros N, Nicolaidis C, Visvikis A, **Dimopoulos MA**. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. *Ann Oncol* 2001;12:1417-22.
151. Papadimitriou CA, Kouroussis C, Mouloupoulos LA, Vlahos G, Rodolakis A, Kiamouris C, Diakomanolis E, Gika D, Michalakis S, **Dimopoulos MA**. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer. *Cancer* 2001;92:1856-63.
152. **Dimopoulos MA**, Zervas K, Kouvatses G, Galani E, Grigoraki V, Kiamouris C, Vervessou E, Samantas E, Papadimitriou C, Economou O, Gika D, Panayiotidis P, Christakis I, Anagnostopoulos N. Thalidomide and dexamethasone combination for refractory multiple myeloma. *Ann Oncol* 2001;12:991-5.
153. **Dimopoulos MA**, Zomas A, Viniou NA, Grigoraki V, Galani E, Matsouka C, Economou O, Anagnostopoulos N, Panayiotidis P. Treatment of Waldenstrom's macroglobulinemia with thalidomide. *J Clin Oncol* 2001;19:3596-601.
154. Shimoni A, Smith TL, Aleman A, Weber D, **Dimopoulos MA**, Anderlini P, Andersson B, Claxton D, Ueno NT, Khouri I, Donato M, Korbling M, Alexanian R, Champlin R, Giral S. Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma. *Bone Marrow Transplant* 2001;27:821-8.
155. Alexanian R, Weber D, Giral S, **Dimopoulos MA**, Delasalle K, Smith T, Champlin R. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. *Bone Marrow Transplant* 2001;27:1037-43.

156. Anagnostopoulos A, **Dimopoulos MA**, Aleman A, Weber D, Alexanian R, Champlin R, Giralt S. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. *Bone Marrow Transplant* 2001;27:1027-9.
157. Fountzilas G, Papadimitriou C, Dafni U, Bafaloukos D, Skarlos D, Moulopoulos LA, Razis E, Kalofonos HP, Aravantinos G, Briassoulis E, Papakostas P, Abela K, Gogas E, Kosmidis P, Pavlidis N, **Dimopoulos MA**. Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group. *J Clin Oncol* 2001;19:2232-9.
158. Agiostratidou G, Sgouros I, Galani E, Voulgari A, Chondrogianni N, Samantas E, **Dimopoulos MA**, Skarlos D, Gonos ES. Correlation of in vitro cytotoxicity and clinical response to chemotherapy in ovarian and breast cancer patients. *Anticancer Res* 2001;21:455-9.
159. Petrocheilou-Paschou V, Prifti H, Kostis E, Papadimitriou C, **Dimopoulos MA**, Stamatelopoulos S. *Rhodotorula* septicemia: case report and minireview. *Clin Microbiol Infect* 2001;7:100-2.
160. Liossis SN, Solomou EE, **Dimopoulos MA**, Panayiotidis P, Mavrikakis MM, Sfikakis PP. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. *J Investig Med* 2001;49:157-65.
161. Briassoulis E, Andreopoulou E, Tolis CF, Bairaktari E, Katsaraki A, **Dimopoulos MA**, Fountzilas G, Seferiadis C, Pavlidis N. G-CSF induces elevation of circulating CA 15-3 in breast carcinoma patients treated in an adjuvant setting. *Cancer* 2001;91:909-17.
162. **Dimopoulos MA**, Galani E. Randomized trials of adjuvant and neoadjuvant chemotherapy in bladder cancer. *Semin Urol Oncol* 2001;19:59-65.
163. Zervas K, Pouli A, Gregoraki B, Anagnostopoulos N, **Dimopoulos MA**, Bourantas K, Tzilianos M, Barbarousi D, Venetis E, Vyniou N, Maniatis A. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group. *Eur J Haematol* 2001;66:18-23.
164. Constantinides C, Giannopoulos A, Kyriakou G, Androulaki A, Ioannou M, **Dimopoulos MA**, Kyroudi A. Lymphoepithelioma-like carcinoma of the bladder. *BJU Int* 2001;87:121-2.
165. Fountzilas G, Papadimitriou C, Aravantinos G, Nicolaidis C, Stathopoulos G, Bafaloukos D, Kalofonos H, Ekonomopoulos T, Skarlos D, Pavlidis N, **Dimopoulos MA**. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer. *Oncology* 2001;60:214-20.
166. Razis E, **Dimopoulos MA**, Bafaloukos D, Papadimitriou C, Kalogera-Fountzila A, Kalofonos H, Briassoulis E, Samantas E, Keramopoulos A, Pavlidis N, Kosmidis P, Fountzilas G. Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer. *Cancer Invest* 2001;19:137-44.

167. **Dimopoulos MA**, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, Panayiotidis P, Vervessou E, Anagnostopoulos N, Christakis J. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. *Clin Lymphoma* 2002;3:163-6.
168. Bacoyiannis C, **Dimopoulos MA**, Kalofonos HP, Nicolaides C, Aravantinos G, Bafaloukos D, Samelis G, Onyenadum A, Kiamouris C, Skarlos D, Pavlidis N, Triantafillidis A, Kosmidis P. Vinblastine and interferon-gamma combination with and without 13-cis retinoic acid for patients with advanced renal cell carcinoma. Results of two phase II clinical trials. *Oncology* 2002;63:130-8.
169. Kosmidis P, Mylonakis N, Nicolaides C, Kalophonos C, Samantas E, Boukovinas J, Fountzilas G, Skarlos D, Economopoulos T, Tsavdaridis D, Papakostas P, Bacoyiannis C, **Dimopoulos MA**. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial. *J Clin Oncol* 2002;20:3578-85.
170. Anagnostopoulos A, Evangelopoulou A, Sotou D, Gika D, Mitsibounas D, **Dimopoulos MA**. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece. *Ann Hematol* 2002;81:357-61.
171. Andreopoulou E, Andreopoulos D, Adamidis K, Fountzila-Kalogera A, Fountzilas G, **Dimopoulos MA**, Aravantinos G, Zamboglou N, Baltas D, Pavlidis N. Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. *Anticancer Res* 2002;22:1903-8.
172. Economopoulos T, **Dimopoulos MA**, Mellou S, Pavlidis N, Samantas E, Nicolaides C, Tsatalas C, Papadopoulos A, Papageorgiou E, Papasavvas P, Fountzilas G. Treatment of intermediate- and high-grade non-Hodgkin's lymphoma using CEOP versus CNOP. *Eur J Haematol* 2002;68:135-43.
173. **Dimopoulos MA**, Hamilos G. Solitary bone plasmacytoma and extramedullary plasmacytoma. *Curr Treat Options Oncol* 2002;3:255-9.
174. **Dimopoulos MA**, Papadimitriou CA, Sarris K, Aravantinos G, Kalofonos C, Gika D, Gourgoulis GM, Efstathiou E, Skarlos D, Bafaloukos D. Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group. *Gynecol Oncol* 2002;85:476-82.
175. Michopoulos S, Petraki K, Petraki C, **Dimopoulos MA**. Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome. *Dig Dis Sci* 2002;47:730-4.
176. **Dimopoulos MA**, Zervas C, Zomas A, Kiamouris C, Viniou NA, Grigoraki V, Karkantaris C, Mitsouli C, Gika D, Christakis J, Anagnostopoulos N. Treatment of Waldenstrom's macroglobulinemia with rituximab. *J Clin Oncol* 2002;20:2327-33.
177. **Dimopoulos MA**, Fountzilas G, Papageorgiou E, Kiamouris C, Mantzios G, Anagnostopoulos A, Nicolaides C, Economopoulos T. Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group. *Leuk Lymphoma* 2002;43:111-4.

178. Dimopoulou I, Galani H, Dafni U, Samakovii A, Roussos C, **Dimopoulos MA**. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin. *Cancer* 2002;94:452-8.
179. Kalofonos HP, Nicolaides C, Samantas E, Mylonakis N, Aravantinos G, **Dimopoulos MA**, Gennatas C, Kouvatseas G, Giannoulis E, Dervenis C, Basdanis G, Pavlidis N, Androulakis I, Fountzilas G. A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. *Am J Clin Oncol* 2002;25:23-30.
180. Katsiari CG, Liossis SN, **Dimopoulos MA**, Charalambopoulo DV, Mavrikakis M, Sfrikakis PP. CD40L overexpression on T cells and monocytes from patients with systemic lupus erythematosus is resistant to calcineurin inhibition. *Lupus* 2002;11:370-8.
181. Katsiari CG, Liossis SN, Souliotis VL, **Dimopoulos MA**, Manoussakis MN, Sfrikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. *Clin Immunol* 2002;103:54-62.
182. **Dimopoulos MA**, Anagnostopoulos A. Thalidomide in relapsed/refractory multiple myeloma: pivotal trials conducted outside the United States. *Semin Hematol* 2003;40:8-16.
183. Bamias A, **Dimopoulos MA**. Angiogenesis in human cancer: implications in cancer therapy. *Eur J Intern Med* 2003;14:459-69.
184. **Dimopoulos MA**, Anagnostopoulos A, Weber D. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. *J Clin Oncol* 2003;21:4444-54.
185. Souliotis VL, **Dimopoulos MA**, Sfrikakis PP. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. *Clin Cancer Res* 2003;9:4465-74.
186. Lekakis J, **Dimopoulos MA**, Prassopoulos V, Mavrikakis M, Gerali S, Sifakis N, Athanassoulis T, Stamatelopoulos S. Myocardial adrenergic denervation in patients with primary (AL) amyloidosis. *Amyloid* 2003;10:117-20.
187. Economopoulos T, Fountzilas G, **Dimopoulos MA**, Papageorgiou S, Xiros N, Kalantzis D, Dervenoulas J, Raptis S. Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group Study. *Eur J Haematol* 2003;71:257-62.
188. Athanassoulis T, Koutsikos J, Mouloupoulos LA, Tsiouris S, **Dimopoulos MA**, Zerva C. Reverse of the differential uptake intensity of Tc-99m MIBI and Tc-99m V-DMSA by multiple myeloma lesions in response to therapy. *Clin Nucl Med* 2003;28:631-5.
189. Bamias A, Chorti M, Deliveliotis C, Trakas N, Skolarikos A, Protogerou B, Legaki S, Tsakalou G, Tamvakis N, **Dimopoulos MA**. Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma. *Urology* 2003;62:368-73.
190. **Dimopoulos MA**, Hamilos G, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, Gika D, Karmiris T, Bourantas K, Zomas A, Mitsouli C, Xilouri I, Vervessou E, Matsis K, Anagnostopoulos

- N, Economopoulos T. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. *Ann Oncol* 2003;14:1299-305.
191. **Dimopoulos MA**, Hamilos G, Efstathiou E, Siapkarakas I, Matsouka C, Gika D, Grigoraki V, Papadimitriou C, Mitsibounas D, Anagnostopoulos N. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. *Leuk Lymphoma* 2003;44:993-6.
192. Eleutherakis-Papaiakevou V, Karali M, Kokkonouzis I, Tiliakos I, **Dimopoulos MA**. Bone marrow angiogenesis and progression in multiple myeloma: clinical significance and therapeutic approach. *Leuk Lymphoma* 2003;44:937-48.
193. Aravantinos G, Bafaloukos D, Fountzilias G, Christodoulou C, Papadimitriou C, Pavlidis N, Kalofonos HP, Gogas H, Kosmidis P, **Dimopoulos MA**. Phase II study of docetaxel-vinorelbine in platinum-resistant, paclitaxel-pretreated ovarian cancer. *Ann Oncol* 2003;14:1094-9.
194. **Dimopoulos MA**, Pouli A, Zervas K, Grigoraki V, Symeonidis A, Repoussis P, Mitsouli C, Papanastasiou C, Margaritis D, Tokmaktsis A, Katodritou I, Kokkini G, Terpos E, Vyniou N, Tzilianos M, Chatzivassili A, Kyrtsionis MC, Panayiotidis P, Maniatis A. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. *Ann Oncol* 2003;14:1039-44.
195. Samelis GF, Skarlos D, Bafaloukos D, Kosmidis P, Anagnostopoulos A, Aravantinos G, **Dimopoulos MA**. The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. *Urology* 2003;61:1211-5.
196. Economopoulos T, Fountzilias G, Pavlidis N, Kalantzis D, Papageorgiou E, Christodoulou C, Hamilos G, Nicolaidis C, **Dimopoulos MA**. Rituximab in combination with CNOP chemotherapy in patients with previously untreated indolent non-Hodgkin's lymphoma. *Hematol J* 2003;4:110-5.
197. **Dimopoulos MA**, Tsatalas C, Zomas A, Hamilos G, Panayiotidis P, Margaritis D, Matsouka C, Economopoulos T, Anagnostopoulos N. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. *Semin Oncol* 2003;30:265-9.
198. Weber DM, **Dimopoulos MA**, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. *Semin Oncol* 2003;30:243-7.
199. Alexanian R, Weber D, Delasalle K, Cabanillas F, **Dimopoulos MA**. Asymptomatic Waldenstrom's macroglobulinemia. *Semin Oncol* 2003;30:206-10.
200. Owen RG, Treon SP, Al-Katib A, Fonseca R, Greipp PR, McMaster ML, Morra E, Pangalis GA, San Miguel JF, Branagan AR, **Dimopoulos MA**. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. *Semin Oncol* 2003;30:110-5.

201. Treon SP, **Dimopoulos MA**, Kyle RA. Defining Waldenstrom's macroglobulinemia. *Semin Oncol* 2003;30:107-9.
202. **Dimopoulos MA**, Papadimitriou C, Anagnostopoulos A, Mitsibounas D, Femand JP. High dose therapy with autologous stem cell transplantation for solitary bone plasmacytoma complicated by local relapse or isolated distant recurrence. *Leuk Lymphoma* 2003;44:153-5.
203. Stathopoulos GP, Rigatos SK, **Dimopoulos MA**, Giannakakis T, Foutzilias G, Kouroussis C, Janninis D, Aravantinos G, Androulakis N, Agelaki S, Stathopoulos JG, Georgoulas V. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. *Ann Oncol* 2003;14:388-94.
204. Katopodis O, Liossis SN, Viglis V, Pouli A, **Dimopoulos MA**, Sfikakis PP. Expansion of CD8+ T cells that express low levels of the B cell-specific molecule CD20 in patients with multiple myeloma. *Br J Haematol* 2003;120:478-81.
205. Mouloupoulos LA, Maris TG, Papanikolaou N, Panagi G, Vlahos L, **Dimopoulos MA**. Detection of malignant bone marrow involvement with dynamic contrast-enhanced magnetic resonance imaging. *Ann Oncol* 2003;14:152-8.
206. Pectasides D, Skarlos D, **Dimopoulos MA**, Farmakis D, Pectasides M, Fountzilias G, Aravantinos G. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial. *Anticancer Res* 2003;23:4239-44.
207. Skarlos DV, **Dimopoulos MA**, Kosmidis P, Papakostas P, Pavlidis N, Bacoyiannis C, Kiamouris C, Klouvas G, Gogas H, Fountzilias G, Samantas E. Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group. *Lung Cancer* 2003;41:107-11.
208. **Dimopoulos MA**, Papadimitriou C, Hamilos G, Efstathiou E, Vlahos G, Rodolakis A, Aravantinos G, Kalofonos H, Kouroussis C, Gika D, Skarlos D, Bamias A. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. *Gynecol Oncol* 2004;95:695-700.
209. Abratt RP, Brune D, **Dimopoulos MA**, Kliment J, Breza J, Selvaggi FP, Beuzeboc P, Demkow T, Oudard S. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. *Ann Oncol* 2004;15:1613-21.
210. Anagnostopoulos A, Gika D, Hamilos G, Zervas K, Zomas A, Pouli A, Zorzou M, Kastiris E, Anagnostopoulos N, Tassidou A, Anagnostou D, **Dimopoulos MA**. Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors. *Leuk Lymphoma* 2004;45:2275-9.
211. **Dimopoulos MA**, Eleutherakis-Papaiakovou V. Adverse effects of thalidomide administration in patients with neoplastic diseases. *Am J Med* 2004;117:508-15.
212. **Dimopoulos MA**, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, Kyrtsonis MC, Anagnostopoulos N, Pangalis GA, Weber DM. Treatment of Waldenstrom's

- macroglobulinemia with rituximab: prognostic factors for response and progression. *Leuk Lymphoma* 2004;45:2057-61.
213. Fountzilas G, Kalofonos HP, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Mouloupoulos LA, Economopoulos T, Pectasides D, Maniadakis N, Siafaka V, Briasoulis E, Christodoulou C, Tsavdaridis D, Makrantonakis P, Razis E, Kosmidis P, Skarlos D, **Dimopoulos MA**. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. *Ann Oncol* 2004;15:1517-26.
214. Politou M, Terpos E, Anagnostopoulos A, Szydlo R, Laffan M, Layton M, Apperley JF, **Dimopoulos MA**, Rahemtulla A. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). *Br J Haematol* 2004;126:686-9.
215. Bamias A, Deliveliotis C, Karayiannis A, Varkarakis I, Zervas I, Pantazopoulos D, Gika D, **Dimopoulos MA**. Neoadjuvant chemotherapy with docetaxel and cisplatin in patients with high-risk resectable bladder carcinoma: long term results. *Eur Urol* 2004;46:344-50; discussion 50-1.
216. Anagnostopoulos A, Galani E, Gika D, Sotou D, Evangelopoulou A, **Dimopoulos MA**. Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein. *Ann Hematol* 2004;83:658-60.
217. Dimopoulou I, Efstathiou E, Samakovli A, Dafni U, Mouloupoulos LA, Papadimitriou C, Lyberopoulos P, Kastritis E, Roussos C, **Dimopoulos MA**. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment. *Ann Oncol* 2004;15:1250-5.
218. Eleutherakis-Papaiakovou V, Bamias A, **Dimopoulos MA**. Thalidomide in cancer medicine. *Ann Oncol* 2004;15:1151-60.
219. **Dimopoulos MA**, Gika D, Zervas K, Kyrtsolis M, Symeonidis A, Anagnostopoulos A, Bourantas K, Matsouka C, Pangalis G. The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia. *Leuk Lymphoma* 2004;45:1809-13.
220. Andreopoulou E, Pectasides D, **Dimopoulos MA**, Nikolaidis C, Fountzilas G, Valsami S, Economopoulos T. Primary mediastinal large B-cell lymphoma: clinical study of a distinct clinical entity and treatment outcome in 20 patients: review of the literature. *Am J Clin Oncol* 2004;27:312-6.
221. Bamias A, Deliveliotis C, Fountzilas G, Gika D, Anagnostopoulos A, Zorzou MP, Kastritis E, Constantinides C, Kosmidis P, **Dimopoulos MA**. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. *J Clin Oncol* 2004;22:2150-4.
222. Janinis J, Stathopoulos GP, Nikolaidis P, Kalofonos HP, Kalogera-Fountzila A, Samantas E, Aravantinos G, Anagnostopoulos A, Tolis C, Makatsoris T, Rigatos SK, Bafaloukos D, **Dimopoulos MA**, Daniilidis J, Fountzilas G. Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study

- conducted by the Hellenic Cooperative Oncology Group (HeCOG). *Anticancer Drugs* 2004;15:479-87.
223. Papadimitriou CA, Markaki S, Siapkarakas J, Vlachos G, Efstathiou E, Grimani I, Hamilos G, Zorzou M, **Dimopoulos MA**. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. *Oncology* 2004;66:112-7.
224. Anagnostopoulos A, Hamilos G, Zorzou MP, Grigoraki V, Anagnostou D, **Dimopoulos MA**. Discordant response or progression in patients with myeloma treated with thalidomide-based regimens. *Leuk Lymphoma* 2004;45:113-6.
225. **Dimopoulos MA**, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, Poziopoulos C, Xilouri I, Zorzou MP, Anagnostopoulos N, Anagnostopoulos A. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. *Hematol J* 2004;5:112-7.
226. Bamias A, Deliveliotis C, Aravantinos G, Kalofonos C, Karayiannis A, **Dimopoulos MA**. Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology Group. *J Urol* 2004;171:1467-70.
227. **Dimopoulos MA**, Kiamouris C, Gika D, Deliveliotis C, Giannopoulos A, Zervas A, Alamanis C, Constantinidis C, Koutsilieris M. Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study. *Urology* 2004;63:120-5.
228. Papadimitriou CA, Fountzilias G, Aravantinos G, Kalofonos C, Mouloupoulos LA, Briassoulis E, Gika D, **Dimopoulos MA**. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study. *Gynecol Oncol* 2004;92:152-9.
229. Zervas K, **Dimopoulos MA**, Hatzicharissi E, Anagnostopoulos A, Papaioannou M, Mitsouli C, Panagiotidis P, Korantzis J, Tzilianos M, Maniatis A. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. *Ann Oncol* 2004;15:134-8.
230. Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, Zervas A, Mitropoulos D, Samantas E, Pectasides D, Papakostas P, Gika D, Kourousis C, Koutras A, Papadimitriou C, Bamias C, Kosmidis P, **Dimopoulos MA**. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. *J Clin Oncol* 2004;22:220-8.
231. Terrovitis JV, Matsouka C, Anagnostopoulos A, Anastasiou-Nana MI, **Dimopoulos MA**. Hemophagocytic lymphohistiocytosis after chemotherapy for multiple myeloma. *Clin Lymphoma* 2004;5:194-6.
232. Bafaloukos D, Papadimitriou C, Linardou H, Aravantinos G, Papakostas P, Skarlos D, Kosmidis P, Fountzilias G, Gogas H, Kalofonos C, **Dimopoulos MA**. Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group. *Br J Cancer* 2004;91:1639-44.

233. Protopapas A, Diakomanolis E, Bamias A, Milingos S, Markaki S, Papadimitriou C, **Dimopoulos MA**, Michalakis S. The prognostic significance of the immunohistochemical expression of p53, bcl-2, c-erb B-2 and cathepsin-D in ovarian cancer patients receiving platinum with cyclophosphamide or paclitaxel chemotherapy. *Eur J Gynaecol Oncol* 2004;25:225-9.
234. Bozas GT, Bamias A, Kastritis E, Rodolakis A, Vlahos G, Papadimitriou CA, Markaki S, **Dimopoulos MA**. Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus. *Eur J Gynaecol Oncol* 2005;26:627-31.
235. Psyrri A, Kassar M, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, **Dimopoulos MA**. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. *Clin Cancer Res* 2005;11:8637-43.
236. Bamias A, **Dimopoulos MA**. Neoadjuvant chemotherapy in invasive bladder cancer. *Expert Rev Anticancer Ther* 2005;5:993-1000.
237. **Dimopoulos MA**, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. *Haematologica* 2005;90:1655-8.
238. **Dimopoulos MA**. Tandem autologous stem cell transplantation for multiple myeloma: is it applicable and effective outside clinical trials? *Haematologica* 2005;90:1588.
239. Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, **Dimopoulos MA**. Subcellular localization and protein levels of cyclin-dependent kinase inhibitor p27 independently predict for survival in epithelial ovarian cancer. *Clin Cancer Res* 2005;11:8384-90.
240. Bamias A, Kastritis E, Bamia C, Mouloupoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, **Dimopoulos MA**. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. *J Clin Oncol* 2005;23:8580-7.
241. Economopoulos T, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Tsatalas C, Pavlidis N, Pectasides D, Papageorgiou E, **Dimopoulos MA**. Multifocal extranodal non-hodgkin lymphoma: a clinicopathologic study of 37 cases in Greece, a Hellenic Cooperative Oncology Group study. *Oncologist* 2005;10:734-8.
242. Anagnostopoulos A, Gika D, Symeonidis A, Zervas K, Pouli A, Repoussis P, Grigoraki V, Anagnostopoulos N, Economopoulos T, Maniatis A, **Dimopoulos MA**. Multiple myeloma in elderly patients: prognostic factors and outcome. *Eur J Haematol* 2005;75:370-5.
243. Bamias A, Efstathiou E, Vassilakopoulou M, Koutsoukou V, Papadimitriou C, Rodolakis A, Mitsibounas D, Vlahos G, **Dimopoulos MA**. Late relapse of epithelial ovarian cancer: a single institution experience. *Eur J Gynaecol Oncol* 2005;26:439-42.
244. Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, **Dimopoulos MA**. Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. *Anticancer Res* 2005;25:3553-8.

245. Mouloupoulos LA, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R, **Dimopoulos MA**. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. *Ann Oncol* 2005;16:1824-8.
246. Skarlos DV, Kalofonos HP, Fountzilas G, **Dimopoulos MA**, Pavlidis N, Razis E, Economopoulos T, Pectasides D, Gogas H, Kosmidis P, Bafaloukos D, Klouvas G, Kyratzis G, Aravantinos G. Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. *Anticancer Res* 2005;25:3103-8.
247. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M, Voskaridou E, Rahemtulla A, **Dimopoulos MA**, Zervas K. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. *Leukemia* 2005;19:1969-76.
248. Kastiris E, Bamias A, Efstathiou E, Gika D, Bozas G, Zorzou P, Sarris K, Papadimitriou C, **Dimopoulos MA**. The outcome of advanced or recurrent non-squamous carcinoma of the uterine cervix after platinum-based combination chemotherapy. *Gynecol Oncol* 2005;99:376-82.
249. **Dimopoulos MA**, Anagnostopoulos A. Waldenstrom's macroglobulinemia. *Best Pract Res Clin Haematol* 2005;18:747-65.
250. Papageorgiou ES, Tsirigotis P, **Dimopoulos MA**, Pavlidis N, Fountzilas G, Papageorgiou S, Economopoulos T. Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group. *Eur J Haematol* 2005;75:124-9.
251. Skolarikos A, Alivizatos G, Bamias A, Mitropoulos D, Ferakis N, Deliveliotis C, **Dimopoulos MA**. Bcl-2 protein and DNA ploidy in renal cell carcinoma: do they affect patient prognosis? *Int J Urol* 2005;12:563-9.
252. Briasoulis E, Samantas E, Kalofonos H, Skarlos D, Makatsoris T, Christodoulou C, Fountzilas G, Bamias A, **Dimopoulos MA**, Kosmidis P, Pavlidis N. Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer. *Cancer Chemother Pharmacol* 2005;56:521-8.
253. Terpos E, Rahemtulla A, **Dimopoulos MA**. Current treatment options for myeloma. *Expert Opin Pharmacother* 2005;6:1127-42.
254. Sfikakis PP, Gourgoulis GM, Mouloupoulos LA, Kouvatseas G, Theofilopoulos AN, **Dimopoulos MA**. Age-related thymic activity in adults following chemotherapy-induced lymphopenia. *Eur J Clin Invest* 2005;35:380-7.
255. Koutsikos J, Athanasoulis T, Anagnostopoulos A, Velidaki A, Passadi M, **Dimopoulos MA**, Zerva C. Combined use of 99mTc-sestamibi and 99mTc-V-DMSA in the assessment of chemotherapy effectiveness in patients with multiple myeloma. *J Nucl Med* 2005;46:978-82.
256. Aravantinos G, Fountzilas G, Kosmidis P, **Dimopoulos MA**, Stathopoulos GP, Pavlidis N, Bafaloukos D, Papadimitriou C, Karpathios S, Georgoulis V, Papakostas P, Kalofonos HP, Grimani E, Skarlos DV. Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin

- and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study. *Ann Oncol* 2005;16:1116-22.
257. Terpos E, **Dimopoulos MA**. Myeloma bone disease: pathophysiology and management. *Ann Oncol* 2005;16:1223-31.
258. **Dimopoulos MA**, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. *J Clin Oncol* 2005;23:4381-9.
259. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos HP, Efstathiou E, Salamalekis E, Farmakis D, Skarlos D, Briasoulis E, Economopoulos T, **Dimopoulos MA**. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. *Gynecol Oncol* 2005;97:436-41.
260. Chamilos G, Bamias A, Efstathiou E, Zorzou PM, Kastritis E, Kostis E, Papadimitriou C, **Dimopoulos MA**. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. *Cancer* 2005;103:2629-35.
261. Kalofonos HP, Aravantinos G, Kosmidis P, Papakostas P, Economopoulos T, **Dimopoulos MA**, Skarlos D, Bamias A, Pectasides D, Chalkidou S, Karina M, Koutras A, Samantas E, Bacoyiannis C, Samelis GF, Basdanis G, Kalfarentzos F, Fountzilas G. Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. *Ann Oncol* 2005;16:869-77.
262. Zorzou MP, Efstathiou E, Galani E, Bozas G, Kastritis E, Papadimitriou C, **Dimopoulos MA**, Bamias A. Carboplatin hypersensitivity reactions: a single institution experience. *J Chemother* 2005;17:104-10.
263. Economopoulos T, Papageorgiou S, **Dimopoulos MA**, Pavlidis N, Tsatalas C, Symeonidis A, Foudoulakis A, Pectasides D, Rontogianni D, Rizos E, Chalkia P, Anagnostopoulos A, Melachrinou M, Papageorgiou E, Fountzilas G. Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases. *Acta Haematol* 2005;113:97-103.
264. **Dimopoulos MA**, Anagnostopoulos A, Zervas C, Kyrtsolis MC, Zomas A, Bourantas C, Anagnostopoulos N, Pangalis G. Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia. *Clin Lymphoma* 2005;5:270-2.
265. **Dimopoulos MA**, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. *J Clin Oncol* 2005;23:1564-77.
266. Bamias A, **Dimopoulos MA**. Thalidomide and immunomodulatory drugs in the treatment of cancer. *Expert Opin Investig Drugs* 2005;14:45-55.
267. Bamias A, Efstathiou E, Mouloupoulos LA, Gika D, Hamilos G, Zorzou MP, Kakoyiannis C, Kastritis E, Bozas G, Papadimitriou C, **Dimopoulos MA**. The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy. *Ann Oncol* 2005;16:307-13.

268. Efstathiou E, Bozas G, Kostakopoulos A, Kastritis E, Deliveliotis C, Antoniou N, Skarlos D, Papadimitriou C, **Dimopoulos MA**, Bamias A. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment. *Urology* 2005;65:126-30.
269. Razis E, Skarlos D, Briasoulis E, **Dimopoulos MA**, Fountzilas G, Lambropoulos S, Rigatos S, Kopterides P, Efstathiou H, Tzamakou E, Bakoyannis C, Pectasides D, Makatsoris T, Varthalitis G, Papadopoulos S, Kosmidis P. Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program. *Anticancer Drugs* 2005;16:191-8.
270. **Dimopoulos MA**, Merlini G, Leblond V, Anagnostopoulos A, Alexanian R. How we treat Waldenstrom's macroglobulinemia. *Haematologica* 2005;90:117-25.
271. Galani E, Alamanis C, **Dimopoulos MA**. Familial female and male germ cell cancer. A new syndrome? *Gynecol Oncol* 2005;96:254-5.
272. Zorzou MP, Markaki S, Rodolakis A, Kastritis E, Bozas G, **Dimopoulos MA**, Papadimitriou CA. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. *Gynecol Oncol* 2005;96:136-42.
273. Fountzilas G, Skarlos D, Dafni U, Gogas H, Briasoulis E, Pectasides D, Papadimitriou C, Markopoulos C, Polychronis A, Kalofonos HP, Siafaka V, Kosmidis P, Timotheadou E, Tsavdaridis D, Bafaloukos D, Papakostas P, Razis E, Makrantonakis P, Aravantinos G, Christodoulou C, **Dimopoulos MA**. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. *Ann Oncol* 2005;16:1762-71.
274. Samelis GF, Kalofonos H, Adamou A, Kosmidis P, Skarlos D, Aravantinos G, Kiamouris C, Adimchi O, Fountzilas G, **Dimopoulos MA**. The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: a Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. *Urology* 2005;66:382-5.
275. Anagnostopoulos A, Zervas K, Kyrtsionis M, Symeonidis A, Gika D, Bourantas K, Zomas A, Anagnostopoulos N, Pangalis G, **Dimopoulos MA**. Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment. *Clin Lymphoma Myeloma* 2006;7:205-9.
276. Koutsikos J, Grigoraki V, Athanasoulis T, Velidaki A, Mamoulakis C, Zomas A, Anagnostopoulos N, Georgiou E, **Dimopoulos MA**, Zerva C. Scintigraphy with technetium-99m methoxyisobutylisonitrile in multiple myeloma patients: correlation with the International Staging System. *Hell J Nucl Med* 2006;9:177-80.
277. Mountzios G, Pavlakis G, Terpos E, Sakorafas G, Revelos K, Bamias A, Nikolaou N, Pappasavvas P, Soria JC, **Dimopoulos MA**. Concurrent development of testicular seminoma and choriocarcinoma of the superior mediastinum, presented as cervical mass: a case report and implications about pathogenesis of germ-cell tumours. *BMC Clin Pathol* 2006;6:8.

278. **Dimopoulos MA**, Kastritis E. Is there still place for VAD as primary treatment for patients with multiple myeloma who are candidates for high-dose therapy? *Leuk Lymphoma* 2006;47:2271-2.
279. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, **Dimopoulos MA**, Croucher PI. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. *Br J Haematol* 2006;135:688-92.
280. Kastritis E, **Dimopoulos MA**, Antoniou N, Deliveliotis C, Chrisofos M, Skolarikos A, Gika D, Bamias A. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. *Anticancer Res* 2006;26:3865-9.
281. Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, **Dimopoulos MA**, Tsatalas C, Xiros N, Economopoulos T. Primary gastrointestinal non-Hodgkin's lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). *Leuk Lymphoma* 2006;47:2140-6.
282. **Dimopoulos MA**, Kastritis E, Anagnostopoulos A. Hematological malignancies: myeloma. *Ann Oncol* 2006;17 Suppl 10:x137-43.
283. Bamias A, Papadimitriou C, Efstathiou E, Rodolakis A, Vlahos G, Voulgaris Z, Bozas G, Fountzilas G, Aravantinos G, Razis E, Gika D, **Dimopoulos MA**. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. *BMC Cancer* 2006;6:228.
284. Bamias A, Yu Z, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, **Dimopoulos MA**, Psyrris A. Automated quantitative analysis of DCC tumor suppressor protein in ovarian cancer tissue microarray shows association with beta-catenin levels and outcome in patients with epithelial ovarian cancer. *Ann Oncol* 2006;17:1797-802.
285. **Dimopoulos MA**, Pouli A, Anagnostopoulos A, Repoussis P, Symeonidis A, Terpos E, Delimbasi S, Tsolakis F, Economopoulos T, Zervas C. Macrofocal multiple myeloma in young patients: a distinct entity with favorable prognosis. *Leuk Lymphoma* 2006;47:1553-6.
286. Bozas G, **Dimopoulos MA**, Kastritis E, Efstathiou E, Koutsoukou V, Rodolakis A, Vlahos G, Voulgaris Z, Papageorgiou T, Gika D, Papadimitriou C, Bamias A. Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. *Oncology* 2006;70:265-72.
287. Kastritis E, Terpos E, Anagnostopoulos A, Xilouri I, **Dimopoulos MA**. Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. *Clin Lymphoma Myeloma* 2006;7:73-6.
288. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, **Dimopoulos MA**, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV. International uniform response criteria for multiple myeloma. *Leukemia* 2006;20:1467-73.

289. **Dimopoulos MA**. Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation. *Leuk Lymphoma* 2006;47:963-4.
290. Kostadima L, Pentheroudakis G, Fountzilas G, **Dimopoulos MA**, Pectasides D, Gogas H, Stropp U, Christodoulou C, Samantas E, Wirtz R, Hennig G, Bafaloukos D, Arapantoni P, Kalofonos H, Papakostas P, Economopoulos T, Bamias A, Pavlidis N. Survivin and glycodefin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. *Breast Cancer Res Treat* 2006;100:161-7.
291. Kastritis E, Efstathiou E, Gika D, Bozas G, Koutsoukou V, Papadimitriou C, Pissakas G, **Dimopoulos MA**, Bamias A. Brain metastases as isolated site of relapse in patients with epithelial ovarian cancer previously treated with platinum and paclitaxel-based chemotherapy. *Int J Gynecol Cancer* 2006;16:994-9.
292. Souliotis VL, **Dimopoulos MA**, Episkopou HG, Kyrtopoulos SA, Sfrikakis PP. Preferential in vivo DNA repair of melphalan-induced damage in human genes is greatly affected by the local chromatin structure. *DNA Repair (Amst)* 2006;5:972-85.
293. Psyrris A, Yu Z, Bamias A, Weinberger PM, Markakis S, Kowalski D, Camp RL, Rimm DL, **Dimopoulos MA**. Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis. *Cancer Epidemiol Biomarkers Prev* 2006;15:1179-83.
294. **Dimopoulos MA**, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Mouloupoulos LA, Bamias C, Terpos E, Tsionos K, Bamias A. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. *Haematologica* 2006;91:968-71.
295. Kilidireas C, Anagnostopoulos A, Karandreas N, Mouselimi L, **Dimopoulos MA**. Rituximab therapy in monoclonal IgM-related neuropathies. *Leuk Lymphoma* 2006;47:859-64.
296. Terpos E, Eleutherakis-Papaiakovou V, **Dimopoulos MA**. Clinical implications of chromosomal abnormalities in multiple myeloma. *Leuk Lymphoma* 2006;47:803-14.
297. Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, **Dimopoulos MA**, Croucher PI, Terpos E. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. *Int J Cancer* 2006;119:1728-31.
298. Terpos E, Anagnostopoulos A, Kastritis E, Bamias A, Tsionos K, **Dimopoulos MA**. Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia. *Br J Haematol* 2006;133:301-4.
299. Bozas G, Tassidou A, Mouloupoulos LA, Constandinidis C, Bamias A, **Dimopoulos MA**. Non-Hodgkin's lymphoma of the renal pelvis. *Clin Lymphoma Myeloma* 2006;6:404-6.
300. Kimby E, Treon SP, Anagnostopoulos A, **Dimopoulos MA**, Garcia-Sanz R, Gertz MA, Johnson S, LeBlond V, Fermand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone M, Blade J. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. *Clin Lymphoma Myeloma* 2006;6:380-3.

301. Kostopoulos I, Arapantoni-Dadioti P, Gogas H, Papadopoulos S, Malamou-Mitsi V, Scopa CD, Markaki S, Karagianni E, Kyriakou V, Margariti A, Kyrkou E, Pavlakis K, Zaramboukas T, Skordalaki A, Bourli A, Markopoulos C, Pectasides D, **Dimopoulos MA**, Skarlos D, Fountzilas G. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. *Breast Cancer Res Treat* 2006;96:251-61.
302. Bamias A, **Dimopoulos MA**. Inhibition of angiogenesis: common theme for cancer and atheromatosis? *Hellenic J Cardiol* 2006;47:11-2.
303. Pectasides D, Fountzilas G, Aravantinos G, Kalofonos C, Efstathiou H, Farmakis D, Skarlos D, Pavlidis N, Economopoulos T, **Dimopoulos MA**. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. *Gynecol Oncol* 2006;102:285-91.
304. Kastritis E, Mouloupoulos LA, Politi E, Kostis E, Pissakas G, **Dimopoulos MA**, Bamias A. Intramedullary spinal cord and leptomeningeal metastases in a patient with carcinoma of the uterine cervix. *Gynecol Oncol* 2006;102:124-7.
305. **Dimopoulos MA**, Anagnostopoulos A, Terpos E, Repoussis P, Zomas A, Katodritou E, Kyrtsionis MC, Delibasi S, Vassou A, Pouli A, Zervas K, Anagnostopoulos N, Maniatis A. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. *Haematologica* 2006;91:252-4.
306. Treon SP, Gertz MA, **Dimopoulos MA**, Anagnostopoulos A, Blade J, Branagan AR, Garcia-Sanz R, Johnson S, Kimby E, Leblond V, Femand JP, Maloney DG, Merlini G, Morel P, Morra E, Nichols G, Ocio EM, Owen R, Stone MJ. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. *Blood* 2006;107:3442-6.
307. Bamias A, Mouloupoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D, Kastritis E, Gika D, Skarlos D, Linardou H, Kalofonos HP, **Dimopoulos MA**. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. *Cancer* 2006;106:297-303.
308. Bozas G, Anagnostou D, Tassidou A, Mouloupoulos LA, Bamias A, **Dimopoulos MA**. Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature. *Leuk Lymphoma* 2006;47:329-32.
309. Bamias A, Tiliakos I, Karali MD, **Dimopoulos MA**. Systemic chemotherapy in inoperable or metastatic bladder cancer. *Ann Oncol* 2006;17:553-61.
310. Dimopoulou I, Bamias A, Lyberopoulos P, **Dimopoulos MA**. Pulmonary toxicity from novel antineoplastic agents. *Ann Oncol* 2006;17:372-9.
311. Zotos PG, Psimenou E, Roussou M, Kontogiannis S, Panoutsopoulos A, **Dimopoulos MA**. Nephrotic syndrome as a manifestation of *Toxocara canis* infection. *Nephrol Dial Transplant* 2006;21:2675-6.
312. Vassilakopoulos TP, Angelopoulou MK, Siakantaris MP, Konstantinou N, Symeonidis A, Karmiris T, Repoussis P, Roussou P, **Dimopoulos MA**, Kokoris SI, Dimitriadou EM, Kyrtsionis MC, Dimopoulou MN, Tsatalas C, Kokkinis G, Vrakidou E, Grigoraki V, Poziopoulos C,

- Stamatellou M, Liapis D, Georgiou G, Panayiotidis P, Pangalis GA. Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease. *Haematologica* 2006;91:32-9.
313. Bamias A, Lainakis G, Kastritis E, Antoniou N, Alivizatos G, Koureas A, Chrisofos M, Skolarikos A, Karayiotis E, **Dimopoulos MA**. Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment. *Oncology* 2007;73:290-7.
314. Bamias A, Aravantinos G, Deliveliotis C, Thanos A, Klouvas G, Antoniou N, Poulias I, Makatsoris T, Samantas E, **Dimopoulos MA**. Two cycles of etoposide/cisplatin cured all patients with stage I testicular seminoma: risk-adapted protocol of the Hellenic Cooperative Oncology Group. *Urology* 2007;70:1179-83.
315. Kastritis E, **Dimopoulos MA**. Thalidomide in the treatment of multiple myeloma. *Best Pract Res Clin Haematol* 2007;20:681-99.
316. Kastritis E, **Dimopoulos MA**. How to prevent deep vein thrombosis in myeloma patients receiving thalidomide or lenalidomide. *Leuk Lymphoma* 2007;48:2295-7.
317. **Dimopoulos MA**, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foa R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. *N Engl J Med* 2007;357:2123-32.
318. **Dimopoulos MA**, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I, Terpos E, Kyrtopoulos SA, Sfrikakis PP. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. *Haematologica* 2007;92:1505-12.
319. Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, **Dimopoulos MA**. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. *Haematologica* 2007;92:1351-8.
320. Kastritis E, Mitsiades CS, **Dimopoulos MA**, Richardson PG. Management of relapsed and relapsed refractory myeloma. *Hematol Oncol Clin North Am* 2007;21:1175-215, x.
321. Gakiopoulou H, Korkolopoulou P, Levidou G, Thymara I, Saetta A, Piperi C, Givalos N, Vassilopoulos I, Ventouri K, Tsenga A, Bamias A, **Dimopoulos MA**, Agapitos E, Patsouris E. Minichromosome maintenance proteins 2 and 5 in non-benign epithelial ovarian tumours: relationship with cell cycle regulators and prognostic implications. *Br J Cancer* 2007;97:1124-34.
322. Economopoulos T, Psyrris A, **Dimopoulos MA**, Kalogera-Fountzila A, Pavlidis N, Tsatalas C, Nikolaidis C, Mellou S, Xiros N, Fountzilas G. CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: results of the HE22A99 trial of the Hellenic Cooperative Oncology Group. *Cancer J* 2007;13:327-34.
323. Pectasides D, Samantas E, Fountzilas G, Briasoulis E, Kosmidis P, Skarlos D, **Dimopoulos MA**, Kalofonos HP, Economopoulos T, Syrigos K. Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group. *Lung Cancer* 2007;58:355-61.

324. Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, Delibasi S, Kyrtsionis MC, Anagnostopoulos N, Terpos E, Zikos P, Maniatis A, **Dimopoulos MA**. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. *Ann Oncol* 2007;18:1369-75.
325. **Dimopoulos MA**, Anagnostopoulos A. Treatment of Waldenstrom's Macroglobulinemia. *Curr Treat Options Oncol* 2007;8:144-53.
326. Terpos E, **Dimopoulos MA**, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. *Leukemia* 2007;21:1875-84.
327. **Dimopoulos MA**, Anagnostopoulos A, Kyrtsionis MC, Zervas K, Tsatalas C, Kokkinis G, Repoussis P, Symeonidis A, Delimpasi S, Katodritou E, Vervessou E, Michali E, Pouli A, Gika D, Vassou A, Terpos E, Anagnostopoulos N, Economopoulos T, Pangalis G. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. *J Clin Oncol* 2007;25:3344-9.
328. Terpos E, Sezer O, Croucher P, **Dimopoulos MA**. Myeloma bone disease and proteasome inhibition therapies. *Blood* 2007;110:1098-104.
329. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, **Dimopoulos MA**. Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. *Haematologica* 2007;92:546-9.
330. Papadimitriou CA, Zorzou MP, Markaki S, Rodolakis A, Voulgaris Z, Bozas G, Kastritis E, Bamias A, Gika D, **Dimopoulos MA**. Anthracycline-based adjuvant chemotherapy in early-stage uterine sarcomas: long-term results of a single institution experience. *Eur J Gynaecol Oncol* 2007;28:109-16.
331. Roussou M, Anagnostopoulos A, Kastritis E, Matsouka C, Barmparousi D, Koutsoukou V, **Dimopoulos MA**. Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments. *Leuk Lymphoma* 2007;48:754-8.
332. Mountzios G, **Dimopoulos MA**, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, Pavlakis G, Terpos E. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. *Acta Oncol* 2007;46:221-9.
333. Anagnostopoulos A, Eleftherakis-Papaiakovou V, Kastritis E, Tsionos K, Bamias A, Meletis J, **Dimopoulos MA**, Terpos E. Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. *Br J Haematol* 2007;137:560-8.
334. Bamias A, Tsiatas ML, Kafantari E, Liakou C, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Tsitsilonis O, Bamia C, Papatheodoridis G, Politi E, Archimandritis A, Antsaklis A, **Dimopoulos MA**. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. *Gynecol Oncol* 2007;106:75-81.

335. Kosmidis PA, **Dimopoulos MA**, Syrigos K, Nicolaides C, Aravantinos G, Boukovinas I, Pectasides D, Fountzilas G, Bafaloukos D, Bacoyiannis C, Kalofonos HP. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. *J Thorac Oncol* 2007;2:135-40.
336. Karagiannis S, Papadimitriou CA, Sotiropoulou M, Dimopoulos F, Chrysanthopoulou H, **Dimopoulos MA**, Michopoulos S. Squamous cell esophageal carcinoma as a second primary malignancy in a woman with epithelial ovarian cancer. *Dig Dis Sci* 2007;52:3099-101.
337. Pectasides D, Fountzilas G, Aravantinos G, Bamias A, Kalofonos HP, Skarlos D, Briasoulis E, Konstantara A, Economopoulos T, **Dimopoulos MA**. Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience. *Int J Gynecol Cancer* 2007;17:1003-10.
338. Efstathiou E, **Dimopoulos MA**, Bozas G, Kastritis E, Mouloupoulos LA, Rodolakis A, Vlahos G, Gika D, Papadimitriou C, Bamias A. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. *Anticancer Res* 2007;27:611-7.
339. Eleutherakis-Papaiakovou V, Bamias A, Gika D, Simeonidis A, Pouli A, Anagnostopoulos A, Michali E, Economopoulos T, Zervas K, **Dimopoulos MA**. Renal failure in multiple myeloma: incidence, correlations, and prognostic significance. *Leuk Lymphoma* 2007;48:337-41.
340. Kastritis E, **Dimopoulos MA**. The evolving role of lenalidomide in the treatment of hematologic malignancies. *Expert Opin Pharmacother* 2007;8:497-509.
341. Psyri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp RL, Economopoulos T, **Dimopoulos MA**. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. *Ann Oncol* 2007;18:709-15.
342. Milingos S, Protopapas A, Papadimitriou C, Rodolakis A, Kallipolitis G, Skartados N, Markaki S, **Dimopoulos MA**, Antsaklis A. Laparoscopy in the evaluation of women with unexplained ascites: an invaluable diagnostic tool. *J Minim Invasive Gynecol* 2007;14:43-8.
343. Bozas G, Bamias A, Koutsoukou V, Efstathiou E, Gika D, Papadimitriou CA, **Dimopoulos MA**. Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma. *Gynecol Oncol* 2007;104:580-5.
344. Kastritis E, Bamias A, Bozas G, Koutsoukou V, Voulgaris Z, Vlahos G, Rodolakis A, Gika D, Papadimitriou C, **Dimopoulos MA**. The impact of age in the outcome of patients with advanced or recurrent cervical cancer after platinum-based chemotherapy. *Gynecol Oncol* 2007;104:372-6.
345. Kosmidis P, Fountzilas G, Baka S, Samantas E, **Dimopoulos MA**, Gogas H, Skarlos D, Papacostas P, Boukovinas J, Bakogiannis C, Pantelakos P, Athanasiou H, Misailidou D, Tsekeris P, Pavlidis N. Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A hellenic cooperative oncology group (HeCOG) phase II study. *Anticancer Res* 2007;27:4391-5.

346. Kafantari E, Sotiropoulou M, Sfikakis P, Dimitrakakis K, Zagouri F, Mandrekas K, Dimopoulos S, **Dimopoulos MA**, Papadimitriou CA. Giant cell arteritis of the breast and breast cancer: paraneoplastic manifestation or concomitant disease? A case report. *Onkologie* 2008;31:685-8.
347. Edwards BJ, Gounder M, McKoy JM, Boyd I, Farrugia M, Migliorati C, Marx R, Ruggiero S, **Dimopoulos MA**, Raisch DW, Singhal S, Carson K, Obadina E, Trifilio S, West D, Mehta J, Bennett CL. Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. *Lancet Oncol* 2008;9:1166-72.
348. Koutras AK, Fountzilas G, Dafni U, **Dimopoulos MA**, Pectasides D, Klouvas G, Papakostas P, Kosmidis P, Samantas E, Gogas H, Briasoulis E, Vourli G, Petsas T, Xiros N, Kalofonos HP. Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. *Anticancer Res* 2008;28:2913-20.
349. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, Zervas K, Baer MR, Meiller T, **Dimopoulos MA**. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. *J Clin Oncol* 2008;26:5904-9.
350. Koutras AK, Kalogeras KT, **Dimopoulos MA**, Wirtz RM, Dafni U, Briasoulis E, Pectasides D, Gogas H, Christodoulou C, Aravantinos G, Zografos G, Timotheadou E, Papakostas P, Linardou H, Razis E, Economopoulos T, Kalofonos HP, Fountzilas G. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. *Br J Cancer* 2008;99:1775-85.
351. Kountourakis P, Psyrris A, Scorilas A, Camp R, Markakis S, Kowalski D, Diamandis EP, **Dimopoulos MA**. Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). *Cancer Sci* 2008;99:2224-9.
352. Terpos E, **Dimopoulos MA**. Genetic predisposition for the development of ONJ. *Blood* 2008;112:2596-7.
353. **Dimopoulos MA**, Kastritis E. The role of novel drugs in multiple myeloma. *Ann Oncol* 2008;19 Suppl 7:vii121-7.
354. Wang M, **Dimopoulos MA**, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. *Blood* 2008;112:4445-51.
355. **Dimopoulos MA**, Kastritis E. Thalidomide plus dexamethasone as primary therapy for newly diagnosed patients with multiple myeloma. *Nat Clin Pract Oncol* 2008;5:690-1.
356. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N, Eleftherakis-Papaikovou E, Tsionos K, Croucher P, **Dimopoulos MA**. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. *Leukemia* 2008;22:2247-56.

357. San Miguel JF, Schlag R, Khuageva NK, **Dimopoulos MA**, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoiloova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. *N Engl J Med* 2008;359:906-17.
358. Bamias A, Kyriakou F, Chorti M, Kavantzias N, Noni A, Kyrouti-Voulgari A, Rontoyianni D, Kastritis E, Xiros N, Patsouris ES, Murray S, Tamvakis N, **Dimopoulos MA**. Microvessel density (MVD) and cyclooxygenase-2 (COX-2)/ beta-catenin interaction are associated with relapse in patients with transitional carcinoma receiving adjuvant chemotherapy with paclitaxel/carboplatin: a hellenic cooperative oncology group (HECOG) study. *Anticancer Res* 2008;28:2479-86.
359. Papadimitriou CA, Peitsidis P, Bozas G, Grimani I, Vlahos G, Rodolakis A, Lianos E, Bamias A, Lainakis G, **Dimopoulos MA**. Paclitaxel- and platinum-based postoperative chemotherapy for primary fallopian tube carcinoma: a single institution experience. *Oncology* 2008;75:42-8.
360. Aravantinos G, Fountzilas G, Bamias A, Grimani I, Rizos S, Kalofonos HP, Skarlos DV, Economopoulos T, Kosmidis PA, Stathopoulos GP, Briasoulis E, Pectasides D, Samantas E, Timotheadou E, Papadimitriou C, Papanikolaou A, Onyenadum A, Papakostas P, Bafaloukos D, **Dimopoulos MA**. Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. *Eur J Cancer* 2008;44:2169-77.
361. Papadimitriou CA, Fountzilas G, Bafaloukos D, Bozas G, Kalofonos H, Pectasides D, Aravantinos G, Bamias A, **Dimopoulos MA**. Paclitaxel, topotecan, and carboplatin in metastatic endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. *Gynecol Oncol* 2008;111:27-34.
362. **Dimopoulos MA**, Kastritis E, Delimpassi S, Zomas A, Kyrtsionis MC, Zervas K. The International Prognostic Scoring System for Waldenstrom's macroglobulinemia is applicable in patients treated with rituximab-based regimens. *Haematologica* 2008;93:1420-2.
363. Mountzios G, Planchard D, Besse B, Validire P, Girard P, Devisme C, **Dimopoulos MA**, Soria JC, Fouret P. Mitogen-activated protein kinase activation in lung adenocarcinoma: a comparative study between ever smokers and never smokers. *Clin Cancer Res* 2008;14:4096-102.
364. **Dimopoulos MA**, Kastritis E, Rosinol L, Blade J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. *Leukemia* 2008;22:1485-93.
365. **Dimopoulos MA**, Kastritis E, Rajkumar SV. Treatment of plasma cell dyscrasias with lenalidomide. *Leukemia* 2008;22:1343-53.
366. Terpos E, Roussou M, **Dimopoulos MA**. Bortezomib in multiple myeloma. *Expert Opin Drug Metab Toxicol* 2008;4:639-54.
367. Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, Barmparousi D, Terpos E, **Dimopoulos MA**. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. *Leuk Lymphoma* 2008;49:890-5.

368. Papadimitriou CA, Bafaloukos D, Bozas G, Kalofonos H, Kosmidis P, Aravantinos G, Fountzilas G, **Dimopoulos MA**. Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study. *Gynecol Oncol* 2008;110:87-92.
369. Lainakis G, Nikos A, Gerassimos A, Michael C, Iraklis M, Konstantinos L, Ioannis V, Harilaos K, **Dimopoulos MA**, Bamias A. Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer. *Urology* 2008;71:1181-5.
370. Anargyrou K, **Dimopoulos MA**, Sezer O, Terpos E. Novel anti-myeloma agents and angiogenesis. *Leuk Lymphoma* 2008;49:677-89.
371. Grapsa E, Triantafyllou N, Rombos A, Lagouranis A, **Dimopoulos MA**. Therapeutic plasma exchange combined with immunomodulating agents in secondary progressive multiple sclerosis patients. *Ther Apher Dial* 2008;12:105-8.
372. Michopoulos S, Petraki K, Matsouka C, Kastritis E, Chrysanthopoulou H, **Dimopoulos MA**. Mantle-cell lymphoma (multiple lymphomatous polyposis) of the entire GI tract. *J Clin Oncol* 2008;26:1555-7.
373. Roussou M, Dimopoulos SK, **Dimopoulos MA**, Anastasiou-Nana MI. Wegener's granulomatosis presenting as a renal mass. *Urology* 2008;71:547 e1-2.
374. Psyrris A, Kountourakis P, Scorilas A, Markakis S, Camp R, Kowalski D, Diamandis EP, **Dimopoulos MA**. Human tissue kallikrein 7, a novel biomarker for advanced ovarian carcinoma using a novel in situ quantitative method of protein expression. *Ann Oncol* 2008;19:1271-7.
375. Anargyrou K, Terpos E, Vassilakopoulos TP, Pouli A, Sachanas S, Tzenou T, Masouridis S, Christoulas D, Angelopoulou MK, Dimitriadou EM, Kalpadakis C, Tsionos K, Panayiotidis P, **Dimopoulos MA**, Pangalis GA, Kyrtsonis MC. Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. *Haematologica* 2008;93:451-4.
376. Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, **Dimopoulos MA**, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. *Blood* 2008;111:4039-47.
377. Economopoulos T, Psyrris A, Fountzilas G, Tsatalas C, Anagnostopoulos A, Papageorgiou S, Xiros N, **Dimopoulos MA**. Phase II study of low-grade non-Hodgkin lymphomas with fludarabine and mitoxantrone followed by rituximab consolidation: promising results in marginal zone lymphoma. *Leuk Lymphoma* 2008;49:68-74.
378. **Dimopoulos MA**, Kastritis E. High dose therapy for light chain amyloidosis: can we reduce treatment related mortality further? *Leuk Lymphoma* 2008;49:4-5.
379. Bamias A, **Dimopoulos MA**. Editorial comment on: new treatment approaches for prostate cancer based on peptide analogues. *Eur Urol* 2008;53:899-900.

380. Mountzios G, **Dimopoulos MA**, Papadimitriou C. Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. *Biomark Insights* 2008;3:219-26.
381. Papaxoinis G, Fountzilas G, Rontogianni D, **Dimopoulos MA**, Pavlidis N, Tsatalas C, Pectasides D, Xiros N, Economopoulos T. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). *Ann Oncol* 2008;19:780-6.
382. Palumbo A, Rajkumar SV, **Dimopoulos MA**, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. *Leukemia* 2008;22:414-23.
383. Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Papatheodoridis G, Archimandritis A, Antsaklis A, **Dimopoulos MA**. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. *Gynecol Oncol* 2008;108:421-7.
384. Papadimitriou C, Dafni U, Anagnostopoulos A, Vlachos G, Voulgaris Z, Rodolakis A, Aravantinos G, Bamias A, Bozas G, Kiosses E, Gourgoulis GM, Efsthathiou E, **Dimopoulos MA**. High-dose melphalan and autologous stem cell transplantation as consolidation treatment in patients with chemosensitive ovarian cancer: results of a single-institution randomized trial. *Bone Marrow Transplant* 2008;41:547-54.
385. Mountzios G, Terpos E, **Dimopoulos MA**. Aurora kinases as targets for cancer therapy. *Cancer Treat Rev* 2008;34:175-82.
386. Kosmidis PA, Kalofonos HP, Christodoulou C, Syrigos K, Makatsoris T, Skarlos D, Bakogiannis C, Nicolaidis C, Bafaloukos D, Bamias A, Samantas E, Xiros N, Boukovinas I, Fountzilas G, **Dimopoulos MA**. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. *Ann Oncol* 2008;19:115-22.
387. Briasoulis E, Fountzilas G, Bamias A, **Dimopoulos MA**, Xiros N, Aravantinos G, Samantas E, Kalofonos H, Makatsoris T, Mylonakis N, Papakostas P, Skarlos D, Varthalitis I, Pavlidis N. Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. *Cancer Chemother Pharmacol* 2008;62:277-84.
388. Bamias A, Bozas G, Antoniou N, Poulias I, Katsifotis H, Skolarikos A, Mitropoulos D, Alamanis C, Alivizatos G, Deliveliotis H, **Dimopoulos MA**. Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. *Eur Urol* 2008;53:323-31.

389. Ikonomidis I, Papadimitriou C, Vamvakou G, Katsichti P, Venetsanou K, Stamatelopoulos K, Papamichael C, **Dimopoulos MA**, Lekakis J. Treatment with granulocyte colony stimulating factor is associated with improvement in endothelial function. *Growth Factors* 2008;26:117-24.
390. Fountzilas G, Dafni U, Gogas H, Linardou H, Kalofonos HP, Briasoulis E, Pectasides D, Samantas E, Bafaloukos D, Stathopoulos GP, Karina M, Papadimitriou C, Skarlos D, Pisanidis N, Papakostas P, Markopoulos C, Tzorakoeleftherakis E, Dimitrakakis K, Makrantonakis P, Xiros N, Polichronis A, Varthalitis I, Karanikiotis C, **Dimopoulos MA**. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. *Ann Oncol* 2008;19:853-60.
391. Zagouri F, Papaefthimiou M, Chalazonitis AN, Antoniou N, **Dimopoulos MA**, Bamias A. Prostate cancer with metastasis to the omentum and massive ascites: a rare manifestation of a common disease. *Onkologie* 2009;32:758-61.
392. Tsiatas ML, Gyftaki R, Liacos C, Politi E, Rodolakis A, **Dimopoulos MA**, Bamias A. Study of T lymphocytes infiltrating peritoneal metastases in advanced ovarian cancer: associations with vascular endothelial growth factor levels and prognosis in patients receiving platinum-based chemotherapy. *Int J Gynecol Cancer* 2009;19:1329-34.
393. **Dimopoulos MA**, Terpos E. Hematology: first-line bortezomib benefits patients with multiple myeloma. *Nat Rev Clin Oncol* 2009;6:683-5.
394. **Dimopoulos MA**, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. *J Clin Oncol* 2009;27:6086-93.
395. Papadimitriou CA, Markaki S, Lianos E, Peitsidis P, Vourli G, Nikitas N, Vlachos G, Rodolakis A, Antsaklis A, **Dimopoulos MA**. Clinicopathological features of primary fallopian tube carcinoma: a single institution experience. *Eur J Gynaecol Oncol* 2009;30:389-95.
396. Savvari P, Peitsidis P, Alevizaki M, **Dimopoulos MA**, Antsaklis A, Papadimitriou CA. Paraneoplastic humorally mediated hypercalcemia induced by parathyroid hormone-related protein in gynecologic malignancies: a systematic review. *Onkologie* 2009;32:517-23.
397. Katodritou E, **Dimopoulos MA**, Zervas K, Terpos E. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma. *Cancer Treat Rev* 2009;35:738-43.
398. Papadimitriou CA, Kalofonos H, Zagouri F, Papakostas P, Bozas G, Makatsoris T, **Dimopoulos MA**, Fountzilas G. Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group. *Oncology* 2009;77:212-6.
399. **Dimopoulos MA**, Mouloupoulos LA, Terpos E. A new pet for myeloma. *Blood* 2009;114:2007-8.

400. **Dimopoulos MA**, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors. *Clin Lymphoma Myeloma* 2009;9:302-6.
401. Christoulas D, Terpos E, **Dimopoulos MA**. Pathogenesis and management of myeloma bone disease. *Expert Rev Hematol* 2009;2:385-98.
402. Lainakis G, Bamias A, Psimenou E, Fountzilias G, **Dimopoulos MA**. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group. *Clin Nephrol* 2009;72:73-8.
403. **Dimopoulos MA**, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. *Leukemia* 2009;23:2147-52.
404. Roussou M, Tasidou A, **Dimopoulos MA**, Kastritis E, Migkou M, Christoulas D, Gavriatopoulou M, Zagouri F, Matsouka C, Anagnostou D, Terpos E. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. *Leukemia* 2009;23:2177-81.
405. Bamias A, Lainakis G, Manios E, Koroboki E, Gyftaki R, Zakopoulos N, **Dimopoulos MA**. Diagnosis and management of hypertension in advanced renal cell carcinoma: prospective evaluation of an algorithm in patients treated with sunitinib. *J Chemother* 2009;21:347-50.
406. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, **Dimopoulos MA**, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). *Leukemia* 2009;23:1904-12.
407. Alevizaki M, Papageorgiou G, Rentziou G, Saltiki K, Marafelia P, Loukari E, Koutras DA, **Dimopoulos MA**. Increasing prevalence of papillary thyroid carcinoma in recent years in Greece: the majority are incidental. *Thyroid* 2009;19:749-54.
408. Gavriatopoulou M, **Dimopoulos MA**, Christoulas D, Migkou M, Iakovaki M, Gkatzamanidou M, Terpos E. Dickkopf-1: a suitable target for the management of myeloma bone disease. *Expert Opin Ther Targets* 2009;13:839-48.
409. Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Blade J, Einsele H, **Dimopoulos MA**, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S. International Myeloma Working Group guidelines for

- the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. *Leukemia* 2009;23:1716-30.
410. Terpos E, Sezer O, Croucher PI, Garcia-Sanz R, Boccadoro M, San Miguel J, Ashcroft J, Blade J, Cavo M, Delforge M, **Dimopoulos MA**, Facon T, Macro M, Waage A, Sonneveld P. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. *Ann Oncol* 2009;20:1303-17.
411. Mountzios G, **Dimopoulos MA**, Bamias A, Vourli G, Kalofonos H, Aravantinos G, Fountzilas G, Papadimitriou CA. Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study. *Ann Oncol* 2009;20:1362-8.
412. **Dimopoulos MA**, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. *Leukemia* 2009;23:1545-56.
413. Episkopou H, Kyrtopoulos SA, Sfrikakis PP, Fousteri M, **Dimopoulos MA**, Mullenders LH, Souliotis VL. Association between transcriptional activity, local chromatin structure, and the efficiencies of both subpathways of nucleotide excision repair of melphalan adducts. *Cancer Res* 2009;69:4424-33.
414. Kastritis E, Palumbo A, **Dimopoulos MA**. Treatment of relapsed/refractory multiple myeloma. *Semin Hematol* 2009;46:143-57.
415. **Dimopoulos MA**, Attal M. Multiple myeloma in the era of novel agents. *Semin Hematol* 2009;46:107-9.
416. **Dimopoulos MA**, Kastritis E, Roussou M, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Tassidou A, Terpos E. Rituximab-based treatments in Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma* 2009;9:59-61.
417. Kastritis E, Zervas K, Repoussis P, Michali E, Katodrytu E, Zomas A, Simeonidis A, Terpos E, Delimbassi S, Vassou A, Gika D, **Dimopoulos MA**. Prognostication in young and old patients with Waldenstrom's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. *Clin Lymphoma Myeloma* 2009;9:50-2.
418. Terpos E, Tasidou A, Kastritis E, Eleftherakis-Papaiakovou E, Gavriatopoulou M, Migkou M, **Dimopoulos MA**. Angiogenesis in Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma* 2009;9:46-9.
419. Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, **Dimopoulos MA**. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. *Expert Opin Biol Ther* 2009;9:465-79.
420. Kastritis E, Charidimou A, Varkaris A, **Dimopoulos MA**. Targeted therapies in multiple myeloma. *Target Oncol* 2009;4:23-36.
421. Bamias A, Lainakis G, Manios E, Koroboki E, Karadimou A, Zakopoulos N, **Dimopoulos MA**. Could rigorous diagnosis and management of hypertension reduce cardiac events in patients

- with renal cell carcinoma treated with tyrosine kinase inhibitors? *J Clin Oncol* 2009;27:2567-9; author reply 9-70.
422. Pectasides D, Papaxoinis G, Fountzilias G, Aravantinos G, Bamias A, Pavlidis N, Kalofonos HP, Timotheadou E, Samantas E, Briasoulis E, Skarlos DV, Economopoulos T, **Dimopoulos MA**. Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG). *Anticancer Res* 2009;29:745-51.
423. Evangelopoulos ME, Toumanidis S, Sotou D, Evangelopoulos C, Mavrikakis M, Alevizaki M, **Dimopoulos MA**. Mitral valve prolapse in young healthy individuals. An early index of autoimmunity? *Lupus* 2009;18:436-40.
424. Stadtmauer EA, Weber DM, Niesvizky R, Belch A, Prince MH, San Miguel JF, Facon T, Olesnyckyj M, Yu Z, Zeldis JB, Knight RD, **Dimopoulos MA**. Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. *Eur J Haematol* 2009;82:426-32.
425. Kountourakis P, Psyrris A, Scorilas A, Markakis S, Kowalski D, Camp RL, Diamandis EP, **Dimopoulos MA**. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. *Thromb Haemost* 2009;101:541-6.
426. Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, **Dimopoulos MA**, Zervas K. Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. *Haematologica* 2009;94:372-9.
427. Migkou M, **Dimopoulos MA**, Gavriatopoulou M, Terpos E. Applications of monoclonal antibodies for the treatment of hematological malignancies. *Expert Opin Biol Ther* 2009;9:207-20.
428. Kastritis E, Zervas K, Symeonidis A, Terpos E, Delimbassi S, Anagnostopoulos N, Michali E, Zomas A, Katodritou E, Gika D, Pouli A, Christoulas D, Roussou M, Kartasis Z, Economopoulos T, **Dimopoulos MA**. Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG). *Leukemia* 2009;23:1152-7.
429. Georgaki S, Skopeliti M, Tsiatas M, Nicolaou KA, Ioannou K, Husband A, Bamias A, **Dimopoulos MA**, Constantinou AI, Tsitsilonis OE. Phenoxodiol, an anticancer isoflavene, induces immunomodulatory effects in vitro and in vivo. *J Cell Mol Med* 2009;13:3929-38.
430. Morel P, Duhamel A, Gobbi P, **Dimopoulos MA**, Dhodapkar MV, McCoy J, Crowley J, Ocio EM, Garcia-Sanz R, Treon SP, Leblond V, Kyle RA, Barlogie B, Merlini G. International prognostic scoring system for Waldenstrom macroglobulinemia. *Blood* 2009;113:4163-70.
431. Kranidiotis GP, Voidonikola PT, **Dimopoulos MA**, Anastasiou-Nana MI. Stauffer's syndrome as a prominent manifestation of renal cancer: a case report. *Cases J* 2009;2:49.
432. Kastritis E, Migkou M, Gavriatopoulou M, Ziropiannis P, Hadjikonstantinou V, **Dimopoulos MA**. Treatment of light chain deposition disease with bortezomib and dexamethasone. *Haematologica* 2009;94:300-2.

433. **Dimopoulos MA**, Gertz MA, Kastritis E, Garcia-Sanz R, Kimby EK, Leblond V, Femand JP, Merlini G, Morel P, Morra E, Ocio EM, Owen R, Ghobrial IM, Seymour J, Kyle RA, Treon SP. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. *J Clin Oncol* 2009;27:120-6.
434. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, **Dimopoulos MA**, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. *Leukemia* 2009;23:215-24.
435. Kastritis E, Murray S, Kyriakou F, Horti M, Tamvakis N, Kavantzias N, Patsouris ES, Noni A, Legaki S, **Dimopoulos MA**, Bamias A. Somatic mutations of adenomatous polyposis coli gene and nuclear b-catenin accumulation have prognostic significance in invasive urothelial carcinomas: evidence for Wnt pathway implication. *Int J Cancer* 2009;124:103-8.
436. Palumbo A, **Dimopoulos MA**, San Miguel J, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. *Blood Rev* 2009;23:87-93.
437. **Dimopoulos MA**, Kastritis E, Bamias C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakevou E, Christoulas D, Terpos E, Bamias A. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. *Ann Oncol* 2009;20:117-20.
438. Fountzilas G, Dafni U, **Dimopoulos MA**, Koutras A, Skarlos D, Papakostas P, Gogas H, Bafaloukos D, Kalogera-Fountzila A, Samantas E, Briasoulis E, Pectasides D, Maniadakis N, Matsiakou F, Aravantinos G, Papadimitriou C, Karina M, Christodoulou C, Kosmidis P, Kalofonos HP. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. *Breast Cancer Res Treat* 2009;115:87-99.
439. Kostopoulou V, Tsiatas ML, Kelekis DA, **Dimopoulos MA**, Papadimitriou CA. Endovascular stenting for the management of port-a-cath associated superior vena cava syndrome. *Emerg Radiol* 2009;16:143-6.
440. Zagouri F, Linardou H, **Dimopoulos MA**, Papadimitriou CA. Management of advanced stage uterine sarcomas: a bone of contention. *Eur J Gynaecol Oncol* 2009;30:483-92.
441. Triantafyllou NI, Grapsa EI, Kararizou E, Psimenou E, Lagguranis A, **Dimopoulos MA**. Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: an eight year follow-up. *Ther Apher Dial* 2009;13:174-8.
442. Zagouri F, **Dimopoulos MA**, Fotiou S, Kouloulis V, Papadimitriou CA. Treatment of early uterine sarcomas: disentangling adjuvant modalities. *World J Surg Oncol* 2009;7:38.
443. Gavalas NG, Karadimou A, **Dimopoulos MA**, Bamias A. Immune response in ovarian cancer: how is the immune system involved in prognosis and therapy: potential for treatment utilization. *Clin Dev Immunol* 2010;2010:791603.

444. **Dimopoulos MA**, Terpos E. Renal insufficiency and failure. Hematology Am Soc Hematol Educ Program 2010;2010:431-6.
445. Kastritis E, **Dimopoulos MA**. High dose melphalan in primary systemic amyloidosis: status quo? Leuk Lymphoma 2010;51:2149-51.
446. **Dimopoulos MA**, Terpos E. Lenalidomide: an update on evidence from clinical trials. Blood Rev 2010;24 Suppl 1:S21-6.
447. Zagouri F, **Dimopoulos MA**, Bournakis E, Papadimitriou CA. Molecular markers in epithelial ovarian cancer: their role in prognosis and therapy. Eur J Gynaecol Oncol 2010;31:268-77.
448. Thomakos N, Papadimitriou CA, Zagouri F, **Dimopoulos MA**, Antsaklis A. Venous thromboembolic events alert for gynecologic neoplasms. Onkologie 2010;33:632-6.
449. **Dimopoulos MA**, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Femand JP, Blade J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010;28:4976-84.
450. **Dimopoulos MA**, Terpos E. Multiple myeloma. Ann Oncol 2010;21 Suppl 7:vii143-50.
451. Delforge M, Blade J, **Dimopoulos MA**, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086-95.
452. Eleutherakis-Papaiakovou E, Kostis E, Migkou M, Christoulas D, Terpos E, Gavriatopoulou M, Roussou M, Bournakis E, Kastritis E, Efstathiou E, **Dimopoulos MA**, Papadimitriou CA. Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: results of a single institution, randomized phase 2 trial. Am J Hematol 2010;85:863-7.
453. Terpos E, **Dimopoulos MA**. Intravenous pamidronate for myeloma bone disease: can the dose be lowered? Lancet Oncol 2010;11:913-4.
454. Savvari P, Matsouka C, Barbaroussi D, Christoulas D, Nikitas N, **Dimopoulos MA**, Papadimitriou CA. Burkitt's lymphoma in pregnancy with bilateral breast involvement: case report with review of the literature. Onkologie 2010;33:461-4.
455. Terpos E, **Dimopoulos MA**, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010;24:1700-12.
456. **Dimopoulos MA**, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkatzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010;24:1769-78.

457. Harousseau JL, Palumbo A, Richardson PG, Schlag R, **Dimopoulos MA**, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, Komarnicki M, Mateos MV, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. *Blood* 2010;116:3743-50.
458. Kastritis E, Roussou M, Michael M, Gavriatopoulou M, Michalis E, Migkou M, Delimpasi S, Kyrtsolis MC, Gogos D, Liapis K, Charitaki E, Repousis P, Terpos E, **Dimopoulos MA**. High levels of serum angiogenic growth factors in patients with AL amyloidosis: comparisons with normal individuals and multiple myeloma patients. *Br J Haematol* 2010;150:587-91.
459. **Dimopoulos MA**, Alegre A, Stadtmauer EA, Goldschmidt H, Zonder JA, de Castro CM, Masliak Z, Reece D, Olesnyckyj M, Yu Z, Weber DM. The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. *Cancer* 2010;116:3807-14.
460. Bamias A, Terpos E, **Dimopoulos MA**. Avascular osteonecrosis of the jaw as a side effect of bisphosphonate treatment. *Onkologie* 2010;33:288-9.
461. Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, Psimenou E, Gika D, Terpos E, **Dimopoulos MA**. Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. *Leuk Res* 2010;34:1395-7.
462. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, **Dimopoulos MA**, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschaffter E, Yellin O, Kyle RA. Monoclonal gammopathy of undetermined significance: a consensus statement. *Br J Haematol* 2010;150:28-38.
463. Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M, Tsionos K, **Dimopoulos MA**. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. *Ann Oncol* 2010;21:1561-2.
464. Terpos E, Katodritou E, Roussou M, Pouli A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A, Symeonidis A, Viniou NA, Anagnostopoulos N, Economopoulos T, Zervas K, **Dimopoulos MA**. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. *Eur J Haematol* 2010;85:114-9.
465. Jagannath S, **Dimopoulos MA**, Lonial S. Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. *Leuk Res* 2010;34:1111-8.
466. Vassilakopoulou M, Mountzios G, Papamechael C, Protogerou AD, Aznaouridis K, Katsichti P, Venetsanou K, **Dimopoulos MA**, Ikonomidis I, Papadimitriou CA. Paclitaxel chemotherapy and vascular toxicity as assessed by flow-mediated and nitrate-mediated vasodilatation. *Vascul Pharmacol* 2010;53:115-21.
467. Harousseau JL, **Dimopoulos MA**, Wang M, Corso A, Chen C, Attal M, Spencer A, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Better quality of response to lenalidomide plus

- dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. *Haematologica* 2010;95:1738-44.
468. Kastritis E, Kyrtonis MC, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas C, Michael M, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gavriatopoulou M, Koulieris E, Gika D, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, **Dimopoulos MA**. Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). *Leuk Res* 2010;34:1340-3.
469. Mouloupoulos LA, **Dimopoulos MA**, Christoulas D, Kastritis E, Anagnostou D, Koureas A, Roussou M, Gavriatopoulou M, Migkou M, Iakovaki M, Gkatzamanidou M, Tasidou A, Terpos E. Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. *Leukemia* 2010;24:1206-12.
470. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kroger N, Einsele H, Vesole DH, **Dimopoulos MA**, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. *Leukemia* 2010;24:1121-7.
471. Mountzios G, Terpos E, Syrigos K, Papadimitriou C, Papadopoulos G, Bamias A, Mavrikakis M, **Dimopoulos MA**. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. *Transl Res* 2010;155:247-55.
472. **Dimopoulos MA**, Chen C, Kastritis E, Gavriatopoulou M, Treon SP. Bortezomib as a treatment option in patients with Waldenstrom macroglobulinemia. *Clin Lymphoma Myeloma Leuk* 2010;10:110-7.
473. Mateos MV, Richardson PG, Schlag R, Khuageva NK, **Dimopoulos MA**, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, SamoiloVA OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. *J Clin Oncol* 2010;28:2259-66.
474. Michael M, Kastritis E, Delimpasi S, Michalis E, Repoussis P, Kyrtonis MC, Katodritou E, Anagnostopoulos N, Zervas K, **Dimopoulos MA**. Clinical characteristics and outcome of primary systemic light-chain amyloidosis in Greece. *Clin Lymphoma Myeloma Leuk* 2010;10:56-61.
475. **Dimopoulos MA**, Christoulas D, Roussou M, Kastritis E, Migkou M, Gavriatopoulou M, Matsouka C, Mparmparoussi D, Psimenou E, Grapsa I, Efstathiou E, Terpos E. Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. *Eur J Haematol* 2010;85:1-5.

476. Bamias A, Karadimou A, Lampaki S, Lainakis G, Malettou L, Timotheadou E, Papazisis K, Andreadis C, Kontovinis L, Anastasiou I, Stravodimos K, Xanthakis I, Skolarikos A, Christodoulou C, Syrigos K, Papandreou C, Razi E, Dafni U, Fountzilas G, **Dimopoulos MA**. Prognostic stratification of patients with advanced renal cell carcinoma treated with sunitinib: comparison with the Memorial Sloan-Kettering prognostic factors model. *BMC Cancer* 2010;10:45.
477. Zagouri F, Bozas G, Kafantari E, Tsiatas M, Nikitas N, **Dimopoulos MA**, Papadimitriou CA. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? *Obstet Gynecol Int* 2010;2010:749579.
478. Bozas G, Terpos E, Gika D, Karadimou A, **Dimopoulos MA**, Bamias A. Prechemotherapy serum levels of CD105, transforming growth factor beta2, and vascular endothelial growth factor are associated with prognosis in patients with advanced epithelial ovarian cancer treated with cytoreductive surgery and platinum-based chemotherapy. *Int J Gynecol Cancer* 2010;20:248-54.
479. Bamias A, Karina M, Papakostas P, Kostopoulos I, Bobos M, Vourli G, Samantas E, Christodoulou C, Pentheroudakis G, Pectasides D, **Dimopoulos MA**, Fountzilas G. A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. *Cancer Chemother Pharmacol* 2010;65:1009-21.
480. Murray S, Linardou H, Mountzios G, Manoloukos M, Markaki S, Eleutherakis-Papaiakovou E, **Dimopoulos MA**, Papadimitriou CA. Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. *Mutat Res* 2010;686:68-73.
481. Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, Papadimitriou C, Rodolakis A, Vlahos G, **Dimopoulos MA**. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. *Cancer* 2010;116:1462-8.
482. Ludwig H, Beksac M, Blade J, Boccadoro M, Cavenagh J, Cavo M, **Dimopoulos MA**, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. *Oncologist* 2010;15:6-25.
483. Kastiris E, Wechalekar AD, **Dimopoulos MA**, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. *J Clin Oncol* 2010;28:1031-7.
484. Karadimou A, Lianos E, Pectasides D, **Dimopoulos MA**, Bamias A. Efficacy of methotrexate/vinblastine/doxorubicin cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis. *Open Access J Urol* 2010;2:193-9.
485. Karadimou A, **Dimopoulos MA**, Bamias A. The role of high-dose chemotherapy in the treatment of testicular cancer. *Open Access J Urol* 2010;2:25-30.
486. Blade J, **Dimopoulos MA**, Rosinol L, Rajkumar SV, Kyle RA. Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome, and follow-up recommendations. *J Clin Oncol* 2010;28:690-7.

487. Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, Siasos G, Papageorgiou N, Papadimitriou CA, **Dimopoulos MA**, Stefanadis C. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. *Atherosclerosis* 2010;210:194-8.
488. Mountzios G, **Dimopoulos MA**, Soria JC, Sanoudou D, Papadimitriou CA. Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: a review of published data. *Crit Rev Oncol Hematol* 2010;75:94-109.
489. Zangari M, Tricot G, Polavaram L, Zhan F, Finlayson A, Knight R, Fu T, Weber D, **Dimopoulos MA**, Niesvizky R, Fink L. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. *J Clin Oncol* 2010;28:132-5.
490. Boskos CS, Liacos C, Korkolis D, Aygerinos K, Lamproglou I, Terpos E, Stoupa E, Baltatzis G, Beroukas K, Papasavvas P, **Dimopoulos MA**, Bamias A. Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. *J Surg Oncol* 2010;102:408-12.
491. Terpos E, **Dimopoulos MA**, Shrivastava V, Leitzel K, Christoulas D, Migkou M, Gavriatopoulou M, Anargyrou K, Hamer P, Kastiris E, Carney W, Lipton A. High levels of serum TIMP-1 correlate with advanced disease and predict for poor survival in patients with multiple myeloma treated with novel agents. *Leuk Res* 2010;34:399-402.
492. Mountzios G, Bamias A, Dalianis A, Danias P, Pantelidaki E, Nanas J, **Dimopoulos MA**. Endocardial metastases as the only site of relapse in a patient with bladder carcinoma: a case report and review of the literature. *Int J Cardiol* 2010;140:e4-7.
493. Thomakos N, Rodolakis A, Belitsos P, Zagouri F, Chatzinikolaou I, **Dimopoulos MA**, Papadimitriou CA, Antsaklis A. Gestational trophoblastic neoplasia with retroperitoneal metastases: a fatal complication. *World J Surg Oncol* 2010;8:114.
494. Kalofoutis C, Mourouzis I, Galanopoulos G, **Dimopoulos MA**, Perimenis P, Spanou D, Cokkinos DV, Singh J, Pantos C. Thyroid hormone can favorably remodel the diabetic myocardium after acute myocardial infarction. *Mol Cell Biochem* 2010;345:161-9.
495. Bakarakos P, Theohari I, Nomikos A, Mylona E, Papadimitriou C, **Dimopoulos MA**, Nakopoulou L. Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. *Histopathology* 2010;56:876-82.
496. Bafaloukos D, Linardou H, Aravantinos G, Papadimitriou C, Bamias A, Fountzilas G, Kalofonos HP, Kosmidis P, Timotheadou E, Makatsoris T, Samantas E, Briasoulis E, Christodoulou C, Papakostas P, Pectasides D, **Dimopoulos MA**. A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. *BMC Med* 2010;8:3.
497. Bamias A, Bamia C, Karadimou A, Soupos N, Zagouri F, Rodolakis A, Haidopoulos D, Vlahos G, Thomakos N, Antsaklis A, **Dimopoulos MA**. A risk-adapted strategy of adjuvant

- paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome. *Oncology* 2011;81:365-71.
498. Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, Gkatzamanidou M, Grapsa I, Psimenou E, Nikitas N, Terpos E, **Dimopoulos MA**. Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens. *Leuk Lymphoma* 2011;52:2299-303.
499. Simou M, Thomakos N, Zagouri F, Vlysmas A, Akrivos N, Zacharakis D, Papadimitriou CA, **Dimopoulos MA**, Rodolakis A, Antsaklis A. Non-blood medical care in gynecologic oncology: a review and update of blood conservation management schemes. *World J Surg Oncol* 2011;9:142.
500. **Dimopoulos MA**, Terpos E. Advances in the treatment of multiple myeloma. *Eur J Cancer* 2011;47 Suppl 3:S306-8.
501. Karadimou A, Migou M, Economidi A, Stratigos A, Kittas C, **Dimopoulos MA**, Bamias A. Leukocytoclastic vasculitis after long-term treatment with sunitinib: a case report. *Case Rep Oncol* 2011;4:385-91.
502. Spicka I, Mateos MV, Redman K, **Dimopoulos MA**, Richardson PG. An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantation. *Immunotherapy* 2011;3:1033-40.
503. Gkatzamanidou M, Kastritis E, Gavriatopoulou MR, Nikitas N, Gika D, Mparmparousi D, Matsouka C, Terpos E, **Dimopoulos MA**. Increased serum lactate dehydrogenase should be included among the variables that define very-high-risk multiple myeloma. *Clin Lymphoma Myeloma Leuk* 2011;11:409-13.
504. Palumbo A, Bringhen S, Ludwig H, **Dimopoulos MA**, Blade J, Mateos MV, Rosinol L, Boccadoro M, Cavo M, Lokhorst H, Zweegman S, Terpos E, Davies F, Driessen C, Gimsing P, Gramatzki M, Hajek R, Johnsen HE, Leal Da Costa F, Sezer O, Spencer A, Beksac M, Morgan G, Einsele H, San Miguel JF, Sonneveld P. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). *Blood* 2011;118:4519-29.
505. Ishak KJ, Caro JJ, Drayson MT, **Dimopoulos MA**, Weber D, Augustson B, Child JA, Knight R, Iqbal G, Dunn J, Shearer A, Morgan G. Adjusting for patient crossover in clinical trials using external data: a case study of lenalidomide for advanced multiple myeloma. *Value Health* 2011;14:672-8.
506. Kastritis E, **Dimopoulos MA**. Prognosis and risk assessment in AL amyloidosis--state of the art. *Amyloid* 2011;18 Suppl 1:89-91.
507. Migkou M, Gkatzamanidou M, Terpos E, **Dimopoulos MA**, Kastritis E. Response to bortezomib of a patient with scleromyxedema refractory to other therapies. *Leuk Res* 2011;35:e209-11.
508. Zagouri F, Roussou M, Kastritis E, Koureas A, Tsokou E, Migkou M, Gavriatopoulou M, Nikitas N, Gkatzamanidou M, Terpos E, **Dimopoulos MA**. Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias. *Am J Hematol* 2011;86:882-4.

509. Psaltopoulou T, Kosti RI, Haidopoulos D, **Dimopoulos MA**, Panagiotakos DB. Olive oil intake is inversely related to cancer prevalence: a systematic review and a meta-analysis of 13,800 patients and 23,340 controls in 19 observational studies. *Lipids Health Dis* 2011;10:127.
510. **Dimopoulos MA**, Kastritis E. Bortezomib for AL amyloidosis: moving forward. *Blood* 2011;118:827-8.
511. Terpos E, **Dimopoulos MA**. Zoledronic acid for all patients with newly diagnosed multiple myeloma? *Lancet Oncol* 2011;12:711-2.
512. Kastritis E, Zagouri F, **Dimopoulos MA**, Papadimitriou CA. Carcinomatous meningitis from transitional cell carcinoma of the urinary bladder. *J BUON* 2011;16:373-4.
513. Bamias A, Karadimou A, Soupos N, Sotiropoulou M, Zagouri F, Haidopoulos D, Thomakos N, Rodolakis A, Antsaklis A, **Dimopoulos MA**. Prognostic factors for early-stage epithelial ovarian cancer, treated with adjuvant carboplatin/paclitaxel chemotherapy: a single institution experience. *Gynecol Oncol* 2011;123:37-42.
514. Episkopou H, Kyrtopoulos SA, Sfrikakis PP, **Dimopoulos MA**, Souliotis VL. The repair of melphalan-induced DNA adducts in the transcribed strand of active genes is subject to a strong polarity effect. *Mutat Res* 2011;714:78-87.
515. Drivalos A, Papatsoris AG, Chrisofos M, Efstathiou E, **Dimopoulos MA**. The role of the cell adhesion molecules (integrins/cadherins) in prostate cancer. *Int Braz J Urol* 2011;37:302-6.
516. **Dimopoulos MA**, Hussein M, Swern AS, Weber D. Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. *Leukemia* 2011;25:1620-6.
517. Bournakis E, **Dimopoulos MA**, Bamias A. Management of advanced bladder cancer in patients with impaired renal function. *Expert Rev Anticancer Ther* 2011;11:931-9.
518. Such E, Cervera J, Terpos E, Bagan JV, Avaria A, Gomez I, Margaix M, Ibanez M, Luna I, Cordon L, Roig M, Sanz MA, **Dimopoulos MA**, de la Rubia J. CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. *Haematologica* 2011;96:1557-9.
519. Zagouri F, Papadimitriou CA, **Dimopoulos MA**, Pectasides D. Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. *Cancer Treat Rev* 2011;37:599-610.
520. Kontou N, Psaltopoulou T, Panagiotakos D, **Dimopoulos MA**, Linos A. The mediterranean diet in cancer prevention: a review. *J Med Food* 2011;14:1065-78.
521. Vassilakopoulou M, de la Motte Rouge T, Colin P, Ouzzane A, Khayat D, **Dimopoulos MA**, Papadimitriou CA, Bamias A, Pignot G, Nouhaud FX, Hurel S, Guy L, Bigot P, Roumiguie M, Roupret M. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. *Cancer* 2011;117:5500-8.
522. Migkou M, Kastritis E, Roussou M, Gkatzamanidou M, Gavriatopoulou M, Nikitas N, Mparmparoussi D, Matsouka C, Gika D, Terpos E, **Dimopoulos MA**. Short progression-free

- survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy. *Eur J Haematol* 2011;87:323-9.
523. Bamias A, Manios E, Karadimou A, Michas F, Lainakis G, Constantinidis C, Deliveliotis C, Zakopoulos N, **Dimopoulos MA**. The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer. *Eur J Cancer* 2011;47:1660-8.
524. Lainakis G, Zagouri F, Kastritis E, Sergentanis TN, Bozas G, **Dimopoulos MA**, Papadimitriou CA. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. *Tumori* 2011;97:25-9.
525. Kastritis E, Kyrtsolis MC, Hatjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Michael M, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gavriatopoulou M, Koulieris E, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, **Dimopoulos MA**. No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years. *Am J Hematol* 2011;86:479-83.
526. Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Bamias A, **Dimopoulos MA**. Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. *Anticancer Res* 2011;31:1475-82.
527. Lymvaivos I, Mourouzis I, Cokkinos DV, **Dimopoulos MA**, Toumanidis ST, Pantos C. Thyroid hormone and recovery of cardiac function in patients with acute myocardial infarction: a strong association? *Eur J Endocrinol* 2011;165:107-14.
528. Terpos E, Mouloupoulos LA, **Dimopoulos MA**. Advances in imaging and the management of myeloma bone disease. *J Clin Oncol* 2011;29:1907-15.
529. Kastritis E, Gavriatopoulou M, Kyrtsolis MC, Michael M, Hadjiharissi E, Symeonidis A, Michalis E, Repoussis P, Tsatalas K, Sioni A, Kartasis Z, Stefanoudaki E, Voulgarelis M, Delimpasi S, Gika D, Vervesou E, Konstantopoulos K, Kokkini G, Zomas A, Roussou P, Anagnostopoulos N, Economopoulos T, Terpos E, Zervas K, **Dimopoulos MA**. Prognostication of the high-risk WM patient. *Clin Lymphoma Myeloma Leuk* 2011;11:127-9.
530. Terpos E, Tasidou A, Eleftherakis-Papaiakovou E, Christoulas D, Gavriatopoulou M, Gkatzamanidou M, Roussou M, Kastritis E, Papadaki T, **Dimopoulos MA**. Expression of CCL3 by neoplastic cells in patients with Waldenstrom's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients. *Clin Lymphoma Myeloma Leuk* 2011;11:115-7.
531. **Dimopoulos MA**, Mitsiades CS, Anderson KC, Richardson PG. Tanespimycin as antitumor therapy. *Clin Lymphoma Myeloma Leuk* 2011;11:17-22.
532. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orłowski R, Blade J, Sezer O, Ludwig H, **Dimopoulos MA**, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. *Blood* 2011;117:6063-73.

533. Ludwig H, Beksac M, Blade J, Cavenagh J, Cavo M, Delforge M, **Dimopoulos MA**, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. *Oncologist* 2011;16:388-403.
534. Coleman R, Costa L, Saad F, Cook R, Hadji P, Terpos E, Garnero P, Brown J, Body JJ, Smith M, Lee KA, Major P, **Dimopoulos MA**, Lipton A. Consensus on the utility of bone markers in the malignant bone disease setting. *Crit Rev Oncol Hematol* 2011;80:411-32.
535. Richardson P, Schlag R, Khuageva N, **Dimopoulos MA**, Shpilberg O, Kropff M, Vekemans MC, Petrucci MT, Rossiev V, Hou J, Robak T, Mateos MV, Anderson K, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF. Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. *Br J Haematol* 2011;153:212-21.
536. Terpos E, **Dimopoulos MA**, Berenson J. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease. *Crit Rev Oncol Hematol* 2011;77 Suppl 1:S13-23.
537. Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R, **Dimopoulos MA**, Kropff M, Spicka I, Petrucci MT, SamoiloVA OS, Mateos MV, Magen-Nativ H, Goldschmidt H, Esseltine DL, Ricci DS, Liu K, Deraedt W, Cakana A, van de Velde H, San Miguel JF. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma. *Eur J Haematol* 2011;86:372-84.
538. Zagouri F, **Dimopoulos MA**, Thomakos N, Chrysikos D, Papadimitriou CA. Sarcomas of the fallopian tube: disentangling a rare entity. *Onkologie* 2011;34:132-8.
539. Kastritis E, Terpos E, **Dimopoulos MA**. Emerging drugs for Waldenstrom's macroglobulinemia. *Expert Opin Emerg Drugs* 2011;16:45-57.
540. **Dimopoulos MA**, Palumbo A, Attal M, Beksac M, Davies FE, Delforge M, Einsele H, Hajek R, Harousseau JL, da Costa FL, Ludwig H, Mellqvist UH, Morgan GJ, San-Miguel JF, Zweegman S, Sonneveld P. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. *Leukemia* 2011;25:749-60.
541. **Dimopoulos MA**, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksac M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giral S, Munshi NC, Jagannath S. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. *Blood* 2011;117:4701-5.
542. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, **Dimopoulos MA**, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H. Consensus

recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. *Blood* 2011;117:4696-700.

543. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, **Dimopoulos MA**, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood* 2011;117:4691-5.
544. Papadimitriou CA, Papakostas P, Karina M, Malettou L, **Dimopoulos MA**, Pentheroudakis G, Samantas E, Bamias A, Miliaras D, Basdanis G, Xiros N, Klouvas G, Bafaloukos D, Kafiri G, Papaspirou I, Pectasides D, Karanikiotis C, Economopoulos T, Efstratiou I, Korantzis I, Pisanidis N, Makatsoris T, Matsiakou F, Aravantinos G, Kalofonos HP, Fountzilas G. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. *BMC Med* 2011;9:10.
545. San-Miguel JF, **Dimopoulos MA**, Stadtmauer EA, Rajkumar SV, Siegel D, Bravo ML, Olesnyckyj M, Knight RD, Zeldis JB, Harousseau JL, Weber DM. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. *Clin Lymphoma Myeloma Leuk* 2011;11:38-43.
546. Mountzios I, Bournakis E, Efstathiou E, Varkaris A, Wen S, Chrisofos M, Deliveliotis C, Alamanis C, Anastasiou I, Constantinides C, Karadimou A, Tsiatas M, Papadimitriou C, Bamias A, **Dimopoulos MA**. Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. *Urology* 2011;77:682-7.
547. Christoulas D, Matsouka C, Chatzinikolaou I, Barmparoussi D, **Dimopoulos MA**, Papadimitriou CA. Relapse of ovarian cancer with bone marrow infiltration and concurrent emergence of therapy-related acute myeloid leukemia: a case report. *J Clin Oncol* 2011;29:e295-6.
548. Terpos E, **Dimopoulos MA**. Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications. *Cancer Immunol Immunother* 2011;60:305-17.
549. Grass S, Preuss KD, Wikowicz A, Terpos E, Ziepert M, Nikolaus D, Yang Y, Fadle N, Regitz E, **Dimopoulos MA**, Treon SP, Hunter ZR, Pfreundschuh M. Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia. *Blood* 2011;117:2918-23.
550. Tousoulis D, Andreou I, Tsiatas M, Miliou A, Tentolouris C, Siasos G, Papageorgiou N, Papadimitriou CA, **Dimopoulos MA**, Stefanadis C. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. *Atherosclerosis* 2011;214:151-7.
551. **Dimopoulos MA**, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. *Eur J Haematol* 2011;86:1-15.
552. Kosmidis PA, Fountzilas G, Eleftheraki AG, Kalofonos HP, Pentheroudakis G, Skarlos D, **Dimopoulos MA**, Bafaloukos D, Pectasides D, Samantas E, Boukovinas J, Lambaki S,

- Katirtzoglou N, Bakogiannis C, Syrigos KN. Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). *Ann Oncol* 2011;22:827-34.
553. **Dimopoulos MA**, Mateos MV, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine DL, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. *Eur J Haematol* 2011;86:23-31.
554. van de Donk NW, Lokhorst HM, **Dimopoulos MA**, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Blade J, San-Miguel JF, Palumbo A. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. *Cancer Treat Rev* 2011;37:266-83.
555. Mountzios G, Pectasides D, Bournakis E, Pectasides E, Bozas G, **Dimopoulos MA**, Papadimitriou CA. Developments in the systemic treatment of endometrial cancer. *Crit Rev Oncol Hematol* 2011;79:278-92.
556. Bamias A, Aravantinos G, Kastriotis I, Alivizatos G, Anastasiou I, Christodoulou C, Gyftaki R, Kalofonos HP, **Dimopoulos MA**. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group. *Urol Oncol* 2011;29:189-93.
557. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, **Dimopoulos MA**, Driver WR, Dunnebie T, Durcan L, Eccles D, Edlund CK, Ekici AB, Fasching PA, Feigelson HS, Flesch-Janys D, Fostira F, Forsti A, Fountzilas G, Gerty SM, Giles GG, Godwin AK, Goodfellow P, Graham N, Greco D, Hamann U, Hankinson SE, Hartmann A, Hein R, Heinz J, Holbrook A, Hoover RN, Hu JJ, Hunter DJ, Ingles SA, Irwanto A, Ivanovich J, John EM, Johnson N, Jukkola-Vuorinen A, Kaaks R, Ko YD, Kolonel LN, Konstantopoulou I, Kosma VM, Kulkarni S, Lambrechts D, Lee AM, Marchand LL, Lesnick T, Liu J, Lindstrom S, Mannermaa A, Margolin S, Martin NG, Miron P, Montgomery GW, Nevanlinna H, Nickels S, Nyante S, Olswold C, Palmer J, Pathak H, Pectasides D, Perou CM, Peto J, Pharoah PD, Pooler LC, Press MF, Pylkas K, Rebbeck TR, Rodriguez-Gil JL, Rosenberg L, Ross E, Rudiger T, Silva Idos S, Sawyer E, Schmidt MK, Schulz-Wendtland R, Schumacher F, Severi G, Sheng X, Signorello LB, Sinn HP, Stevens KN, Southey MC, Tapper WJ, Tomlinson I, Hogervorst FB, Wauters E, Weaver J, Wildiers H, Winqvist R, Van Den Berg D, Wan P, Xia LY, Yannoukakos D, Zheng W, Ziegler RG, Siddiq A, Slager SL, Stram DO, Easton D, Kraft P, Henderson BE, Couch FJ. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nat Genet* 2011;43:1210-4.
558. Fountzilas G, Kourea HP, Bobos M, Televantou D, Kotoula V, Papadimitriou C, Papazisis KT, Timotheadou E, Efstratiou I, Koutras A, Pentheroudakis G, Christodoulou C, Aravantinos G, Miliaras D, Petraki K, Papandreou CN, Papakostas P, Bafaloukos D, Repana D, Razis E, Pectasides D, **Dimopoulos MA**. Paclitaxel and bevacizumab as first line combined treatment in

- patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. *Anticancer Res* 2011;31:3007-18.
559. Stevens KN, Vachon CM, Lee AM, Slager S, Lesnick T, Olswold C, Fasching PA, Miron P, Eccles D, Carpenter JE, Godwin AK, Ambrosone C, Winqvist R, Brauch H, Schmidt MK, Cox A, Cross SS, Sawyer E, Hartmann A, Beckmann MW, Schulz-Wendtland R, Ekici AB, Tapper WJ, Gerty SM, Durcan L, Graham N, Hein R, Nickels S, Flesch-Janys D, Heinz J, Sinn HP, Konstantopoulou I, Fostira F, Pectasides D, **Dimopoulos MA**, Fountzilas G, Clarke CL, Balleine R, Olson JE, Fredericksen Z, Diasio RB, Pathak H, Ross E, Weaver J, Rudiger T, Forsti A, Dunnebie T, Ademuyiwa F, Kulkarni S, Pylkas K, Jukkola-Vuorinen A, Ko YD, Van Limbergen E, Janssen H, Peto J, Fletcher O, Giles GG, Baglietto L, Verhoef S, Tomlinson I, Kosma VM, Beesley J, Greco D, Blomqvist C, Irwanto A, Liu J, Blows FM, Dawson SJ, Margolin S, Mannermaa A, Martin NG, Montgomery GW, Lambrechts D, dos Santos Silva I, Severi G, Hamann U, Pharoah P, Easton DF, Chang-Claude J, Yannoukakos D, Nevanlinna H, Wang X, Couch FJ. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. *Cancer Res* 2011;71:6240-9.
560. Iakovou I, **Dimopoulos MA**, Dangas G. Normal to normal: a method of treatment of coronary aneurysms with deployment of bare-metal stents. *J Invasive Cardiol* 2011;23:E121-5.
561. Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Ioannou K, Ziogas AC, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Terpos E, Antsaklis A, **Dimopoulos MA**, Bamias A. VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. *Br J Cancer* 2012;107:1869-75.
562. Nikitas N, Karadimou A, Tsitoura E, Soupos N, Tsiatas M, Karavasilis V, Pectasides D, Pavlidis N, Chrisofos M, Adamakis I, Murray S, Fountzilas G, **Dimopoulos MA**, Bamias A. Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study. *Pharmacogenomics* 2012;13:1595-607.
563. Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastiris E, **Dimopoulos MA**, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. *J Clin Oncol* 2012;30:4541-9.
564. Kastiris E, **Dimopoulos MA**. VWF, WM, and angiogenesis: is there a link? *Blood* 2012;120:3163-4.
565. Zagouri F, Dimitrakakis C, **Dimopoulos MA**, Tsigginou A, Antsaklis A, Papadimitriou CA. A woman with breast cancer and severe impaired lactose tolerance: an intriguing therapeutic dilemma. *Breast J* 2012;18:628-9.
566. Colombo N, Kutarska E, **Dimopoulos MA**, Bae DS, Rzepka-Gorska I, Bidzinski M, Scambia G, Engelholm SA, Joly F, Weber D, El-Hashimy M, Li J, Souami F, Wing P, Engelholm S, Bamias A, Schwartz P. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. *J Clin Oncol* 2012;30:3841-7.

567. Zis P, Spengos K, Manios E, Vemmos K, Zis V, **Dimopoulos MA**, Zakopoulos N. Ambulatory blood pressure monitoring in acute stroke: the importance of time rate of blood pressure variation. *Blood Press Monit* 2012;17:220-1; author reply 1-2.
568. Terpos E, Kastritis E, **Dimopoulos MA**. Prevention and treatment of myeloma bone disease. *Curr Hematol Malig Rep* 2012;7:249-57.
569. Kastritis E, **Dimopoulos MA**, Blade J. Evolving chemotherapy options for the treatment of myeloma kidney: a 40-year perspective. *Adv Chronic Kidney Dis* 2012;19:312-23.
570. Gkatzamanidou M, **Dimopoulos MA**, Kastritis E, Christoulas D, Mouloupoulos LA, Terpos E. Sclerostin: a possible target for the management of cancer-induced bone disease. *Expert Opin Ther Targets* 2012;16:761-9.
571. Chanan-Khan AA, Lonial S, Weber D, Borrello I, Foa R, Hellmann A, **Dimopoulos MA**, Swern AS, Knight R. Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥ 65 years old with relapsed or refractory multiple myeloma. *Int J Hematol* 2012;96:254-62.
572. Terpos E, Asli B, Christoulas D, Brouet JC, Kastritis E, Rybojad M, Bengoufa D, **Dimopoulos MA**, Femand JP. Increased angiogenesis and enhanced bone formation in patients with IgM monoclonal gammopathy and urticarial skin rash: new insight into the biology of Schnitzler syndrome. *Haematologica* 2012;97:1699-703.
573. Fountzilias G, Dafni U, Bobos M, Batistatou A, Kotoula V, Trihia H, Malamou-Mitsi V, Miliaras S, Chrisafi S, Papadopoulos S, Sotiropoulou M, Filippidis T, Gogas H, Koletsa T, Bafaloukos D, Televantou D, Kalogeras KT, Pectasides D, Skarlos DV, Koutras A, **Dimopoulos MA**. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. *PLoS One* 2012;7:e37946.
574. Nicolatou-Galitis O, Migkou M, Psyrris A, Bamias A, Pectasides D, Economopoulos T, Raber-Durlacher JE, Dimitriadis G, **Dimopoulos MA**. Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2012;113:234-8.
575. Levidou G, Ventouri K, Nonni A, Gakiopoulou H, Bamias A, Sotiropoulou M, Papaspiro I, **Dimopoulos MA**, Patsouris E, Korkolopoulou P. Replication protein A in nonearly ovarian adenocarcinomas: correlation with MCM-2, MCM-5, Ki-67 index and prognostic significance. *Int J Gynecol Pathol* 2012;31:319-27.
576. Mouloupoulos LA, **Dimopoulos MA**, Kastritis E, Christoulas D, Gkatzamanidou M, Roussou M, Koureas A, Migkou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Gika D, Koutoulidis V, Terpos E. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. *Am J Hematol* 2012;87:861-4.
577. **Dimopoulos MA**, Terpos E, Goldschmidt H, Alegre A, Mark T, Niesvizky R. Treatment with lenalidomide and dexamethasone in patients with multiple myeloma and renal impairment. *Cancer Treat Rev* 2012;38:1012-9.

578. Thomakos N, Zacharakis D, Akrivos N, Zagouri F, Simou M, Bamias A, **Dimopoulos MA**, Rodolakis A, Antsaklis A. Merkel cell carcinoma in pelvic lymph nodes after surgical staging for endometrial cancer: A case report and review of the literature. *Int J Surg Case Rep* 2012;3:340-2.
579. Ludwig H, Avet-Loiseau H, Blade J, Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi S, **Dimopoulos MA**, Drach J, Einsele H, Facon T, Goldschmidt H, Hess U, Mellqvist UH, Moreau P, San-Miguel J, Sondergeld P, Sonneveld P, Udvardy M, Palumbo A. European perspective on multiple myeloma treatment strategies: update following recent congresses. *Oncologist* 2012;17:592-606.
580. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Blade J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, **Dimopoulos MA**. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. *N Engl J Med* 2012;366:1759-69.
581. Tasidou A, Roussou M, Terpos E, Kastritis E, Gkatzamanidou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Nikitas N, Anagnostou D, **Dimopoulos MA**. Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents. *Am J Hematol* 2012;87:734-6.
582. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, Marinaki S, Apostolou T, Nikitas N, Gkortzolidis G, Michalis E, Delimpasi S, **Dimopoulos MA**. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. *Blood* 2012;119:5384-90.
583. Terpos E, Kastritis E, Christoulas D, Gkatzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, **Dimopoulos MA**. Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. *Ann Oncol* 2012;23:2681-6.
584. **Dimopoulos MA**, Kastritis E, Delimpasi S, Katodritou E, Hatzimichael E, Kyrtsolis MC, Repousis P, Tsirogianni M, Kartasis Z, Parcharidou A, Michael M, Michalis E, Tsatalas C, Stefanoudaki E, Hatjiharissi E, Gika D, Symeonidis A, Terpos E, Zervas K. Multiple myeloma in octogenarians: clinical features and outcome in the novel agent era. *Eur J Haematol* 2012;89:10-5.
585. Stefanou DT, Episkopou H, Kyrtopoulos SA, Bamias A, Gkatzamanidou M, Bamia C, Liakou C, Bekyrou M, Sfrikakis PP, **Dimopoulos MA**, Souliotis VL. Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs. *Br J Clin Pharmacol* 2012;74:842-53.
586. Zagouri F, Thomakos N, Rodolakis A, Bamias A, Chalazonitis A, Sotiropoulou M, Antsaklis A, **Dimopoulos MA**, Papadimitriou CA. Quiz case: a 19-year-old woman with hypercalcemia and abdominal pain. *Onkologie* 2012;35:126-7.

587. Chanan-Khan AA, San Miguel JF, Jagannath S, Ludwig H, **Dimopoulos MA**. Novel therapeutic agents for the management of patients with multiple myeloma and renal impairment. *Clin Cancer Res* 2012;18:2145-63.
588. **Dimopoulos MA**, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, Morgan GJ. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. *Blood* 2012;119:2764-7.
589. Vassilakopoulos TP, Pangalis GA, Katsigiannis A, Papageorgiou SG, Constantinou N, Terpos E, Zorbala A, Vrakidou E, Repoussis P, Poziopoulos C, Galani Z, Dimopoulou MN, Kokoris SI, Sachanas S, Kalpadakis C, Dimitriadou EM, Siakantaris MP, Kyrtsonis MC, Dervenoulas J, **Dimopoulos MA**, Meletis J, Roussou P, Panayiotidis P, Beris P, Angelopoulou MK. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. *Oncologist* 2012;17:239-49.
590. Kastritis E, **Dimopoulos MA**. When a little aspirin may be enough. *Blood* 2012;119:905-6.
591. Kosmidis PA, Syrigos K, Kalofonos HP, **Dimopoulos MA**, Skarlos D, Pavlidis N, Boukovinas I, Bafaloukos D, Pectasides D, Bacoyiannis C, Fountzilas G. Vinorelbine versus paclitaxel for patients with advanced non-small cell lung cancer (NSCLC) and a performance status of 2. *Anticancer Res* 2012;32:175-81.
592. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orłowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, **Dimopoulos MA**, Lonial S, Jagannath S, Blade J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. *Leukemia* 2012;26:595-608.
593. Gogas H, Dafni U, Karina M, Papadimitriou C, Batistatou A, Bobos M, Kalofonos HP, Eleftheraki AG, Timotheadou E, Bafaloukos D, Christodoulou C, Markopoulos C, Briasoulis E, Papakostas P, Samantas E, Kosmidis P, Stathopoulos GP, Karanikiotis C, Pectasides D, **Dimopoulos MA**, Fountzilas G. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. *Breast Cancer Res Treat* 2012;132:609-19.
594. Palumbo A, Blade J, Boccadoro M, Palladino C, Davies F, **Dimopoulos MA**, Dmoszynska A, Einsele H, Moreau P, Sezer O, Spencer A, Sonneveld P, San Miguel J. How to manage neutropenia in multiple myeloma. *Clin Lymphoma Myeloma Leuk* 2012;12:5-11.
595. Stefanadis C, Synetos A, Tousoulis D, Tsiamis E, Michelongona A, Zagouri F, Bamias A, **Dimopoulos MA**, Kyvelou S, Kapelakis I, Toutouzas K. Systemic administration of bevacizumab increases the risk of cardiovascular events in patients with metastatic cancer. *Int J Cardiol* 2012;154:341-4.
596. Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkatzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, **Dimopoulos MA**. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in

- symptomatic myeloma: reduction post-bortezomib monotherapy. *Int J Cancer* 2012;131:1466-71.
597. Bamias A, Sotiropoulou M, Zagouri F, Trachana P, Sakellariou K, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, **Dimopoulos MA**. Prognostic evaluation of tumour type and other histopathological characteristics in advanced epithelial ovarian cancer, treated with surgery and paclitaxel/carboplatin chemotherapy: cell type is the most useful prognostic factor. *Eur J Cancer* 2012;48:1476-83.
598. Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, **Dimopoulos MA**, Papadimitriou C. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. *Cancer Treat Rev* 2012;38:473-83.
599. **Dimopoulos MA**, Kastritis E, Michalis E, Tsatalas C, Michael M, Pouli A, Kartasis Z, Delimpasi S, Gika D, Zomas A, Roussou M, Konstantopoulos K, Parcharidou A, Zervas K, Terpos E. The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal function. *Ann Oncol* 2012;23:722-9.
600. Terpos E, Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, Christoulas D, Pouli A, Michalis E, Delimpasi S, Gkatzamanidou M, Nikitas N, Koumoustiotis V, Margaritis D, Tsionos K, Stefanoudaki E, Meletis J, Zervas K, **Dimopoulos MA**. Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. *Int J Cancer* 2012;130:735-42.
601. Ziogas AC, Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Terpos E, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Antsaklis A, **Dimopoulos MA**, Bamias A. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. *Int J Cancer* 2012;130:857-64.
602. Kontovinis L, Laschos K, Karadimou A, Andreadis C, Bamias A, Paraskevopoulos P, **Dimopoulos MA**, Papazisis K. Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study. *Med Oncol* 2012;29:750-4.
603. Zagouri F, Sergentanis TN, Gazouli M, Tsigginou A, Dimitrakakis C, Papaspyrou I, Eleutherakis-Papaiakovou E, Chrysikos D, Theodoropoulos G, Zografos GC, Antsaklis A, **Dimopoulos MA**, Papadimitriou CA. HSP90, HSPA8, HIF-1 alpha and HSP70-2 polymorphisms in breast cancer: a case-control study. *Mol Biol Rep* 2012;39:10873-9.
604. Zagouri F, Sergentanis TN, Gazouli M, Tsigginou A, Dimitrakakis C, Eleutherakis-Papaiakovou E, Papaspyrou I, Chrysikos D, Theodoropoulos G, Zografos GC, Antsaklis A, **Dimopoulos MA**, Papadimitriou CA. HTERT MNS16A polymorphism in breast cancer: a case-control study. *Mol Biol Rep* 2012;39:10859-63.
605. Pectasides D, Papaxoinis G, Kotoula V, Fountzilas H, Korantzis I, Koutras A, **Dimopoulos MA**, Papakostas P, Aravantinos G, Varthalitis I, Kosmidis P, Skarlos D, Bournakis E, Bafaloukos D, Kalofonos HP, Kalogeras KT, Fountzilas G. Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study. *Oncol Rep* 2012;27:216-24.

606. Dimitrakakis C, Zagouri F, Tsigginou A, Marinopoulos S, Sergentanis TN, Keramopoulos A, Zografos GC, Ampela K, Mpaltas D, Papadimitriou C, **Dimopoulos MA**, Antsaklis A. Does pregnancy-associated breast cancer imply a worse prognosis? A matched case-case study. *Breast Care (Basel)* 2013;8:203-7.
607. Gkatzamanidou M, Christoulas D, Souliotis VL, Papatheodorou A, **Dimopoulos MA**, Terpos E. Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma. *Med Sci Monit* 2013;19:1188-94.
608. **Dimopoulos MA**, Kastritis E, Terpos E. Non-secretory myeloma: one, two, or more entities? *Oncology (Williston Park)* 2013;27:930-2.
609. Buske C, Leblond V, **Dimopoulos MA**, Kimby E, Jager U, Dreyling M. Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2013;24 Suppl 6:vi155-9.
610. **Dimopoulos MA**, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. *Lancet Oncol* 2013;14:1129-40.
611. Palladini G, Dispenzieri A, Gertz M, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, **Dimopoulos MA**, Jaccard A, Klersy C, Merlini G. Reply to S. Girnius et al. *J Clin Oncol* 2013;31:2750-1.
612. San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, **Dimopoulos MA**. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. *Lancet Oncol* 2013;14:1055-66.
613. **Dimopoulos MA**, Garcia-Sanz R, Gavriatopoulou M, Morel P, Kyrtsolis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Kastritis E, Sonneveld P. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). *Blood* 2013;122:3276-82.
614. Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, **Dimopoulos MA**, Dreyling M. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2013;24 Suppl 6:vi133-7.
615. Pentheroudakis G, Kotoula V, Eleftheraki AG, Tsolaki E, Wirtz RM, Kalogeras KT, Batistatou A, Bobos M, **Dimopoulos MA**, Timotheadou E, Gogas H, Christodoulou C, Papadopoulou K, Efstratiou I, Scopa CD, Papaspyrou I, Vlachodimitropoulos D, Linardou H, Samantas E, Pectasides D, Pavlidis N, Fountzilas G. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). *PLoS One* 2013;8:e70634.

616. Gavalas NG, Lontos M, Trachana SP, Bagratuni T, Arapinis C, Liacos C, **Dimopoulos MA**, Bamias A. Angiogenesis-related pathways in the pathogenesis of ovarian cancer. *Int J Mol Sci* 2013;14:15885-909.
617. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, **Dimopoulos MA**, Psaltopoulou T. Hsp90 inhibitors in breast cancer: a systematic review. *Breast* 2013;22:569-78.
618. Terpos E, Christoulas D, Kastritis E, Katodritou E, Pouli A, Michalis E, Papassotiriou I, **Dimopoulos MA**. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations? *Eur J Haematol* 2013;91:347-55.
619. Zagouri F, Psaltopoulou T, Dimitrakakis C, Bartsch R, **Dimopoulos MA**. Challenges in managing breast cancer during pregnancy. *J Thorac Dis* 2013;5 Suppl 1:S62-7.
620. **Dimopoulos MA**, Terpos E, Niesvizky R. How lenalidomide is changing the treatment of patients with multiple myeloma. *Crit Rev Oncol Hematol* 2013;88 Suppl 1:S23-35.
621. Dimitrakakis C, Tsigginou A, Zagouri F, Marinopoulos S, Sergentanis TN, Keramopoulos A, Liakou P, Zografos GC, Papadimitriou CA, **Dimopoulos MA**, Antsaklis A. Breast cancer in women aged 25 years and younger. *Obstet Gynecol* 2013;121:1235-40.
622. Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Filipits M, Bartsch R, **Dimopoulos MA**, Psaltopoulou T. Pertuzumab in breast cancer: a systematic review. *Clin Breast Cancer* 2013;13:315-24.
623. Bamias A, Tzannis K, Beuselinck B, Oudard S, Escudier B, Diosynopoulos D, Papazisis K, Lang H, Wolter P, de Guillebon E, Stravodimos K, Chrisofos M, Fountzilias G, Elaidi RT, **Dimopoulos MA**, Bamia C. Development and validation of a prognostic model in patients with metastatic renal cell carcinoma treated with sunitinib: a European collaboration. *Br J Cancer* 2013;109:332-41.
624. Zagouri F, Sergentanis TN, Chrysikos D, Zografos CG, Papadimitriou CA, **Dimopoulos MA**, Filipits M, Bartsch R. Molecularly targeted therapies in metastatic pancreatic cancer: a systematic review. *Pancreas* 2013;42:760-73.
625. Mountzios G, Soultati A, Pectasides D, **Dimopoulos MA**, Papadimitriou CA. Novel approaches for concurrent irradiation in locally advanced cervical cancer: platinum combinations, non-platinum-containing regimens, and molecular targeted agents. *Obstet Gynecol Int* 2013;2013:536765.
626. Bagratuni T, Kastritis E, Politou M, Roussou M, Kostouros E, Gavriatopoulou M, Eleutherakis-Papaiakevou E, Kanelias N, Terpos E, **Dimopoulos MA**. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. *Am J Hematol* 2013;88:765-70.
627. Tsakiri EN, Sykiotis GP, Papassideri IS, Terpos E, **Dimopoulos MA**, Gorgoulis VG, Bohmann D, Trougakos IP. Proteasome dysfunction in *Drosophila* signals to an Nrf2-dependent regulatory circuit aiming to restore proteostasis and prevent premature aging. *Aging Cell* 2013;12:802-13.

628. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnani M, **Dimopoulos MA**, Bartsch R. Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. *Br J Cancer* 2013;108:2259-63.
629. **Dimopoulos MA**, Beksac M, Benboubker L, Roddie H, Allietta N, Broer E, Couturier C, Mazier MA, Angermund R, Facon T. Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. *Haematologica* 2013;98:1264-72.
630. Kastritis E, Terpos E, **Dimopoulos MA**. Current treatments for renal failure due to multiple myeloma. *Expert Opin Pharmacother* 2013;14:1477-95.
631. Terpos E, Kanellias N, Christoulas D, Kastritis E, **Dimopoulos MA**. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. *Onco Targets Ther* 2013;6:531-8.
632. Terpos E, Morgan G, **Dimopoulos MA**, Drake MT, Lentzsch S, Raje N, Sezer O, Garcia-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczynski A, Merlini G, Spencer A, Leleu X, Cavo M, Munshi N, Rajkumar SV, Durie BG, Roodman GD. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. *J Clin Oncol* 2013;31:2347-57.
633. Zagouri F, Sergentanis TN, Gazouli M, Dimitrakakis C, Tsigginou A, Papaspyrou I, Chrysikos D, Lymperi M, Zografos GC, Antsaklis A, **Dimopoulos MA**, Papadimitriou CA. MMP-2 -1306C>T polymorphism in breast cancer: a case-control study in a South European population. *Mol Biol Rep* 2013;40:5035-40.
634. Alevizaki M, Kyrtzoglou E, Bamias A, Tzanela M, **Dimopoulos MA**, Saltiki K. Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature. *Endocrine* 2013;44:610-5.
635. Zagouri F, Sergentanis TN, Bartsch R, Berghoff AS, Chrysikos D, de Azambuja E, **Dimopoulos MA**, Preusser M. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. *Breast Cancer Res Treat* 2013;139:13-22.
636. Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, **Dimopoulos MA**, Moreau P, Siegel DS, Jagannath S, Anderson KC. Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. *Leuk Res* 2013;37:829-37.
637. **Dimopoulos MA**, Terpos E, Kastritis E. Proteasome inhibitor therapy for Waldenstrom's macroglobulinemia. *Clin Lymphoma Myeloma Leuk* 2013;13:235-7.
638. Fountzilias G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, **Dimopoulos MA**. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. *BMC Cancer* 2013;13:163.

639. Stavropoulou AV, Fostira F, Pertesi M, Tsiplaidou M, Voutsinas GE, Triantafyllidou O, Bamias A, **Dimopoulos MA**, Timotheadou E, Pectasides D, Christodoulou C, Klouvas G, Papadimitriou C, Makatsoris T, Pentheroudakis G, Aravantinos G, Karydakis V, Yannoukakos D, Fountzilas G, Konstantopoulou I. Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. *PLoS One* 2013;8:e58182.
640. Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, **Dimopoulos MA**, Lane T, Foli A, Foard D, Milani P, Rannigan L, Hegenbart U, Hawkins PN, Merlini G, Palladini G. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. *Blood* 2013;121:3420-7.
641. Zagouri F, Bago-Horvath Z, Rossler F, Brandstetter A, Bartsch R, Papadimitriou CA, Dimitrakakis C, Tsigginou A, Papaspyrou I, Giannos A, **Dimopoulos MA**, Filipits M. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. *Br J Cancer* 2013;108:1100-5.
642. Terpos E, Roodman GD, **Dimopoulos MA**. Optimal use of bisphosphonates in patients with multiple myeloma. *Blood* 2013;121:3325-8.
643. Zis P, Vemmos K, Spengos K, Manios E, Zis V, **Dimopoulos MA**, Zakopoulos N. Ambulatory blood pressure monitoring in acute stroke: pathophysiology of the time rate of blood pressure variation and association with the 1-year outcome. *Blood Press Monit* 2013;18:94-100.
644. Bamias A, Bamia C, Zagouri F, Kostouros E, Kakoyianni K, Rodolakis A, Vlahos G, Haidopoulos D, Thomakos N, Antsaklis A, **Dimopoulos MA**. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. *Oncology* 2013;84:158-65.
645. Petrucci MT, Giraldo P, Corradini P, Teixeira A, **Dimopoulos MA**, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Blade J. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. *Br J Haematol* 2013;160:649-59.
646. Fernandez de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, **Dimopoulos MA**, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Blade J, Orłowski RZ, Shah JJ. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. *Leukemia* 2013;27:780-91.
647. Voutsas IF, Pistamaltzian N, Tsiatas ML, Skopeliti M, Katsila T, Mavrothalassiti I, Spyrou S, **Dimopoulos MA**, Tsitsilonis OE, Bamias A. Ovarian malignant ascites-derived lymphocytes stimulated with prothymosin alpha or its immunoreactive decapeptide lyse autologous tumour cells in vitro and retard tumour growth in SCID mice. *Eur J Cancer* 2013;49:1706-14.
648. Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, **Dimopoulos MA**, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. *Breast Cancer Res Treat* 2013;137:349-57.

649. **Dimopoulos MA**, Delforge M, Hajek R, Kropff M, Petrucci MT, Lewis P, Nixon A, Zhang J, Mei J, Palumbo A. Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial. *Haematologica* 2013;98:784-8.
650. San Miguel JF, Schlag R, Khuageva NK, **Dimopoulos MA**, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. *J Clin Oncol* 2013;31:448-55.
651. Kastiris E, Terpos E, Mouloupoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, Gkatzamanidou M, Migkou M, Gavriatopoulou M, Roussou M, Tasidou A, **Dimopoulos MA**. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. *Leukemia* 2013;27:947-53.
652. Chaidos A, Barnes CP, Cowan G, May PC, Melo V, Hatjiharissi E, Papaioannou M, Harrington H, Doolittle H, Terpos E, **Dimopoulos MA**, Abdalla S, Yarranton H, Naresh K, Foroni L, Reid A, Rahemtulla A, Stumpf M, Roberts I, Karadimitris A. Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. *Blood* 2013;121:318-28.
653. Bamias A, Dafni U, Karadimou A, Timotheadou E, Aravantinos G, Psyrri A, Xanthakis I, Tsiatas M, Koutoulidis V, Constantinidis C, Hatzimouratidis C, Samantas E, Visvikis A, Chrisophos M, Stravodimos K, Deliveliotis C, Eleftheraki A, Pectasides D, Fountzilas G, **Dimopoulos MA**. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). *Ann Oncol* 2013;24:1011-7.
654. Zagouri F, Serghentanis TN, Chrysikos D, Dimitrakakis C, Tsigginou A, Zografos CG, **Dimopoulos MA**, Papadimitriou CA. Taxanes for breast cancer during pregnancy: a systematic review. *Clin Breast Cancer* 2013;13:16-23.
655. Psaltopoulou T, Serghentanis TN, Kanellias N, Kanavidis P, Terpos E, **Dimopoulos MA**. Tobacco smoking and risk of multiple myeloma: a meta-analysis of 40 observational studies. *Int J Cancer* 2013;132:2413-31.
656. Maltezas D, **Dimopoulos MA**, Katodritou I, Repousis P, Pouli A, Terpos E, Panayiotidis P, Delimpasi S, Michalis E, Anargyrou K, Gavriatopoulou M, Stefanoudaki A, Tzenou T, Koulteris E, Sachanas S, Dimou M, Vassilakopoulos TP, Angelopoulou MK, Pangalis GA, Kyrtsolis MC. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. *Hematol Oncol* 2013;31:96-102.

657. Thomakos N, Rodolakis A, Zagouri F, Zacharakis D, Sotiropoulou M, Akrivos N, Haidopoulos D, Papadimitriou CA, **Dimopoulos MA**, Antsaklis A. Serum CA 125, CA 15-3, CEA, and CA 19-9: a prognostic factor for uterine carcinosarcomas? *Arch Gynecol Obstet* 2013;287:97-102.
658. **Dimopoulos MA**, Roussou M, Gkatzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. *Leukemia* 2013;27:423-9.
659. Mountzios G, Soultati A, Pectasides D, Pectasides E, **Dimopoulos MA**, Papadimitriou CA. Developments in the systemic treatment of metastatic cervical cancer. *Cancer Treat Rev* 2013;39:430-43.
660. Papageorgiou SG, Diamantopoulos P, Levidou G, Angelopoulou MK, Economopoulou P, Efthimiou A, Constantinou N, Katsigiannis A, Korkolopoulou P, Pappa V, Economopoulou C, Georgiou G, Dimou M, Tsirigotis P, Kyrtsonis MC, Kotsianidis I, Kalpadakis C, **Dimopoulos MA**, Beris P, Meletis J, Pangalis GA, Dervenoulas J, Panayiotidis P, Vassilakopoulos TP. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab. *Hematol Oncol* 2013;31:10-7.
661. Agrotou S, Karatzi K, Papamichael C, Fatouros I, Mitrakou A, Zakopoulos N, **Dimopoulos MA**, Stamatelopoulos K. Effects of chronic anaerobic training on markers of sub-clinical atherosclerosis. *Hellenic J Cardiol* 2013;54:178-85.
662. Rajkumar SV, **Dimopoulos MA**, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. *Lancet Oncol* 2014;15:e538-48.
663. **Dimopoulos MA**, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y, Baz R. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. *Blood Cancer J* 2014;4:e257.
664. Lontos M, Lykka M, **Dimopoulos MA**, Bamias A. Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer. *Onco Targets Ther* 2014;7:1837-45.
665. Karavasilis V, Kosmidis P, Syrigos KN, Mavropoulou P, **Dimopoulos MA**, Kotoula V, Pectasides D, Boukovinas I, Klouvas G, Kalogera-Fountzila A, Papandreou CN, Fountzilas G, Briasoulis E. Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group. *Anticancer Res* 2014;34:5649-55.
666. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, **Dimopoulos MA**, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N, Corradini P, Chuncharunee S, Lee JJ, Schlossman RL, Shelekhova T, Yong K, Tan D, Numbenjapon T, Cavenagh JD, Hou J, LeBlanc R, Nahi H, Qiu L, Salwender H, Pulini S, Moreau P, Warzocha K, White D, Blade J, Chen W, de la Rubia J, Gimsing P, Lonial S, Kaufman JL, Ocio EM, Veskovski L, Sohn SK, Wang MC, Lee JH, Einsele H, Sopala M, Corrado C, Bengoudifa BR, Binlich F, Richardson PG.

- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. *Lancet Oncol* 2014;15:1195-206.
667. Matikas A, Kanellis G, Papadimitriou C, Papadaki T, Kotsakis A, **Dimopoulos MA**, Georgoulas V. Plasmablastic lymphoma of the breast in an immunocompetent patient: long-lasting complete response induced by chemotherapy and autologous stem cell transplantation. *Anticancer Res* 2014;34:5111-5.
668. Benboubker L, **Dimopoulos MA**, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldine C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Ferman J, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med* 2014;371:906-17.
669. **Dimopoulos MA**, Terpos E. Solitary bone plasmacytomas need to flow. *Blood* 2014;124:1209-10.
670. Kastritis E, Moulopoulos LA, Terpos E, Koutoulidis V, **Dimopoulos MA**. The prognostic importance of the presence of more than one focal lesion in spine MRI of patients with asymptomatic (smoldering) multiple myeloma. *Leukemia* 2014;28:2402-3.
671. Ludwig H, Sonneveld P, Davies F, Blade J, Boccadoro M, Cavo M, Morgan G, de la Rubia J, Delforge M, **Dimopoulos MA**, Einsele H, Facon T, Goldschmidt H, Moreau P, Nahi H, Plesner T, San-Miguel J, Hajek R, Sondergeld P, Palumbo A. European perspective on multiple myeloma treatment strategies in 2014. *Oncologist* 2014;19:829-44.
672. Gkotsamanidou M, Sfrikakis PP, Kyrtopoulos SA, Bamia C, **Dimopoulos MA**, Souliotis VL. Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma. *Br J Cancer* 2014;111:1293-304.
673. Melea PI, Melakopoulos I, Kastritis E, Tesseromatis C, Margaritis V, **Dimopoulos MA**, Terpos E. Conservative treatment of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma patients. *Int J Dent* 2014;2014:427273.
674. **Dimopoulos MA**, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, Garcia-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP. Treatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensus. *Blood* 2014;124:1404-11.
675. Fountzilias G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, Xanthakis I, Christodoulou C, Koutras A, Papandreou CN, Papakostas P, Miliaras S, Markopoulos C, Dimitrakakis C, Korantzopoulos P, Karanikiotis C, Bafaloukos D, Kosmidis P, Samantas E, Varthalitis I, Pavlidis N, Pectasides D, **Dimopoulos MA**. Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial. *BMC Cancer* 2014;14:515.

676. Gkatzamanidou M, Terpos E, Kastritis E, **Dimopoulos MA**. Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach? *Clin Lymphoma Myeloma Leuk* 2014;14:e179-81.
677. Zagouri F, Sergentanis TN, Tsigginou A, Dimitrakakis C, Zografos GC, **Dimopoulos MA**, Psaltopoulou T. Female breast cancer in Europe: statistics, diagnosis and treatment modalities. *J Thorac Dis* 2014;6:589-90.
678. Bamias A, Tzannis K, Papatsoris A, Oudard S, Beuselinck B, Escudier B, Lontos M, Elaidi TR, Chrisofos M, Stravodimos K, Anastasiou I, Mitropoulos D, Deliveliotis C, Constantinides C, **Dimopoulos MA**, Bamia C. Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study. *Clin Genitourin Cancer* 2014;12:373-83.
679. Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsolis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, **Dimopoulos MA**. Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. *Am J Hematol* 2014;89:803-8.
680. Siegel DS, Richardson P, **Dimopoulos MA**, Moreau P, Mitsiades C, Weber D, Houp J, Gause C, Vuocolo S, Eid J, Graef T, Anderson KC. Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. *Blood Cancer J* 2014;4:e202.
681. Pentheroudakis G, Kotoula V, Kouvatseas G, Charalambous E, Dionysopoulos D, Zagouri F, Koutras A, Papazisis K, Pectasides D, Samantas E, **Dimopoulos MA**, Papandreou CN, Fountzilas G. Association of VEGF-A splice variant mRNA expression with outcome in bevacizumab-treated patients with metastatic breast cancer. *Clin Breast Cancer* 2014;14:330-8.
682. Thomakos N, Zacharakis D, Rodolakis A, Zagouri F, Papadimitriou CA, Bamias A, **Dimopoulos MA**, Haidopoulos D, Vlahos G, Antsaklis A. Gynecologic oncology patients in the surgical high dependency unit: an analysis of indications. *Arch Gynecol Obstet* 2014;290:335-9.
683. Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, Hatzimichael E, Vassou A, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsolis MC, Konstantopoulos K, Spyropoulou-Vlachou M, Terpos E, **Dimopoulos MA**. Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. *Leukemia* 2014;28:2075-9.
684. Zagouri F, Brandstetter A, Moussiolis D, Chrysikos D, Dimitrakakis C, Tsigginou A, Marinopoulos S, Zografos GC, Sergentanis TN, **Dimopoulos MA**, Filipits M. Low protein expression of MET in ER-positive and HER2-positive breast cancer. *Anticancer Res* 2014;34:1227-31.
685. Stofas A, Levidou G, Piperi C, Adamopoulos C, Dalagiorgou G, Bamias A, Karadimou A, Lainakis GA, Papadoukakis S, Stravodimos K, **Dimopoulos MA**, Patsouris E, Gakiopoulou H,

- Korkolopoulou P. The role of CXC-chemokine receptor CXCR2 and suppressor of cytokine signaling-3 (SOCS-3) in renal cell carcinoma. *BMC Cancer* 2014;14:149.
686. Kastritis E, Terpos E, **Dimopoulos MA**. Author's reply: To PMID 23705905. *Expert Opin Pharmacother* 2014;15:300.
687. Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, **Dimopoulos MA**, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. *Lancet Oncol* 2014;15:333-42.
688. Engelhardt M, Terpos E, Kleber M, Gay F, Wasch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, **Dimopoulos MA**, Einsele H, Sonneveld P, Palumbo A. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. *Haematologica* 2014;99:232-42.
689. **Dimopoulos MA**, Leleu X, Palumbo A, Moreau P, Delforge M, Cavo M, Ludwig H, Morgan GJ, Davies FE, Sonneveld P, Schey SA, Zweegman S, Hansson M, Weisel K, Mateos MV, Facon T, Miguel JF. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. *Leukemia* 2014;28:1573-85.
690. Fonseca R, Monge J, **Dimopoulos MA**. Staging and prognostication of multiple myeloma. *Expert Rev Hematol* 2014;7:21-31.
691. Terpos E, **Dimopoulos MA**. Less strength and more fractures for MGUS bones. *Blood* 2014;123:603-4.
692. Zagouri F, Kastritis E, Symeonidis AS, Giannakoulas N, Katodritou E, Delimpasi S, Repousis P, Terpos E, **Dimopoulos MA**. Immunoglobulin D myeloma: clinical features and outcome in the era of novel agents. *Eur J Haematol* 2014;92:308-12.
693. Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, **Dimopoulos MA**, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orłowski RZ. International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. *J Clin Oncol* 2014;32:587-600.
694. **Dimopoulos MA**, Delimpasi S, Katodritou E, Vassou A, Kyrtsionis MC, Repousis P, Kartasis Z, Parcharidou A, Michael M, Michalis E, Gika D, Symeonidis A, Pouli A, Konstantopoulos K, Terpos E, Kastritis E. Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents. *Ann Oncol* 2014;25:195-200.
695. Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, Carpenter J, Chang-Claude J, Martin NG, Montgomery GW, Kristensen V, Anton-Culver H, Goodfellow P, Tapper WJ, Rafiq S, Gerty SM, Durcan L, Konstantopoulou I, Fostira F, Vratimos A, Apostolou

- P, Konstanta I, Kotoula V, Lakis S, **Dimopoulos MA**, Skarlos D, Pectasides D, Fountzilas G, Beckmann MW, Hein A, Ruebner M, Ekici AB, Hartmann A, Schulz-Wendtland R, Renner SP, Janni W, Rack B, Scholz C, Neugebauer J, Andergassen U, Lux MP, Haeberle L, Clarke C, Pathmanathan N, Rudolph A, Flesch-Janys D, Nickels S, Olson JE, Ingle JN, Olswold C, Slettedahl S, Eckel-Passow JE, Anderson SK, Visscher DW, Cafourek VL, Sicotte H, Prodduturi N, Weiderpass E, Bernstein L, Ziogas A, Ivanovich J, Giles GG, Baglietto L, Southey M, Kosma VM, Fischer HP, Reed MW, Cross SS, Deming-Halverson S, Shrubsole M, Cai Q, Shu XO, Daly M, Weaver J, Ross E, Klemp J, Sharma P, Torres D, Rudiger T, Wolfing H, Ulmer HU, Forsti A, Khoury T, Kumar S, Pilarski R, Shapiro CL, Greco D, Heikkila P, Aittomaki K, Blomqvist C, Irwanto A, Liu J, Pankratz VS, Wang X, Severi G, Mannermaa A, Easton D, Hall P, Brauch H, Cox A, Zheng W, Godwin AK, Hamann U, Ambrosone C, Toland AE, Nevanlinna H, Vachon CM, Couch FJ. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. *Carcinogenesis* 2014;35:1012-9.
696. Zagouri F, Kastritis E, Gavriatopoulou M, Sergeranis TN, Psaltopoulou T, Terpos E, **Dimopoulos MA**. Lenalidomide in patients with POEMS syndrome: a systematic review and pooled analysis. *Leuk Lymphoma* 2014;55:2018-23.
697. Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, **Dimopoulos MA**, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). *Leukemia* 2014;28:525-42.
698. Ludwig H, Miguel JS, **Dimopoulos MA**, Palumbo A, Garcia Sanz R, Powles R, Lentzsch S, Ming Chen W, Hou J, Jurczynszyn A, Romeril K, Hajek R, Terpos E, Shimizu K, Joshua D, Hungria V, Rodriguez Morales A, Ben-Yehuda D, Sondergeld P, Zamagni E, Durie B. International Myeloma Working Group recommendations for global myeloma care. *Leukemia* 2014;28:981-92.
699. **Dimopoulos MA**, Palumbo A, Hajek R, Kropff M, Petrucci MT, Lewis P, Millar S, Zhang J, Mei J, Delforge M. Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial. *Leuk Lymphoma* 2014;55:1489-97.
700. Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtonis MC, Symeonidis A, Giannakoulas N, Stefanoudaki A, Christoulas D, Chatziaggelidou C, Gastari V, Spyridis N, Verrou E, Konstantinidou P, Zervas K, **Dimopoulos MA**. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. *Am J Hematol* 2014;89:145-50.
701. Gkatzamanidou M, Terpos E, Bamia C, Kyrtopoulos SA, Sfikakis PP, **Dimopoulos MA**, Souliotis VL. Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis. *Leukemia* 2014;28:1113-21.

702. Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Gkatzamanidou M, Kanellias N, Manios E, Papadimitriou C, **Dimopoulos MA**. VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT. *Leukemia* 2014;28:928-34.
703. Terpos E, Christoulas D, Kastritis E, Katodritou E, Papatheodorou A, Pouli A, Kyrtsolis MC, Michalis E, Papanikolaou X, Gkatzamanidou M, Koulieris E, Gavriatopoulou M, Zervas K, **Dimopoulos MA**. The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. *Am J Hematol* 2014;89:34-40.
704. Hajek R, Siegel D, Orlowski RZ, Ludwig H, Palumbo A, **Dimopoulos MA**. The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. *Leuk Lymphoma* 2014;55:11-8.
705. Gyftaki R, Liacos C, Politi E, Lontos M, Saltiki K, Papageorgiou T, Thomakos N, Haidopoulos D, Rodolakis A, Alevizaki M, Bamias A, **Dimopoulos MA**. Differential transcriptional and protein expression of thyroid-stimulating hormone receptor in ovarian carcinomas. *Int J Gynecol Cancer* 2014;24:851-6.
706. Karavasilis V, Papadimitriou C, Gogas H, Kouvatseas G, Pentheroudakis G, Koutras A, Christodoulou C, Bafaloukos D, Samantas E, Pisanidis N, Papakostas P, Aravantinos G, Karanikiotis C, Kosmidis P, Pectasides D, **Dimopoulos MA**, Fountzilas G. Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. *Clin Breast Cancer* 2015.
707. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim J, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, **Dimopoulos MA**, Moreau P, Anderson K, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson P. Management of relapsed multiple myeloma: Recommendations of the international myeloma working group. *Leukemia* 2015.
708. Papantoniou V, Valsamaki P, Kastritis S, Tsiouris S, Delichas Z, Papantoniou Y, Tsiouma M, Athanasoulis T, Fotopoulos A, **Dimopoulos MA**. Imaging of cardiac amyloidosis by (99m)Tc-PYP scintigraphy. *Hell J Nucl Med* 2015;18 Suppl 1:42-50.
709. **Dimopoulos MA**, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. *Haematologica* 2015; Dec 11. pii: haematol.2015.133629. [Epub ahead of print].
710. Drivalos A, Chrisofos M, Efstathiou E, Kapranou A, Kollaitis G, Koutlis G, Antoniou N, Karanastasis D, **Dimopoulos MA**, Bamias A. Expression of alpha5-integrin, alpha7-integrin, Epsilon-cadherin, and N-cadherin in localized prostate cancer. *Urol Oncol* 2015.

711. Richardson PG, Hungria VT, Yoon SS, Beksac M, **Dimopoulos MA**, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in relapsed/relapsed and refractory myeloma: outcomes by prior treatment. *Blood* 2015.
712. Papantoniou V, Valsamaki P, Skorda L, Papantoniou I, Delichas Z, Zacharakis G, Michopoulos S, **Dimopoulos MA**, Koskinas I. Technetium-99m labelled red blood cells scintigraphy and not iminodiacetic acid cholescintigraphy facilitates the discrimination of hepatic cirrhosis from fibrosis. *Hell J Nucl Med* 2015;18:238-42.
713. Liapis K, Kastritis E, Bagratouni T, Vassiliou S, Papachristidis A, Charitaki E, Alevizopoulos N, Harhalakis N, Terpos E, Delimpasi S, **Dimopoulos MA**. Early tumor-cell gene expression changes may predict the response to first-line bortezomib-based therapy in patients with newly diagnosed multiple myeloma. *J BUON* 2015;20:1314-21.
714. Bamias A, Peroukidis S, Stamatopoulou S, Tzannis K, Koutsoukos K, Andreadis C, Bozionelou V, Pistalmatzian N, Papatsoris A, Stravodimos K, Varthalitis I, Karamouzis M, Milaki G, Agorastos A, Kentepozidis N, Androulakis N, Bompolaki I, Kalofonos H, Mavroudis D, **Dimopoulos MA**. Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG). *Clin Genitourin Cancer* 2015.
715. Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, **Dimopoulos MA**, Palumbo A. European Myeloma Network guidelines for the management of multiple myeloma-related complications. *Haematologica* 2015;100:1254-66.
716. Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, **Dimopoulos MA**, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orłowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Tureson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. *Biol Blood Marrow Transplant* 2015;21:2039-51.
717. Katodritou E, Terpos E, Kastritis E, Delimpasi S, Symeonidis AS, Repousis P, Kyrtsionis MC, Vadikolia C, Michalis E, Polychronidou G, Michael M, Papadaki S, Papathanasiou M, Kokoviadou K, Kioumi A, Vlachaki E, Hadjiaggelidou C, Kouraklis A, Patsias I, Gavriatopoulou M, Kotsopoulou M, Verrou E, Gastari V, Christoulas D, Giannopoulou E, Pouli A, Konstantinidou P, Anagnostopoulos A, **Dimopoulos MA**. Lack of survival improvement with novel anti-myeloma

- agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience. *Ann Hematol* 2015;94:2033-42.
718. Koutsoukos K, Tzannis K, Christodoulou C, Karavasilis V, Bakoyiannis C, Makatsoris T, Papandreou CN, Pectasides D, **Dimopoulos MA**, Bamias A. Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG). *World J Urol* 2015.
719. Kastritis E, Gavriatopoulou M, Kyrtsolis MC, Roussou M, Hadjiharissi E, Symeonidis A, Repoussis P, Michalis E, Delimpasi S, Tsatalas K, Tsirigotis P, Vassou A, Vervessou E, Katodritou E, Gika D, Terpos E, **Dimopoulos MA**. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. *Blood* 2015;126:1392-4.
720. Zagouri F, Sergantani TN, Chrysikos D, **Dimopoulos MA**, Bamias A. Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review. *Onco Targets Ther* 2015;8:2187-98.
721. **Dimopoulos MA**, Terpos E, Niesvizky R, Palumbo A. Clinical characteristics of patients with relapsed multiple myeloma. *Cancer Treat Rev* 2015;41:827-35.
722. Kastritis E, Kyrtsolis MC, Morel P, Gavriatopoulou M, Hatjiharissi E, Symeonidis AS, Vassou A, Repousis P, Delimpasi S, Sioni A, Michalis E, Michael M, Vervessou E, Voulgarelis M, Tsatalas C, Terpos E, **Dimopoulos MA**. Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. *Haematologica* 2015;100:e446-9.
723. Sergantani TN, Zagouri F, Tsilimidos G, Tsagianni A, Tseliou M, **Dimopoulos MA**, Psaltopoulou T. Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses. *Clin Lymphoma Myeloma Leuk* 2015;15:563-77 e1-3.
724. Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, **Dimopoulos MA**, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. *J Clin Oncol* 2015;33:3459-66.
725. **Dimopoulos MA**, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Spencer A, Knop S, Bahlis NJ, Renner C, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel JF. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. *Haematologica* 2015;100:1327-33.
726. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orłowski RZ, Zamagni E, Morgan G, **Dimopoulos MA**, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. *J Clin Oncol* 2015;33:2863-9.

727. **Dimopoulos MA**, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y, Baz R. Response to letter, 'immortal time bias in retrospective analysis'. *Blood Cancer J* 2015;5:e327.
728. Giannos A, Filipits M, Zagouri F, Brandstetter A, Tsigginou A, Sotiropoulou M, Papaspyrou I, Sergentanis TN, Psaltopoulou T, Rodolakis A, Antsaklis A, **Dimopoulos MA**, Dimitrakakis C. Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor? *Oncotargets Ther* 2015;8:1843-7.
729. **Dimopoulos MA**, Sonneveld P, Siegel D, Palumbo A, San-Miguel J. Carfilzomib and pomalidomide in patients with relapsed and/or refractory multiple myeloma with baseline risk factors. *Ann Oncol* 2015;26:2247-56.
730. **Dimopoulos MA**, Terpos E. Reply to D.L. Cooper. *J Clin Oncol* 2015;33:2926-7.
731. Zagouri F, Terpos E, Kastritis E, **Dimopoulos MA**. An update on the use of lenalidomide for the treatment of multiple myeloma. *Expert Opin Pharmacother* 2015;16:1865-77.
732. San Miguel JF, Weisel KC, Song KW, Delforge M, Karlin L, Goldschmidt H, Moreau P, Banos A, Oriol A, Garderet L, Cavo M, Ivanova V, Alegre A, Martinez-Lopez J, Chen C, Renner C, Bahlis NJ, Yu X, Teasdale T, Sternas L, Jacques C, Zaki MH, **Dimopoulos MA**. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. *Haematologica* 2015;100:1334-9.
733. Weisel K, **Dimopoulos MA**, Song KW, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Gibson CJ, Zaki M, Jacques C, San Miguel J. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. *Clin Lymphoma Myeloma Leuk* 2015;15:519-30.
734. Richardson PG, Laubach JP, Lonial S, Moreau P, Yoon SS, Hungria VT, **Dimopoulos MA**, Beksac M, Alsina M, San-Miguel JF. Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma. *Expert Rev Anticancer Ther* 2015;15:737-48.
735. Kastritis E, Gavriatopoulou M, **Dimopoulos MA**, Eleutherakis-Papaiakevou E, Kanellias N, Roussou M, Pamboucas C, Toumanidis ST, Terpos E. Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. *Blood Cancer J* 2015;5:e319.
736. Lonial S, **Dimopoulos MA**, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orłowski RZ, Taniwaki M, Rollig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. *N Engl J Med* 2015;373:621-31.
737. Zagouri F, Sergentanis TN, Azim HA, Jr., Chrysikos D, **Dimopoulos MA**, Psaltopoulou T. Aromatase inhibitors in male breast cancer: a pooled analysis. *Breast Cancer Res Treat* 2015;151:141-7.

738. **Dimopoulos MA**, Petrucci MT, Foa R, Catalano J, Kropff M, Terpos E, Zhang J, Grote L, Jacques C, Palumbo A. Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial endpoint. *Haematologica* 2015;100:e328-30.
739. Nooka AK, Kastiris E, **Dimopoulos MA**, Lonial S. Treatment options for relapsed and refractory multiple myeloma. *Blood* 2015;125:3085-99.
740. Zagouri F, Liakou P, Bartsch R, Peccatori FA, Tsigginou A, Dimitrakakis C, Zografos GC, **Dimopoulos MA**, Azim HA, Jr. Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal. *Breast* 2015;24:513-23.
741. Stefanou DT, Bamias A, Episkopou H, Kyrtopoulos SA, Likka M, Kalampokas T, Photiou S, Gavalas N, Sfikakis PP, **Dimopoulos MA**, Souliotis VL. Aberrant DNA damage response pathways may predict the outcome of platinum chemotherapy in ovarian cancer. *PLoS One* 2015;10:e0117654.
742. Andersen JP, Bogsted M, Dybkaer K, Mellqvist UH, Morgan GJ, Goldschmidt H, **Dimopoulos MA**, Einsele H, San Miguel J, Palumbo A, Sonneveld P, Johnsen HE. Global myeloma research clusters, output, and citations: a bibliometric mapping and clustering analysis. *PLoS One* 2015;10:e0116966.
743. Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, **Dimopoulos MA**, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. *Blood* 2015;125:2068-74.
744. **Dimopoulos MA**, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczynszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. *J Clin Oncol* 2015;33:657-64.
745. Kastiris E, Roussou M, Gavriatopoulou M, Migkou M, Kalapanida D, Pamboucas C, Kaldara E, Ntalianis A, Psimenou E, Toumanidis ST, Tasidou A, Terpos E, **Dimopoulos MA**. Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. *Am J Hematol* 2015;90:E60-5.
746. Mateos MV, Richardson PG, **Dimopoulos MA**, Palumbo A, Anderson KC, Shi H, Elliott J, Dow E, van de Velde H, Nculescu L, San Miguel JF. Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. *Am J Hematol* 2015;90:314-9.
747. Kourlaba G, **Dimopoulos MA**, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, Koutras A, Fountzilias G, Maniadakis N. Comparison of filgrastim and pegfilgrastim to prevent

- neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. *Support Care Cancer* 2015;23:2045-51.
748. Zagouri F, Sergentanis TN, Chrysikos D, **Dimopoulos MA**, Psaltopoulou T. Fulvestrant and male breast cancer: a pooled analysis. *Breast Cancer Res Treat* 2015;149:269-75.
749. Stewart AK, Rajkumar SV, **Dimopoulos MA**, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Wang M, Maisnar V, Minarik J, Bensinger WI, Mateos MV, Ben-Yehuda D, Kukreti V, Zojwalla N, Tonda ME, Yang X, Xing B, Moreau P, Palumbo A. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. *N Engl J Med* 2015;372:142-52.
750. Bakogeorgos M, Mountzios G, Bournakis E, Economopoulou P, Kotsantis G, Fytrakis N, Kouvatseas G, **Dimopoulos MA**, Kentepozidis N. Do elderly patients with non-small cell lung cancer get the best out of recent advances in first-line treatment? A comparative study in two tertiary cancer centers in Greece. *J Geriatr Oncol* 2015;6:111-8.
751. Song KW, **Dimopoulos MA**, Weisel KC, Moreau P, Palumbo A, Belch A, Schey S, Sonneveld P, Sternas L, Yu X, Amatya R, Monzini MS, Zaki M, Jacques C, San Miguel J. Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma. *Haematologica* 2015;100:e63-7.
752. **Dimopoulos MA**, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. *Nat Rev Clin Oncol* 2015;12:42-54.
753. Morgan G, Palumbo A, Dhanasiri S, Lee D, Weisel K, Facon T, Delforge M, Oriol A, Zaki M, Yu X, Sternas L, Jacques C, Akehurst R, Offner F, **Dimopoulos MA**. Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. *Br J Haematol* 2015;168:820-3.
754. Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, **Dimopoulos MA**, Cavenagh JD, Spicka I, Maiolino A, Suvorov A, Blade J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF. A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. *Am J Hematol* 2015;90:42-9.
755. Gertz MA, Terpos E, Dispenzieri A, Kumar S, Shah RA, Orlowski R, Kastiris E, **Dimopoulos MA**, Shah J. Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents. *Leuk Lymphoma* 2015;56:1723-6.
756. **Dimopoulos MA**, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG. Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. *Haematologica* 2015;100:100-6.
757. Kastiris E, **Dimopoulos MA**. Appraising myc involvement in high risk myeloma. *Leuk Lymphoma* 2015;56:551-2.

758. Psaltopoulou T, Sergentanis TN, Sergentanis IN, Karadimitris A, Terpos E, **Dimopoulos MA**. Alcohol intake, alcoholic beverage type and multiple myeloma risk: a meta-analysis of 26 observational studies. *Leuk Lymphoma* 2015;56:1484-501.
759. Mills JL, **Dimopoulos MA**. Folic acid fortification for Europe? *BMJ* 2015;351:h6198.
760. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Dohner H, Duyvene' de Wit T, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ, Andre M, Andre-Schmutz I, Bacigalupo A, Bochud PY, den Boer M, Bonini C, Camaschella C, Cant A, Cappellini MD, Lo Celso C, **Dimopoulos MA**, Douay L, Dzierzak E, Einsele H, Ferreri A, Cazzola M, De Franceschi L, Gaulard P, Gottgens B, Greinacher A, Gresele P, Gribben J, de Haan G, Hansen JB, Hochhaus A, Kadir R, Kaveri S, Kouskoff V, Kuhne T, Kyrle P, Ljungman P, Maschmeyer G, Mendez-Ferrer S, Milsom M, Mummery C, Ossenkuppele G, Pecci A, Peyvandi F, Philipson S, Reitsma P, Ribera JM, Risitano A, Rivella S, Ruf W, Schroeder T, Scully M, Socie G, Staal F, Stanworth S, Stauder R, Stilgenbauer S, Tamy H, Theilgaard-Monch K, Thein SL, Tilly H, Trneny M, Vainchenker W, Vannucchi AM, Viscoli C, Vrielink H, Zaaijer H, Zanella A, Zolla L, Zwaginga JJ, Aguilar Martinez P, van den Akker E, Allard S, Anagnou N, Andolfo I, Andrau JC, Angelucci E, Anstee D, Aurer I, Avet-Loiseau H, Aydinok Y, Bakchoul T, Balduini A, Barcellini W, Baruch D, Baruchel A, Bayry J, Bento C, van den Berg A, Bernardi R, Bianchi P, Bigas A, Biondi A, Bohonek M, Bonnet D, Borchmann P, Borregaard N, Braekkan S, van den Brink M, Brodin E, Bullinger L, Buske C, Butzeck B, Cammenga J, Campo E, Carbone A, Cervantes F, Cesaro S, Charbord P, Claas F, Cohen H, Conard J, Coppo P, Vives Corrons JL, da Costa L, Davi F, Delwel R, Dianzani I, Domanovic D, Donnelly P, DovcDrnovsek T, Dreyling M, Du MQ, Dufour C, Durand C, Efremov D, Eleftheriou A, Elion J, Emonts M, Engelhardt M, Ezine S, Falkenburg F, Favier R, Federico M, Fenaux P, Fitzgibbon J, Flygare J, Foa R, Forrester L, Galacteros F, Garagiola I, Gardiner C, Garaud O, van Geet C, Geiger H, Geissler J, Germing U, Ghevaert C, Girelli D, Godeau B, Gokbuget N, Goldschmidt H, Goodeve A, Graf T, Graziadei G, Griesshammer M, Gruel Y, Guilhot F, von Gunten S, Gyssens I, Halter J, Harrison C, Hartevelde C, Hellstrom-Lindberg E, Hermine O, Higgs D, Hillmen P, Hirsch H, Hoskin P, Huls G, Inati A, Johnson P, Kattamis A, Kiefel V, Kleanthous M, Klump H, Krause D, Kremer Hovinga J, Lacaud G, Lacroix-Desmazes S, Landman-Parker J, LeGouill S, Lenz G, von Lilienfeld-Toal M, von Lindern M, Lopez-Guillermo A, Lopriore E, Lozano M, MacIntyre E, Makris M, Mannhalter C, Martens J, Mathas S, Medvinsky A, Menendez P, Migliaccio AR, Miharada K, Mikulska M, Minard V, Montalban C, de Montalambert M, Montserrat E, Morange PE, Mountford J, Muckenthaler M, Muller-Tidow C, Mumford A, Nadel B, Navarro JT, El Nemer W, Noizat-Pirenne F, O'Mahony B, Oldenburg J, Olsson M, Oostendorp R, Palumbo A, Passamonti F, Patient R, Peffault de Latour R, Pflumio F, Pierelli L, Piga A, Pollard D, Raaijmakers M, Radford J, Rambach R, Koneti Rao A, Raslova H, Rebutta P, Rees D, Ribrag V, Rijneveld A, Rinalducci S, Robak T, Roberts I, Rodrigues C, Rosendaal F, Rosenwald A, Rule S, Russo R, Saglio G, Sanchez M, Scharf RE, Schlenke P, Semple J, Sierra J, So-Osman C, Soria JM, Stamatopoulos K, Stagmayr B, Stunnenberg H, Swinkels D, Tabord Barata JP, Taghon T, Taher A, Terpos E, Thachil J, Tissot JD, Touw I, Toye A, Trappe R, Traverse-Glehen A, Unal S, Vaulont S, Viprakasit V, Vitolo U, van Wijck R, Wojtowicz A, Zeerleder S, Zieger B. The European Hematology Association Roadmap for European Hematology Research. A Consensus Document. *Haematologica* 2016;101:115-208.
761. Chng WJ, Goldschmidt H, **Dimopoulos MA**, Moreau P, Joshua D, Palumbo A, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosinol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Feng S, Aggarwal S, Hajek R. Carfilzomib-

- dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR. *Leukemia*. 2017;31:1368-74.
762. **Dimopoulos MA**, Sonneveld P, Sun H. Daratumumab and Blood-Compatibility Testing. *N Engl J Med*. 2016;375:2497-8.
763. Sakelliou A, Fatouros IG, Athanailidis I, Tsoukas D, Chatzinikolaou A, Draganidis D, Jamurtas AZ, Liacos C, Papassotiriou I, Mandalidis D, Stamatelopoulos K, **Dimopoulos MA**, Mitrakou A. Evidence of a Redox-Dependent Regulation of Immune Responses to Exercise-Induced Inflammation. *Oxid Med Cell Longev*. 2016;2016:2840643.
764. Ziogas DC, Kastritis E, Terpos E, Roussou M, Migkou M, Gavriatopoulou M, Spanomichou D, Eleutherakis-Papaiakovou E, Fotiou D, Panagiotidis I, Kafantari E, Psimenou E, Boletis I, Vlahakos DV, Gakiopoulou H, Matsouka C, **Dimopoulos MA**. Hematologic and renal improvement of monoclonal immunoglobulin deposition disease after treatment with bortezomib-based regimens. *Leuk Lymphoma*. 2017;58:1832-9
765. **Dimopoulos MA**, Trotman J, Tedeschi A, Matous JV, Macdonald D, Tam C, Tournilhac O, Ma S, Oriol A, Heffner LT, Shustik C, Garcia-Sanz R, Cornell RF, de Larrea CF, Castillo JJ, Granell M, Kyrtsolis MC, Leblond V, Symeonidis A, Kastritis E, Singh P, Li J, Graef T, Bilotti E, Treon S, Buske C. Ibrutinib for patients with rituximab-refractory Waldenstrom's macroglobulinaemia (iINNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. *Lancet Oncol*. 2017;18:241-250.
766. Ou Y, Doshi S, Nguyen A, Jonsson F, Aggarwal S, Rajangam K, **Dimopoulos MA**, Stewart AK, Badros A, Papadopoulos KP, Siegel D, Jagannath S, Vij R, Niesvizky R, Graham R, Visich J. Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. *J Clin Pharmacol*. 2017;57:663-77.
767. Ziogas DC, Terpos E, **Dimopoulos MA**. When to recommend a second autograft in patients with relapsed myeloma? *Leuk Lymphoma*. 2017;58:781-7.
768. Gavriatopoulou M, Garcia-Sanz R, Kastritis E, Morel P, Kyrtsolis MC, Michalis E, Kartasis Z, Leleu X, Palladini G, Tedeschi A, Gika D, Merlini G, Sonneveld P, **Dimopoulos MA**. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow up of 6 years. *Blood*. 2017;129:456-9.
769. Zagouri F, Dimitrakakis C, Marinopoulos S, Tsigginou A, **Dimopoulos MA**. Cancer in pregnancy: disentangling treatment modalities. *ESMO Open*. 2016;1:e000016.
770. Spanoudakis E, Papoutselis M, Terpos E, **Dimopoulos MA**, Tsatalas C, Margaritis D, Rahemtulla A, Kotsianidis I, Karadimitris A. Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma. *Blood Cancer J*. 2016;6:e500.
771. Kastritis E, **Dimopoulos MA**. Current therapy guidelines for Waldenstrom's macroglobulinaemia. *Best Pract Res Clin Haematol*. 2016;29:194-205.
772. Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas D, Panagiotidis I, Kafantari E, Giannouli S, Zomas A, Konstantopoulos K, **Dimopoulos MA**. Evaluation of the Revised International Staging System (R-ISS) in an

- independent cohort of unselected patients with multiple myeloma. *Haematologica*. 2017;102:593-9.
773. Gavriatopoulou M, Terpos E, Kastritis E, **Dimopoulos MA**. Current treatments for renal failure due to multiple myeloma. *Expert Opin Pharmacother*. 2016;17:2165-77.
774. San-Miguel JF, Hungria VT, Yoon SS, Beksac M, **Dimopoulos MA**, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Binlich F, Richardson PG. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. *Lancet Haematol*. 2016;3:e506-e15.
775. Gavriatopoulou M, Kastritis E, Kyrtsolis MC, Vassilakopoulos TP, Roussou M, Fotiou D, Migkou M, Mpakiri M, Tasidou A, Terpos E, **Dimopoulos MA**. Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenstrom's macroglobulinemia. *Leuk Lymphoma*. 2017;58:1506-8.
776. Terpos E, Christoulas D, Kastritis E, Bagratuni T, Gavriatopoulou M, Roussou M, Papatheodorou A, Eleutherakis-Papaiakovou E, Kanellias N, Liakou C, Panagiotidis I, Migkou M, Kokkoris P, Mouloupoulos LA, **Dimopoulos MA**. High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma. *Blood Cancer J*. 2016;6:e482.
777. **Dimopoulos MA**, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016;375:1319-31.
778. Avivi I, Cohen YC, Joffe E, Benyamini N, Held-Kuznetsov V, Trestman S, Terpos E, **Dimopoulos MA**, Kastritis E. Serum free immunoglobulin light chain fingerprint identifies a subset of newly diagnosed multiple myeloma patients with worse outcome. *Hematol Oncol*. 2016 Sep 19.
779. Koutoulidis V, Fontara S, Terpos E, Zagouri F, Matsaridis D, Christoulas D, Panourgias E, Kastritis E, **Dimopoulos MA**, Mouloupoulos LA. Quantitative Diffusion-weighted Imaging of the Bone Marrow: An Adjunct Tool for the Diagnosis of a Diffuse MR Imaging Pattern in Patients with Multiple Myeloma. *Radiology*. 2017;282:484-93.
780. Papachatzakis Y, Tseliou E, Tatouli I, Dialoupi I, Michas F, Papadopoulou E, Kousouris D, Kontogiannis S, **Dimopoulos MA**. Colon Adenoma Implicating Myasthenia Gravis: A Case Report of a Patient with Postcolectomy Complications. *Case Rep Neurol Med*. 2016;2016:6297656.
781. Stewart AK, **Dimopoulos MA**, Masszi T, Spicka I, Oriol A, Hajek R, Rosinol L, Siegel DS, Niesvizky R, Jakubowiak AJ, San-Miguel JF, Ludwig H, Buchanan J, Cocks K, Yang X, Xing B, Zojwalla N, Tonda M, Moreau P, Palumbo A. Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and

- Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. *J Clin Oncol*. 2016 Sep 06.
782. **Dimopoulos MA**, Kastiris E, Terpos E. Recent Data Supporting Novel Management Strategies for Patients With Multiple Myeloma. *JAMA Oncol*. 2016;2:1261-2.
783. Lontos M, Anastasiou I, Bamias A, **Dimopoulos MA**. DNA damage, tumor mutational load and their impact on immune responses against cancer. *Ann Transl Med*. 2016;4:264.
784. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, **Dimopoulos MA**, Kastiris E, Boccadoro M, Orłowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, San Miguel J, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol*. 2016;17:e328-46.
785. Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, Hajek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosinol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, **Dimopoulos MA**. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. *Leukemia*. 2016 Aug 05.
786. Gkotszamanidou M, Terpos E, Bamia C, Munshi NC, **Dimopoulos MA**, Souliotis VL. DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7. *Blood*. 2016;128:1214-25.
787. Avet-Loiseau H, Fonseca R, Siegel D, **Dimopoulos MA**, Spicka I, Masszi T, Hajek R, Rosinol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos MV, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. *Blood*. 2016;128:1174-80.
788. Leblond V, Kastiris E, Advani R, Ansell SM, Buske C, Castillo JJ, Garcia-Sanz R, Gertz M, Kimby E, Kyriakou C, Merlini G, Minnema MC, Morel P, Morra E, Rummel M, Wechalekar A, Patterson CJ, Treon SP, **Dimopoulos MA**. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. *Blood*. 2016;128:1321-8.
789. Fotiou D, **Dimopoulos MA**, Kastiris E. Managing renal complications in multiple myeloma. *Expert Rev Hematol*. 2016;9:839-50.
790. Hajek R, Masszi T, Petrucci MT, Palumbo A, Rosinol L, Nagler A, Yong KL, Oriol A, Minarik J, Pour L, **Dimopoulos MA**, Maisnar V, Rossi D, Kasparu H, Van Droogenbroeck J, Yehuda DB, Hardan I, Jenner M, Calbecka M, David M, de la Rubia J, Drach J, Gasztonyi Z, Gornik S, Leleu X, Munder M, Offidani M, Zojer N, Rajangam K, Chang YL, San-Miguel JF, Ludwig H. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). *Leukemia*. 2016 Jul 15.

791. Lontos M, Trigka EA, Korkolopoulou P, Tzannis K, Lainakis G, Koutsoukos K, Kostouros E, Lykka M, Papandreou CN, Karavasilis V, Christodoulou C, Papatsoris A, Skolarikos A, Varkarakis I, Adamakis I, Alamanis C, Stravodimos K, Mitropoulos D, Deliveliotis C, Constantinidis CA, Saetta A, Patsouris E, **Dimopoulos MA**, Bamias A. Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients. *World J Urol.* 2016 Jul 09.
792. Castillo JJ, Garcia-Sanz R, Hatjiharissi E, Kyle RA, Leleu X, McMaster M, Merlini G, Minnema MC, Morra E, Owen RG, Poulain S, Stone MJ, Tam C, Varettoni M, **Dimopoulos MA**, Treon SP, Kastritis E. Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia. *Br J Haematol.* 2016;175:77-86.
793. Hulin C, Belch A, Shustik C, Petrucci MT, Duhrsen U, Lu J, Song K, Rodon P, Pegourie B, Garderet L, Hunter H, Azais I, Eek R, Gisslinger H, Macro M, Dakhil S, Goncalves C, LeBlanc R, Romeril K, Royer B, Doyen C, Leleu X, Offner F, Leupin N, Houck V, Chen G, Ervin-Haynes A, **Dimopoulos MA**, Facon T. Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. *J Clin Oncol.* 2016 Jun 20.
794. **Dimopoulos MA**, Moreau P, Palumbo A, Chng WJ, Feng S. Carfilozomib versus bortezomib for relapsed or refractory myeloma - Authors' reply. *Lancet Oncol.* 2016;17:e126.
795. Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D'Agati VD, Kastritis E, **Dimopoulos MA**, Vij R, Bansal D, Dingli D, Nasr SH, Leung N. Proteasome inhibitor associated thrombotic microangiopathy. *Am J Hematol.* 2016;91:E348-52.
796. Siegel DS, Weisel KC, **Dimopoulos MA**, Baz R, Richardson P, Delforge M, Song KW, San Miguel JF, Moreau P, Goldschmidt H, Cavo M, Jagannath S, Yu X, Hong K, Sternas L, Zaki M, Palumbo A. Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. *Leuk Lymphoma.* 2016;57:2833-8.
797. Trachana SP, Pilalis E, Gavalas NG, Tzannis K, Papadodima O, Lontos M, Rodolakis A, Vlachos G, Thomakos N, Haidopoulos D, Lykka M, Koutsoukos K, Kostouros E, Terpos E, Chatziioannou A, **Dimopoulos MA**, Bamias A. The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. *PLoS One.* 2016;11:e0156403.
798. Terpos E, **Dimopoulos MA**, Mouloupoulos LA. The Role of Imaging in the Treatment of Patients With Multiple Myeloma in 2016. *Am Soc Clin Oncol Educ Book.* 2016;35:e407-17.
799. Terpos E, Migkou M, Christoulas D, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Iakovaki M, Panagiotidis I, Ziogas DC, Fotiou D, Kastritis E, **Dimopoulos MA**. Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. *Blood Cancer J.* 2016;6:e428.

800. Fotiou D, Gerotziapas G, Kastritis E, **Dimopoulos MA**, Terpos E. A review of the venous thrombotic issues associated with multiple myeloma. *Expert Rev Hematol*. 2016;9:695-706.
801. **Dimopoulos MA**, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anttila P, Cafo AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Rollig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. *Blood*. 2016;128:497-503.
802. Moreau P, van de Donk NW, Miguel JS, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, **Dimopoulos MA**, Sondergeld P, Sonneveld P, Mateos MV. Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. *Drugs*. 2016;76:989-90.
803. Zagouri F, Terpos E, Kastritis E, **Dimopoulos MA**. Emerging antibodies for the treatment of multiple myeloma. *Expert Opin Emerg Drugs*. 2016;21:225-37.
804. Moreau P, Weisel KC, Song KW, Gibson CJ, Saunders O, Sternas LA, Hong K, Zaki MH, **Dimopoulos MA**. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). *Leuk Lymphoma*. 2016;57:2839-47.
805. Kastritis E, Papassotiriou I, Terpos E, Roussou M, Gavriatopoulou M, Komitopoulou A, Skevaki C, Eleutherakis-Papaiakovou E, Pamboucas C, Psimenou E, Manios E, Giannouli S, Politou M, Gakiopoulou H, Papadopoulou E, Stamatelopoulos K, Tasidou A, **Dimopoulos MA**. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. *Blood*. 2016;128:405-9.
806. Fountzilias G, Giannoulatou E, Alexopoulou Z, Zagouri F, Timotheadou E, Papadopoulou K, Lakis S, Bobos M, Poullos C, Sotiropoulou M, Lyberopoulou A, Gogas H, Pentheroudakis G, Pectasides D, Koutras A, Christodoulou C, Papandreou C, Samantas E, Papakostas P, Kosmidis P, Bafaloukos D, Karanikiotis C, **Dimopoulos MA**, Kotoula V. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. *Oncotarget*. 2016;7:32731-53.
807. Moreau P, van de Donk NW, San Miguel J, Lokhorst H, Nahi H, Ben-Yehuda D, Cavo M, Cook G, Delforge M, Einsele H, Zweegman S, Ludwig H, Driessen C, Palumbo A, Facon T, Plesner T, **Dimopoulos MA**, Sondergeld P, Sonneveld P, Mateos MV. Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma. *Drugs*. 2016;76:853-67.
808. Sergentanis TN, Kastritis E, Terpos E, **Dimopoulos MA**, Psaltopoulou T. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects. *Clin Lymphoma Myeloma Leuk*. 2016;16:335-40.
809. Weisel KC, **Dimopoulos MA**, Moreau P, Lacy MQ, Song KW, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Knop S, Yu X, Hong K, Sternas L, Jacques C, Zaki MH, San Miguel J. Analysis of renal

- impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma. *Haematologica*. 2016;101:872-8.
810. Kokotis P, Schmelz M, Kostouros E, Karandreas N, **Dimopoulos MA**. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study. *Clin Colorectal Cancer*. 2016;15:e133-40.
811. Siegel DS, **Dimopoulos MA**, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC. VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2016;16:329-34.
812. Bamias A, Tsantoulis P, Zilli T, Papatsoris A, Caparrotti F, Kyratsas C, Tzannis K, Stravodimos K, Chrisofos M, Wirth GJ, Skolarikos A, Mitropoulos D, Constantinides CA, Deliveliotis C, Iselin CE, Miralbell R, Dietrich PY, **Dimopoulos MA**. Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis. *Cancer Med*. 2016;5:1098-107.
813. **Dimopoulos MA**, Sonneveld P, Leung N, Merlini G, Ludwig H, Kastiris E, Goldschmidt H, Joshua D, Orłowski RZ, Powles R, Vesole DH, Garderet L, Einsele H, Palumbo A, Cavo M, Richardson PG, Moreau P, San Miguel J, Rajkumar SV, Durie BG, Terpos E. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. *J Clin Oncol*. 2016;34:1544-57.
814. Caers J, Fernandez de Larrea C, Leleu X, Heusschen R, Zojer N, Decaux O, Kastiris E, Minnema M, Jurczynski A, Beguin Y, Wasch R, Palumbo A, **Dimopoulos MA**, Mateos MV, Ludwig H, Engelhardt M. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. *Oncologist*. 2016;21:333-42.
815. Zagouri F, Roussou M, Kastiris E, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Kalapanida D, Christoulas D, Migkou M, Terpos E, **Dimopoulos MA**. Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma. *Leuk Lymphoma*. 2016;57:1776-80.
816. **Dimopoulos MA**, Roussou M, Gavriatopoulou M, Psimenou E, Eleutherakis-Papaiakovou E, Migkou M, Matsouka C, Mparmparousi D, Gika D, Kafantari E, Ziogas D, Fotiou D, Panagiotidis I, Terpos E, Kastiris E. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis. *Am J Hematol*. 2016;91:499-502.
817. Duvic M, **Dimopoulos MA**. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies. *Cancer Treat Rev*. 2016;43:58-66.
818. Karavasili V, Papadimitriou C, Gogas H, Kouvatsas G, Pentheroudakis G, Koutras A, Christodoulou C, Bafaloukos D, Samantas E, Pisanidis N, Papakostas P, Aravantinos G, Karanikiotis C, Kosmidis P, Pectasides D, **Dimopoulos MA**, Fountzilias G. Safety and Tolerability

- of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. *Clin Breast Cancer*. 2016;16:291-8 e3.
819. Cohen YC, Joffe E, Benyamini N, **Dimopoulos MA**, Terpos E, Trestman S, Held-Kuznetsov V, Avivi I, Kastiris E. Primary failure of bortezomib in newly diagnosed multiple myeloma--understanding the magnitude, predictors, and significance. *Leuk Lymphoma*. 2016;57:1382-8.
820. Laubach J, Garderet L, Mahindra A, Gahrton G, Caers J, Sezer O, Voorhees P, Leleu X, Johnsen HE, Streetly M, Jurczynski A, Ludwig H, Mellqvist UH, Chng WJ, Pilarski L, Einsele H, Hou J, Turesson I, Zamagni E, Chim CS, Mazumder A, Westin J, Lu J, Reiman T, Kristinsson S, Joshua D, Roussel M, O'Gorman P, Terpos E, McCarthy P, **Dimopoulos MA**, Moreau P, Orłowski RZ, Miguel JS, Anderson KC, Palumbo A, Kumar S, Rajkumar V, Durie B, Richardson PG. Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group. *Leukemia*. 2016;30:1005-17.
821. **Dimopoulos MA**, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosinol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarzer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orłowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. *Lancet Oncol*. 2016;17:27-38.
822. **Dimopoulos MA**, Cheung MC, Roussel M, Liu T, Gamberi B, Kolb B, Derigs HG, Eom H, Belhadj K, Lenain P, Van der Jagt R, Rigaudeau S, Dib M, Hall R, Jardel H, Jaccard A, Tosikyan A, Karlin L, Bensinger W, Schots R, Leupin N, Chen G, Marek J, Ervin-Haynes A, Facon T. Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma. *Haematologica*. 2016;101:363-70.
823. Drivalos A, Chrisofos M, Efstathiou E, Kapranou A, Kollaitis G, Koutlis G, Antoniou N, Karanastasis D, **Dimopoulos MA**, Bamias A. Expression of alpha5-integrin, alpha7-integrin, Epsilon-cadherin, and N-cadherin in localized prostate cancer. *Urol Oncol*. 2016;34:165 e11-8.
824. Papassotiriou GP, Kastiris E, Gkatzamanidou M, Christoulas D, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Roussou M, Margeli A, Papassotiriou I, **Dimopoulos MA**, Terpos E. Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma. *Clin Lymphoma Myeloma Leuk*. 2016;16:29-35.
825. Richardson PG, Hungria VT, Yoon SS, Beksac M, **Dimopoulos MA**, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Sopala M, Bengoudifa BR, Corrado C, Binlich F, San-Miguel JF. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. *Blood*. 2016;127:713-21.
826. **Dimopoulos MA**, Kastiris E, Ghobrial IM. Waldenstrom's macroglobulinemia: a clinical perspective in the era of novel therapeutics. *Ann Oncol*. 2016;27:233-40.
827. Charitaki E, Kastiris E, Petraki C, Liapis K, Adamidis K, Apostolou T, Christodoulidou C, Nikolopoulou N, Terpos E, Nakopoulou L, **Dimopoulos MA**. Glomerular expression of matrix

- metalloproteinases in AL-amyloidosis and association with renal function at the time of kidney biopsy. *Clin Nephrol.* 2016;85:44-54.
828. Bagratuni T, Terpos E, Eleutherakis-Papaiakovou E, Kalapanida D, Gavriatopoulou M, Migkou M, Liacos CI, Tasidou A, Matsouka C, Mparmparousi D, **Dimopoulos MA**, Kastritis E. TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma. *Br J Haematol.* 2016;172:44-7.
829. Kastritis E, **Dimopoulos MA**. Recent advances in the management of AL Amyloidosis. *Br J Haematol.* 2016;172:170-86.
830. Bamias A, Peroukidis S, Stamatopoulou S, Tzannis K, Koutsoukos K, Andreadis C, Bozionelou V, Pistalimatzian N, Papatsoris A, Stravodimos K, Varthalitis I, Karamouzis M, Milaki G, Agorastos A, Kentepozidis N, Androulakis N, Bompolaki I, Kalofonos H, Mavroudis D, **Dimopoulos MA**. Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG). *Clin Genitourin Cancer.* 2016 Apr;14(2):e153-9.
831. Pistamaltzian N, Tzannis K, Pissanidou V, Peroukidis S, Milaki G, Karavasilis V, Mitsogiannis I, Varkarakis I, Papatsoris A, Dellis A, Adamakis I, Stravodimos K, Molyva D, Athanasiadis I, Androulakis N, Andreadis C, Kalofonos C, Mitropoulos D, Deliveliotis C, Constantinides C, **Dimopoulos MA**, Bamias A. Treatment of relapsed urothelial bladder cancer with vinflunine: real-world evidence by the Hellenic Genitourinary Cancer Group. *Anticancer Drugs.* 2016;27:48-53.
832. Koutsoukos K, Tzannis K, Christodoulou C, Karavasilis V, Bakoyiannis C, Makatsoris T, Papandreou CN, Pectasides D, **Dimopoulos MA**, Bamias A. Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG). *World J Urol.* 2016;34:853-7.
833. Vassilakopoulos TP, Pangalis GA, Chatziioannou S, Papageorgiou S, Angelopoulou MK, Galani Z, Kourti G, Prassopoulos V, Leonidopoulou T, Terpos E, Dimopoulou MN, Sachanas S, Kalpadakis C, Konstantinidou P, Boutsis D, Stefanoudaki E, Kyriazopoulou L, Siakantaris MP, Kyrtsolis MC, Variami E, Kotsianidis I, Symeonidis A, Michali E, Katodritou E, Kokkini G, Tsatalas C, Papadaki H, **Dimopoulos MA**, Sotiropoulos V, Pappa V, Karmiris T, Meletis J, Apostolidis J, Datseris I, Panayiotidis P, Konstantopoulos K, Roussou P, Rondogianni P. PET/CT in primary mediastinal large B-cell lymphoma responding to rituximab-CHOP: An analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. *Leukemia.* 2016;30:238-42.
834. Gavriatopoulou M, Terpos E, Kastritis E, **Dimopoulos MA**. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia. *Expert Opin Investig Drugs.* 2017;26:197-205.
835. Gavriatopoulou M, Terpos E, Kastritis E, **Dimopoulos MA**. Efficacy and safety of elotuzumab for the treatment of multiple myeloma. *Expert Opin Drug Saf.* 2017;16:237-45.
836. Gavriatopoulou M, **Dimopoulos MA**, Kastritis E, Terpos E. Emerging treatment approaches for myeloma-related bone disease. *Expert Rev Hematol.* 2017 Mar;10:217-28

837. Quach H, Fernyhough L, Henderson R, Corbett G, Baker B, Browett P, Blacklock H, Forsyth C, Underhill C, Cannell P, Trotman J, Neylon A, Harrison S, Link E, Swern A, Cowan L, **Dimopoulos MA**, Miles Prince H. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. *Br J Haematol*. 2017 May;177(3):441-448
838. **Dimopoulos MA**, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Palumbo A, Obreja M, Aggarwal S, Moreau P. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. *Br J Haematol*. 2017 May;177(3):404-413
839. Kapelakis I, Toutouzas K, Drakopoulou M, Michelongona A, Zagouri F, Mpamias A, Pliatsika P, **Dimopoulos MA**, Stefanadis C, Tousoulis D. Bevacizumab increases the incidence of cardiovascular events in patients with metastatic breast or colorectal cancer. *Hellenic J Cardiol*. 2017 May - Jun;58(3):215-219
840. D'Sa S, Kersten MJ, Castillo JJ, **Dimopoulos MA**, Kastritis E, Laane E, Leblond V, Merlini G, Treon SP, Vos JM, Lunn MP. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. *Br J Haematol*. 2017;176:728-42
841. Michopoulos S, Chouzouri VI, Manios ED, Grapsa E, Antoniou Z, Papadimitriou CA, Zakopoulos N, **Dimopoulos AM**. Untreated newly diagnosed essential hypertension is associated with nonalcoholic fatty liver disease in a population of a hypertensive center. *Clin Exp Gastroenterol*. 2016;9:1-9
842. Samara P, Skopeliti M, Tsiatas ML, Georgaki S, Gouloumis C, Voelter W, **Dimopoulos AM**, Bamias A, Tsitsilonis OE. A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer. *Anticancer Res*. 2016;36:3373-82.
843. Ludwig H, **Dimopoulos MA**, Moreau P, Chng WJ, Goldschmidt H, Hájek R, Facon T, Pour L, Niesvizky R, Oriol A, Rosiñol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Palumbo A, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Joshua D. Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup. *Leuk Lymphoma*. 2017;58:2501-4.
844. Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, **Dimopoulos MA**, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Role of ¹⁸F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. *Lancet Oncol*. 2017;18:e206-e217.
845. Kastritis E, Gavriatopoulou M, Roussou M, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakevou E, Panagiotidis I, Giannouli S, Psimenou E, Marinaki S, Apostolou T, Gakiopoulou H, Tasidou A, Papassotiriou I, Terpos E, **Dimopoulos MA**. Renal outcomes in

- patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy. *Am J Hematol.* 2017;92:632-9.
846. **Dimopoulos MA**, Stewart AK, Masszi T, Špička I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. *Blood Cancer J.* 2017 Apr 21;7(4):e554.
847. Kastritis E, **Dimopoulos MA**. Prognosis and risk assessment in AL amyloidosis - There and back again. *Br J Haematol.* 2017;177:343-5.
848. Darmon M, Ostermann M, Cerda J, **Dimopoulos MA**, Forni L, Hoste E, Legrand M, Lerolle N, Rondeau E, Schneider A, Souweine B, Schetz M. Diagnostic work-up and specific causes of acute kidney injury. *Intensive Care Med.* 2017;43:829-40.
849. Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, **Dimopoulos MA**, Ludwig H, Einsele H, Zweegman S, Facon T, Cavo M, Terpos E, Goldschmidt H, Attal M, Buske C; ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. *Ann Oncol.* 2017 Jul 1;28(suppl_4):iv52-iv61.
850. Papageorgiou C, Manios E, Tsaltas E, Koroboki E, Alevizaki M, Angelopoulos E, **Dimopoulos MA**, Papageorgiou C, Zakopoulos N. Brain Oscillations Elicited by the Cold Pressor Test: A Putative Index of Untreated Essential Hypertension. *Int J Hypertens.* 2017;2017:7247514.
851. Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, Tzannis K, Kontovinis L, Stravodimos K, Papatsoris A, Mitropoulos D, Deliveliotis C, **Dimopoulos MA**, Constantinides CA. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. *Oncologist.* 2017;22:667-79.
852. Bringhen S, De Wit E, **Dimopoulos MA**. New Agents in Multiple Myeloma: An Examination of Safety Profiles. *Clin Lymphoma Myeloma Leuk.* 2017 Jul;17(7):391-407
853. Kastritis E, Melea P, Bagratuni T, Melakopoulos I, Gavriatopoulou M, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Terpos E, **Dimopoulos MA**. Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy. *Leuk Lymphoma* 2017;58:2304-9.
854. Kumar SK, **Dimopoulos MA**, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. *Leukemia.* 2017 Nov;31(11):2443-2448
855. Kastritis E, Gavriatopoulou M, Roussou M, Fotiou D, Ziogas DC, Migkou M, Eleutherakis-Papaiakovou E, Panagiotidis I, Kanellias N, Psimenou E, Papadopoulou E, Pamboucas C, Manios E, Gakiopoulou H, Ntalianis A, Tasidou A, Giannouli S, Terpos E, **Dimopoulos MA**.

- Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. *Blood Cancer J.* 2017;7:e570.
856. **Dimopoulos MA**, Roussou M, Gavriatopoulou M, Fotiou D, Ziogas DC, Migkou M, Panagiotidis I, Eleutherakis-Papaiakovou E, Kanellias N, Psimenou E, Marinaki S, Bacharaki D, Mparmparoussi D, Matsouka C, Giannouli S, Terpos E, Kastritis E. Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit. *Blood Cancer J.* 2017;7(6):e571.
857. San-Miguel JF, Hungria VTM, Yoon SS, Beksac M, **Dimopoulos MA**, Elghandour A, Jedrzejczak WW, Guenther A, Na Nakorn T, Siritanaratkul N, Schlossman RL, Hou J, Moreau P, Lonial S, Lee JH, Einsele H, Salwender H, Sopala M, Redhu S, Paul S, Corrado C, Richardson PG. Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. *Br J Haematol.* 2017 Oct;179(1):66-74
858. Karageorgopoulou S, Kostakis ID, Gazouli M, Markaki S, Papadimitriou M, Bournakis E, **Dimopoulos MA**, Papadimitriou CA. Prognostic and predictive factors in patients with metastatic or recurrent cervical cancer treated with platinum-based chemotherapy. *BMC Cancer.* 2017;17:451.
859. Michopoulos S, Manios E, Kourkoutas H, Argyriou K, Leonidakis G, Zampeli E, Stamatelopoulos K, **Dimopoulos AM**. Predictors of colorectal cancer screening awareness among people working in a hospital environment. *Ann Gastroenterol.* 2017;30:315-321.
860. Sergentanis TN, Psaltopoulou T, Ntanasis-Stathopoulos I, Liaskas A, Tzanninis IG, **Dimopoulos MA**. Consumption of fruits, vegetables, and risk of hematological malignancies: a systematic review and meta-analysis of prospective studies. *Leuk Lymphoma.* 2018 Feb;59(2):434-447
861. **Dimopoulos MA**, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. *Lancet Oncol.* 2017 Oct;18(10):1327-1337
862. Hillengass J, Mouloupoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, **Dimopoulos MA**, Lentzsch S, Durie B, Terpos E. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. *Blood Cancer J.* 2017 Aug 25;7(8):e599.
863. Kastritis E, **Dimopoulos MA**. Daratumumab combinations: what can we learn? *Blood.* 2017 Aug 24;130(8):957-958.
864. Eleutherakis-Papaiakovou E, **Dimopoulos MA**, Kastritis E, Christoulas D, Roussou M, Migkou M, Gavriatopoulou M, Fotiou D, Panagiotidis I, Ziogas DC, Kanellias N, Papadimitriou C, Terpos E. Low circulating mannan-binding lectin levels correlate with increased frequency and

- severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis. *Bone Marrow Transplant*. 2017 Nov;52(11):1537-1542
865. Ziogas DC, Terpos E, Gavriatopoulou M, Migkou M, Fotiou D, Roussou M, Kanellias N, Tatouli I, Eleutherakis-Papaiakovou E, Panagiotidis I, Ntanasis-Stathopoulos I, Kastritis E, **Dimopoulos MA**. Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases. *Leuk Lymphoma*. 2018 Apr;59(4):983-987
866. Terpos E, Matsaridis D, Koutoulidis V, Zagouri F, Christoulas D, Fontara S, Panourgias E, Gavriatopoulou M, Kastritis E, **Dimopoulos MA**, Mouloupoulos LA. Dynamic contrast-enhanced magnetic resonance imaging parameters correlate with advanced revised-ISS and angiopoietin-1/angiopoietin-2 ratio in patients with multiple myeloma. *Ann Hematol*. 2017 Oct;96(10):1707-1714
867. **Dimopoulos MA**, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. *Br J Haematol*. 2017 Sep;178(6):896-905
868. Zagouri F, Kastritis E, Zomas A, Terpos E, Katodritou E, Symeonidis A, Delimpasi S, Pouli A, Vassilakopoulos TP, Michalis E, Giannouli S, Kartasis Z, Christoforidou A, Kokoviadou K, Hatzimichael E, Gika D, Megalakaki C, Papaioannou M, Kyrtsonis MC, Konstantopoulos K, **Dimopoulos MA**. Hypercalcemia remains an adverse prognostic factor for newly diagnosed multiple myeloma patients in the era of novel anti-myeloma therapies. *Eur J Haematol*. 2017 Nov;99(5):409-414
869. Goldschmidt H, Moreau P, Ludwig H, Niesvizky R, Chng WJ, Joshua D, Weisel K, Spencer A, Orlowski RZ, Feng S, Iskander KS, **Dimopoulos MA**. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. *Leuk Lymphoma*. 2018 Jun;59(6):1364-1374. Epub 2017 Sep 22.
870. Terpos E, Christoulas D, Gavriatopoulou M, **Dimopoulos MA**. Mechanisms of bone destruction in multiple myeloma. *Eur J Cancer Care (Engl)*. 2017 Nov;26(6).
871. Ziogas DC, Terpos E, Kastritis E, **Dimopoulos MA**. An overview of the role of carfilzomib in the treatment of multiple myeloma. *Expert Opin Pharmacother*. 2017 Dec;18(17):1883-1897.
872. Facon T, **Dimopoulos MA**, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldès C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. *Blood*. 2018 Jan 18;131(3):301-310.
873. Gavriatopoulou M, Kastritis E, Ntanasis-Stathopoulos I, Fotiou D, Roussou M, Migkou M, Ziogas DC, Kanellias N, Terpos E, **Dimopoulos MA**. The addition of IMiDs for patients with

- daratumumab-refractory multiple myeloma can overcome refractoriness to both agents. *Blood*. 2018 Jan 25;131(4):464-467
874. Li Y, Wang X, O'Mara E, **Dimopoulos MA**, Sonneveld P, Weisel KC, Matous J, Siegel DS, Shah JJ, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S. Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. *Clin Pharmacol*. 2017 Nov 8;9:133-145.
875. Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaselan V, Tai YT, Mudie L, O'Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, **Dimopoulos MA**, Corradini P, Anderson K, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. *Leukemia*. 2017 Dec 6. doi: 10.1038/leu.2017.344. [Epub ahead of print]
876. Ntanasis-Stathopoulos I, Gavriatopoulou M, Eleftherakis-Papaiakovou E, Kastritis E, Terpos E, **Dimopoulos MA**. Rare manifestations of extramedullary myeloma: testicular plasmacytomas. *Leuk Lymphoma*. 2018 Aug;59(8):2002-2004.
877. Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, Caers J, Gramatzki M, van de Donk N, Oliva S, Zamagni E, Garderet L, Straka C, Hajek R, Ludwig H, Einsele H, **Dimopoulos MA**, Boccadoro M, Kröger N, Cavo M, Goldschmidt H, Bruno B, Sonneveld P. From transplant to novel cellular therapies in multiple myeloma: EMN guidelines and future perspectives. *Haematologica*. 2018 Feb;103(2):197-211
878. Mateos MV, **Dimopoulos MA**, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. *N Engl J Med*. 2018 Feb 8;378(6):518-528.
879. Tsakiri EN, Terpos E, Papanagnou ED, Kastritis E, Briudes V, Halabalaki M, Bagratuni T, Florea BI, Overkleeft HS, Scorrano L, Skaltsounis AL, **Dimopoulos MA**, Trougakos IP. Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events. *Sci Rep*. 2017 Dec 19;7(1):17802.
880. Anastasiou M, Oikonomou E, Zagouri F, Siasos G, Antonopoulos AS, Psaltopoulou T, Bamias A, **Dimopoulos MA**, Tousoulis D. Flow-Mediated Dilation of Brachial Artery as a Screening Tool for Anthracycline-Induced Cardiotoxicity. *J Am Coll Cardiol*. 2017 Dec 19;70(24):3072.
881. Kastritis E, **Dimopoulos MA**. Disease control should be the goal of therapy for WM patients. *Blood Adv*. 2017 Nov 28;1(25):2483-2485.
882. **Dimopoulos MA**, Roussou M, Gavriatopoulou M, Psimenou E, Ziogas D, Eleftherakis-Papaiakovou E, Fotiou D, Migkou M, Kanellias N, Panagiotidis I, Ntalianis A, Papadopoulou E, Stamatelopoulos K, Manios E, Pamboukas C, Kontogiannis S, Terpos E, Kastritis E. Cardiac and renal complications of carfilzomib in patients with multiple myeloma. *Blood Adv*. 2017 Feb 27;1(7):449-454.

883. **Dimopoulos MA**, Kimball AS. Carfilzomib for relapsed or refractory multiple myeloma - Authors' reply. *Lancet Oncol*. 2018 Jan;19(1):e2.
884. Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, **Dimopoulos MA**. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. *Blood Cancer J*. 2018 Jan 12;8(1):7.
d
885. Kouerinis IA, Tolia M, Zagouri F, Nikolaou M, Tsoukalas N, Kyrgias G, **Dimopoulos MA**, Vlachopoulos C, Karathanassis I, Zoubouli CK, Kokakis I, Kouloulas V, Triantafillou K. Stage-II thymoma and emergency coronary artery bypass. To irradiate or not to irradiate to avoid radiation induced vascular injury? Case report and literature review. *J BUON*. 2017 Nov-Dec;22(6):1385-1389.
886. Siegel DS, **Dimopoulos MA**, Ludwig H, Facon T, Goldschmidt H, Jakubowiak A, San-Miguel J, Obreja M, Blaedel J, Stewart AK. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. *J Clin Oncol*. 2018 Mar 10;36(8):728-734
887. Kastritis E, Papassotiriou I, Merlini G, Milani P, Terpos E, Basset M, Akalestos A, Russo F, Psimenou E, Apostolakou F, Roussou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Fotiou D, Ziogas DC, Papadopoulou E, Pamboucas C, **Dimopoulos MA**, Palladini G. Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis. *Blood*. 2018 Apr 5;131(14):1568-1575
888. **Dimopoulos MA**, Kastritis E. Denosumab for myeloma bone disease: ready for prime time? *Lancet Oncol*. 2018 Mar;19(3):277-278.
889. **Dimopoulos MA**, Kaufman JL, White D, Cook G, Rizzo M, Xu Y, Fahrback K, Gaudig M, Slavcev M, Dearden L, Lam A. A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis. *Clin Lymphoma Myeloma Leuk*. 2018 Mar;18(3):163-173.e6.
890. Psaltopoulou T, Sergentanis TN, Ntanasis-Stathopoulos I, Tzanninis IG, Tsilimigras DI, **Dimopoulos MA**. Alcohol consumption and risk of hematological malignancies: A meta-analysis of prospective studies. *Int J Cancer*. 2018 Aug 1;143(3):486-495.
891. Katodritou E, Terpos E, Delimpasi S, Kotsopoulou M, Michalis E, Vadikolia C, Kyrtsionis MC, Symeonidis A, Giannakoulas N, Vadikolia C, Michael M, Kalpadakis C, Gougopoulou T, Prokopiou C, Kaiafa G, Christoulas D, Gavriatopoulou M, Giannopoulou E, Labropoulou V, Verrou E, Kastritis E, Konstantinidou P, Anagnostopoulos A, **Dimopoulos MA**. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group. *Blood Cancer J*. 2018 Mar 9;8(3):31.
892. Gavriatopoulou M, Kastritis E, **Dimopoulos MA**. Ibrutinib for rituximab-refractory Waldenström macro-globulinemia. *Oncotarget*. 2017 Dec 18;9(16):12536-12537.
893. Fotiou D, **Dimopoulos MA**, Kastritis E. How We Manage Patients with Plasmacytomas. *Curr Hematol Malig Rep*. 2018 Jun;13(3):227-235

894. Eleutherakis-Papaiakovou E, Kastritis E, Gavriatopoulou M, Christoulas D, Roussou M, Ntanasis-Stathopoulos I, Kanellias N, Papatheodorou A, **Dimopoulos MA**, Terpos E. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia. *Clin Lymphoma Myeloma Leuk*. 2018 Jun;18(6):431-437.
895. Papanagnou ED, Terpos E, Kastritis E, Papassideri IS, Tsitsilonis OE, **Dimopoulos MA**, Trougakos IP. Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent. *Oncotarget*. 2018 Apr 3;9(25):17797-17809.
896. Suzuki K, **Dimopoulos MA**, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, Kosugi H, Yoon SS, Huang SY, Qin X, Qi M, Iida S. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. *Blood Cancer J*. 2018 May 1;8(4):41.
897. Ludwig H, Delforge M, Facon T, Einsele H, Gay F, Moreau P, Avet-Loiseau H, Boccadoro M, Hajek R, Mohty M, Cavo M, **Dimopoulos MA**, San-Miguel JF, Terpos E, Zweegman S, Garderet L, Mateos MV, Cook G, Leleu X, Goldschmidt H, Jackson G, Kaiser M, Weisel K, van de Donk NWCJ, Waage A, Beksac M, Mellqvist UH, Engelhardt M, Caers J, Driessen C, Bladé J, Sonneveld P. Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. *Leukemia*. 2018 Jul;32(7):1542-1560
898. Kumar S, Durie B, Nahi H, Vij R, **Dimopoulos MA**, Kastritis E, Terpos E, Leleu X, Beksac M, Goldschmidt H, Hillengass J, Su Z, Hutton B, Cameron C, Khan I, Lam A. Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. *Leuk Lymphoma*. 2019 Jan;60(1):163-171
899. Terpos E, Ntanasis-Stathopoulos I, Christoulas D, Bagratuni T, Bakogeorgos M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, **Dimopoulos MA**. Semaphorin 4D correlates with increased bone resorption, hypercalcemia, and disease stage in newly diagnosed patients with multiple myeloma. *Blood Cancer J*. 2018 May 11;8(5):42.
900. Dumontet C, Hulin C, **Dimopoulos MA**, Belch A, Dispenzieri A, Ludwig H, Rodon P, Van Droogenbroeck J, Qiu L, Cavo M, Van de Velde A, Lahuerta JJ, Allangba O, Lee JH, Boyle E, Perrot A, Moreau P, Manier S, Attal M, Roussel M, Mohty M, Mary JY, Civet A, Costa B, Tinel A, Gaston-Mathé Y, Facon T. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. *Leukemia*. 2018 Jun;32(6):1404-1413.
901. Migkou M, Gavriatopoulou M, Terpos E, **Dimopoulos MA**. Optimizing therapy in bortezomib-exposed patients with multiple myeloma. *Expert Rev Hematol*. 2018 Jun;11(6):463-469.
902. Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, Kanellias N, Ziogas DC, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Trougakos IP, Tsitsilonis O, **Dimopoulos MA**. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. *Blood Cancer J*. 2018 May 24;8(5):46.
903. **Dimopoulos MA**, Tedeschi A, Trotman J, García-Sanz R, Macdonald D, Leblond V, Mahe B, Herbaux C, Tam C, Orsucci L, Palomba ML, Matous JV, Shustik C, Kastritis E, Treon SP, Li

- J, Salman Z, Graef T, Buske C; iINNOVATE Study Group and the European Consortium for Waldenström's Macroglobulinemia. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. *N Engl J Med*. 2018 Jun 21;378(25):2399-2410.
904. Ziogas DC, Tsiara A, Tsironis G, Lykka M, Liontos M, Bamias A, **Dimopoulos MA**. Treating ALK-positive non-small cell lung cancer. *Ann Transl Med*. 2018 Apr;6(8):141.
905. Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, **Dimopoulos MA**. Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore? *Ann Transl Med*. 2018 Apr;6(8):143.
906. Tsiara A, Liontos M, Kaparelou M, Zakopoulou R, Bamias A, **Dimopoulos MA**. Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). *Ann Transl Med*. 2018 Apr;6(8):144.
907. Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, **Dimopoulos MA**, Huang M, Zahlten-Kumeli A, Stewart AK. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. *Lancet Oncol*. 2018 Jul;19(7):953-964.
908. Larocca A, Dold SM, Zweegman S, Terpos E, Wäsch R, D'Agostino M, Scheubeck S, Goldschmidt H, Gay F, Cavo M, Ludwig H, Straka C, Bringhen S, Auner HW, Caers J, Gramatzki M, Offidani M, **Dimopoulos MA**, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M. Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). *Leukemia*. 2018 Aug;32(8):1697-1712.
909. Buske C, Sadullah S, Kastritis E, Tedeschi A, García-Sanz R, Bolkun L, Leleu X, Willenbacher W, Hájek R, Minnema MC, Cheng M, Bilotti E, Graef T, **Dimopoulos MA**; European Consortium for Waldenström's Macroglobulinemia. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. *Lancet Haematol*. 2018 Jul;5(7):e299-e309.
910. **Dimopoulos MA**, Kastritis E. Managing myeloma with limited resources in the era of novel drugs. *Leuk Lymphoma*. 2018 Oct;59(10):2269-2270.
911. Kastritis E, Leblond V, **Dimopoulos MA**, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018 Oct 1;29(Supplement_4):iv270.
912. Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, Mavrianou-Koutsoukou N, Liacos C, Patseas D, Kanellias N, Migkou M, Ziogas DC, Eleutherakis-Papaiakovou E, Roussou M, Fotiou D, Terpos E, Kastritis E, **Dimopoulos MA**. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. *Leukemia*. 2018 Dec;32(12):2617-2625.
913. Terpos E, Katodritou E, de la Rubia J, Hungria V, Hulin C, Roussou M, Delforge M, Bries G, Stoppa AM, Aagesen J, Sargin D, Belch A, Ahlberg L, Diels J, Olie RA, Robinson D Jr, Spencer M, Potamianou A, van de Velde H, **Dimopoulos MA**. Bortezomib-based therapy for

- relapsed/refractory multiple myeloma in real-world medical practice. *Eur J Haematol*. 2018 Oct;101(4):556-565.
914. Gavriatopoulou M, Musto P, Caers J, Merlini G, Kastiris E, van de Donk N, Gay F, Hegenbart U, Hajek R, Zweegman S, Bruno B, Straka C, **Dimopoulos MA**, Einsele H, Boccadoro M, Sonneveld P, Engelhardt M, Terpos E. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. *Leukemia*. 2018 Sep;32(9):1883-1898.
915. Goussia A, Simou N, Zagouri F, Manousou K, Lazaridis G, Gogas H, Koutras A, Sotiropoulou M, Pentheroudakis G, Bafaloukos D, Markopoulos C, Patsea H, Christodoulou C, Papakostas P, Zaramboukas T, Samantas E, Kosmidis P, Venizelos V, Karanikiotis C, Papatsibas G, Xepapadakis G, Kalogeras KT, Bamia C, **Dimopoulos MA**, Malamou-Mitsi V, Fountzilias G, Batistatou A. Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. *PLoS One*. 2018 Jul 31;13(7):e0200302.
916. Qian X, **Dimopoulos MA**, Amatangelo M, Bjorklund C, Towfic F, Flynt E, Weisel KC, Ocio EM, Yu X, Peluso T, Sternas L, Zaki M, Moreau P, Thakurta A. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. *Leuk Lymphoma*. 2019 Feb;60(2):462-470.
917. Caers J, Garderet L, Kortüm KM, O'Dwyer ME, van de Donk NWCJ, Binder M, Dold SM, Gay F, Corre J, Beguin Y, Ludwig H, Larocca A, Driessen C, **Dimopoulos MA**, Boccadoro M, Gramatzki M, Zweegman S, Einsele H, Cavo M, Goldschmidt H, Sonneveld P, Delforge M, Auner HW, Terpos E, Engelhardt M. An European Myeloma Network recommendation on tools for diagnosis and monitoring of multiple myeloma: what to use and when. *Haematologica*. 2018 Nov;103(11):1772-1784.
918. Kastiris E, **Dimopoulos MA**. Proteasome Inhibitors in Waldenström Macroglobulinemia. *Hematol Oncol Clin North Am*. 2018 Oct;32(5):829-840.
919. **Dimopoulos MA**, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG. Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial. *Cancer*. 2018 Oct 15;124(20):4032-4043.
920. Mohty M, Terpos E, Mateos MV, Cavo M, Lejniece S, Beksac M, Bekadja MA, Legiec W, **Dimopoulos M**, Stankovic S, Durán MS, De Stefano V, Corso A, Kochkareva Y, Laane E, Berthou C, Salwender H, Masliak Z, Pečeliūnas V, Willenbacher W, Silva J, Louw V, Nemet D, Borbényi Z, Abadi U, Pedersen RS, Černelč P, Potamianou A, Couturier C, Feys C, Thoret-Bauchet F, Boccadoro M; EMMOS Investigators. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. *Clin Lymphoma Myeloma Leuk*. 2018 Oct;18(10):e401-e419.

921. **Dimopoulos MA**, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, M, Leleu X, LeBlanc R, Suzuki K, Raab M, Richardson P, McKiver MP, Jou Y-M, Shelat S, Robbins M, Rafferty B and San-Miguel J. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. *N Engl J Med* 2018; 379:1811-1822.
922. Gavriatopoulou M, Terpos E, Ntanasis-Stathopoulos I, Pappasotiriou I, Fotiou D, Migkou M, Roussou M, Kanellias N, Ziogas D, Dialoupi I, Eleutherakis Papaikovou E, Kastritis E, **Dimopoulos MA**. Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. *Clin Lymphoma Myeloma Leuk*. 2019 Jan;19(1):23-28.
923. **Dimopoulos MA**, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schechter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. *Haematologica*. 2018 Dec;103(12):2088-2096.
924. Tsiatas M, Kalogeras KT, Manousou K, Wirtz RM, Gogas H, Veltrup E, Zagouri F, Lazaridis G, Koutras A, Christodoulou C, Pentheroudakis G, Petraki C, Bafaloukos D, Pectasides D, Kosmidis P, Samantas E, Karanikiotis C, Papakostas P, **Dimopoulos MA**, Fountzilas G. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. *Cancer Med*. 2018 Oct;7(10):5066-5082.
925. Kastritis E, Leblond V, **Dimopoulos MA**, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C; ESMO Guidelines Committee. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2018 Oct 1;29(Supplement_4):iv270.
926. Kanellias N, Gavriatopoulou M, Terpos E, **Dimopoulos MA**. Management of multiple myeloma bone disease: impact of treatment on renal function. *Expert Rev Hematol*. 2018 Nov;11(11):881-888.
927. Mouloupoulos LA, Koutoulidis V, Hillengass J, Zamagni E, Aquerreta JD, Roche CL, Lentzsch S, Moreau P, Cavo M, Miguel JS, **Dimopoulos MA**, Rajkumar SV, Durie BGM, Terpos E, Delorme S. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group. *Blood Cancer J*. 2018 Oct 4;8(10):95.
928. **Dimopoulos MA**, Kastritis E. Thalidomide for myeloma: still here? *Lancet Haematol*. 2018 Oct;5(10):e439-e440.
929. Koutsoukis A, Ntalianis A, Repasos E, Kastritis E, **Dimopoulos MA**, Paraskevaidis I. Cardio-oncology: A Focus on Cardiotoxicity. *Eur Cardiol*. 2018 Aug;13(1):64-69.
930. Ziogas DC, **Dimopoulos MA**, Kastritis E. Prognostic factors for multiple myeloma in the era of novel therapies. *Expert Rev Hematol*. 2018 Nov;11(11):863-879.

931. Bamias A, Karavasilis V, Gavalas N, Tzannis K, Samantas E, Aravantinos G, Koutras A, Gkerzelis I, Kostouros E, Koutsoukos K, Zagouri F, Fountzilias G, **Dimopoulos MA**. The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. *Int J Clin Oncol*. 2019 Apr;24(4):411-419.
932. Xu XS, **Dimopoulos MA**, Sonneveld P, Ho PJ, Belch A, Leiba M, Capra M, Gomez D, Medvedova E, Iida S, Min CK, Schechter J, Jansson R, Zhang L, Sun YN, Clemens PL. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma. *Adv Ther*. 2018 Nov;35(11):1859-1872.
933. **Dimopoulos MA**, Dytveld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2018 Nov 8;379(19):1811-1822.
934. Fotiou D, Sergentanis TN, Papageorgiou L, Stamatelopoulos K, Gavriatopoulou M, Kastritis E, Psaltopoulou T, Salta S, Van Dreden P, Sangare R, Larsen AK, Terpos E, Elalamy I, **Dimopoulos MA**, Gerotziafas GT. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study. *Blood Cancer J*. 2018 Nov 7;8(11):102.
935. Richardson PG, San Miguel JF, Moreau P, Hajek R, **Dimopoulos MA**, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. *Blood Cancer J*. 2018 Nov 9;8(11):109.
936. Tsironis G, Koutsoukos K, Athanasakis K, Tsiara A, Tzannis K, Gerolympou M, Visvikis A, Oikonomopoulos G, Kollia A, Giannopoulou E, Dimitra M, Kostouros E, Papatsoris A, Dellis A, Stravodimos K, Varkarakis I, Samantas E, Aravantinos G, Kentepozidis N, Christodoulou C, Bozionelou V, **Dimopoulos MA**, Bamias A. Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece--the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). *Expert Rev Pharmacoecon Outcomes Res*. 2019 Aug;19(4):491-501.
937. **Dimopoulos MA**, Salman Z, Buske C. Ibrutinib and Rituximab in Waldenström's Macroglobulinemia. *N Engl J Med*. 2018 Nov 15;379(20):1975-1976.
938. Kumar SK, Grzasko N, Delimpasi S, Jedrzejczak WW, Grosicki S, Kyrtsionis MC, Spencer A, Gupta N, Teng Z, Byrne C, Labotka R, **Dimopoulos MA**. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. *Br J Haematol*. 2019 Feb;184(4):536-546.
939. Gavriatopoulou M, Terpos E, **Dimopoulos MA**. IMiDs for myeloma induced renal impairment. *Oncotarget*. 2018 Oct 26;9(84):35476-35477.
940. **Dimopoulos MA**, Grosicki S, Jędrzejczak WW, Nahi H, Gruber A, Hansson M, Gupta N, Byrne C, Labotka R, Teng Z, Yang H, Grzasko N, Kumar S. All-oral ixazomib, cyclophosphamide,

- and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Eur J Cancer*. 2019 Jan;106:89-98.
941. Efentakis P, Kremastiotis G, Varela A, Nikolaou PE, Papanagnou ED, Davos CH, Tsoumani M, Agrogiannis G, Konstantinidou A, Kastritis E, Kanaki Z, Iliodromitis EK, Klinakis A, **Dimopoulos MA**, Trougkos IP, Andreadou I, Terpos E. Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin. *Blood*. 2019 Feb 14;133(7):710-723.
942. Kastritis E, Leblond V, **Dimopoulos MA**, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C. Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2019 May 1;30(5):860-862.
943. Kyriazoglou A, Lontos M, Ziogas DC, Zagouri F, Koutsoukos K, Tsironis G, Tsiara A, Kaparelou M, Zakopoulou R, Thomakos N, Haidopoulos D, Papaspyrou I, Rodolakis A, Bamias A, **Dimopoulos MA**. Management of uterine sarcomas and prognostic indicators: real world data from a single-institution. *BMC Cancer*. 2018 Dec 13;18(1):1247.
944. **Dimopoulos MA**, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. *Lancet*. 2019 Jan 19;393(10168):253-264.
945. Gavriatopoulou M, Fotiou D, Ntanas-Stathopoulos I, Kastritis E, Terpos E, **Dimopoulos MA**. How I treat elderly patients with plasma cell dyscrasias. *Aging (Albany NY)*. 2018 Dec 18;10(12):4248-4268.
946. Terpos E, Kastritis E, Ntanas-Stathopoulos I, Christoulas D, Papatheodorou A, Eleutherakis-Papaiakovou E, Kanellias N, Fotiou D, Ziogas DC, Migkou M, Roussou M, Trougkos IP, Gavriatopoulou M, **Dimopoulos MA**. Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates. *Am J Hematol*. 2019 Apr;94(4):400-407.
947. Kyriazoglou A, Lontos M, Papadopoulos C, Bilali A, Kostouros E, Pagoni S, Doulas K, **Dimopoulos MA**, Bamias A. Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature. *Clin Genitourin Cancer*. 2019 Apr;17(2):e360-e364.
948. Psaltopoulou T, Sergentanis TN, Ntanas-Stathopoulos I, Tzanninis IG, Riza E, **Dimopoulos MA**. Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies. *Int J Cancer*. 2019 Jul 15;145(2):347-359.
949. Gavriatopoulou M, Ntanas-Stathopoulos I, Kastritis E, **Dimopoulos MA**. How I treat rituximab refractory patients with WM. *Oncotarget*. 2018 Dec 7;9(96):36824-36825.
950. Gavriatopoulou M, Fotiou D, Koloventzou U, Roussou M, Migkou M, Ntanas-Stathopoulos I, Kanellias N, Ziogas DC, Panagiotidis I, Gika D, Eleutherakis-Papaiakovou E, Terpos E,

- Kastritis E, **Dimopoulos MA**. Vulnerability variables among octogenerian myeloma patients: a single-center analysis of 110 patients. *Leuk Lymphoma*. 2019 Mar;60(3):619-628.
951. Terpos E, Katodritou E, Symeonidis A, Zagouri F, Gerofotis A, Christopoulou G, Gavriatopoulou M, Christoulas D, Ntanasis-Stathopoulos I, Kourakli A, Konstantinidou P, Kastritis E, **Dimopoulos MA**. Effect of induction therapy with lenalidomide, doxorubicin and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. *Int J Cancer*. 2019 Jul 15;145(2):559-568.
952. Kalapanida D, Zagouri F, Gazouli M, Zografos E, Dimitrakakis C, Marinopoulos S, Giannos A, Sergentanis TN, Kastritis E, Terpos E, **Dimopoulos MA**. Evaluation of pre-mir-34a rs72631823 single nucleotide polymorphism in triple negative breast cancer: A case-control study. *Oncotarget*. 2018 Dec 11;9(97):36906-36913.
953. Kastritis E, Gavriatopoulou M, Roussou M, Bagratuni T, Migkou M, Fotiou D, Ziogas DC, Kanellias N, Eleutherakis-Papaiakovou E, Dialoupi I, Ntanasis-Stathopoulos I, Spyropoulou-Vlachou M, Psimenou E, Gakiopoulou H, Marinaki S, Papadopoulou E, Ntalianis A, Terpos E, **Dimopoulos MA**. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis. *Amyloid*. 2018 Dec;25(4):234-241.
954. Moutafi M, Ziogas DC, Michopoulos S, Bagratuni T, Vasileiou V, Verga L, Merlini G, Palladini G, Matsouka C, **Dimopoulos MA**, Kastritis E. A new genetic variant of hereditary apolipoprotein A-I amyloidosis: a case-report followed by discussion of diagnostic challenges and therapeutic options. *BMC Med Genet*. 2019 Jan 21;20(1):23.
955. Liapis K, Panagopoulou P, Charitaki E, Rowczenio D, Gilbertson J, Papatoma A, Kostopoulou M, **Dimopoulos MA**, Gillmore JD, Kastritis E. Hereditary systemic amyloidosis caused by K19T apolipoprotein C-II variant. *Amyloid*. 2019 Mar;26(1):52-53.
956. Thakurta A, Ortiz M, Blecua P, Towfic F, Corre J, Serbina NV, Flynt E, Yu Z, Yang Z, Palumbo A, **Dimopoulos MA**, Gutierrez NC, Goldschmidt H, Sonneveld P, Avet-Loiseau H. High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. *Blood*. 2019 Mar 14;133(11):1217-1221.
957. Ntanasis-Stathopoulos I, Terpos E, **Dimopoulos MA**. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma. *Cancer J*. 2019 Jan/Feb;25(1):2-10.
958. Hulin C, de la Rubia J, **Dimopoulos MA**, Terpos E, Katodritou E, Hungria V, De Samblanx H, Stoppa AM, Aagesen J, Sargin D, Sioni A, Belch A, Diels J, Olie RA, Robinson D Jr, Potamianou A, van de Velde H, Delforge M. Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practice. *Health Sci Rep*. 2018 Dec 7;2(1):e104.
959. Gavriatopoulou M, Terpos E, **Dimopoulos MA**. The extended 4-year follow-up results of the ELOQUENT-2 trial. *Oncotarget*. 2019 Jan 4;10(2):82-83.
960. Bringhen S, Milan A, D'Agostino M, Ferri C, Wäsch R, Gay F, Larocca A, Offidani M, Zweegman S, Terpos E, Goldschmidt H, Cavo M, Ludwig H, Driessen C, Auner HW, Caers J, Gramatzki M, **Dimopoulos MA**, Boccadoro M, Einsele H, Sonneveld P, Engelhardt M. Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients

- receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. *J Intern Med.* 2019 Jul;286(1):63-74.
961. Gonzalez-McQuire S, **Dimopoulos MA**, Weisel K, Bouwmeester W, Hájek R, Campioni M, Bennison C, Xu W, Pantiri K, Hensen M, Terpos E, Knop S. Development of an Initial Conceptual Model of Multiple Myeloma to Support Clinical and Health Economics Decision Making. *MDM Policy Pract.* 2019 Jan 17;4(1):2381468318814253.
962. Ioannidis A, Koutserimpas C, Papatsoris A, Argyrou A, Deliveliotis H, Velimezis G, **Dimopoulos AM**. Monophasic synovial sarcoma as a cause of obstructive ileus: A case report. *Mol Clin Oncol.* 2019 Jan;10(1):185-187
963. **Dimopoulos M**, Siegel D, White DJ, Boccia R, Iskander KS, Yang Z, Kimball AS, Mezzi K, Ludwig H, Niesvizky R. Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR. *Blood.* 2019 Jan 10;133(2):147-155.
964. Terpos E, Ntanasis-Stathopoulos I, **Dimopoulos MA**. Myeloma bone disease: from biology findings to treatment approaches. *Blood.* 2019 Apr 4;133(14):1534-1539.
965. Bustoros M, Kastiris E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, **Dimopoulos MA**. Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. *Am J Hematol.* 2019 May;94(5):E146-E149.
966. Ludwig H, Moreau P, **Dimopoulos MA**, Mateos MV, Kaiser M, Hajek R, Feng S, Cocks K, Buchanan J, Weisel K. Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma. *Blood Cancer J.* 2019 Feb 22;9(3):23.
967. Kyriakou C, Molloy S, Vrionis F, Alberico R, Bastian L, Zonder JA, Giralt S, Raje N, Kyle RA, Roodman DGD, **Dimopoulos MA**, Rajkumar SV, Durie BBG, Terpos E. The role of cement augmentation with percutaneous vertebroplasty and balloon kyphoplasty for the treatment of vertebral compression fractures in multiple myeloma: a consensus statement from the International Myeloma Working Group (IMWG). *Blood Cancer J.* 2019 Feb 26;9(3):27.
968. Gavriatopoulou M, Ntanasis-Stathopoulos I, **Dimopoulos MA**, Terpos E. Anti-BCMA antibodies in the future management of multiple myeloma. *Expert Rev Anticancer Ther.* 2019 Apr;19(4):319-326
969. Bagratuni T, Sklirou AD, Kastiris E, Liacos CI, Spilioti C, Eleutherakis-Papaiakovou E, Kanellias N, Gavriatopoulou M, Terpos E, Trougakos IP, **Dimopoulos MA**. Toll-Like Receptor 4 Activation Promotes Multiple Myeloma Cell Growth and Survival Via Suppression of The Endoplasmic Reticulum Stress Factor Chop. *Sci Rep.* 2019 Mar 1;9(1):3245.
970. Kastiris E, **Dimopoulos MA**. A 50-Year-Long Study of Waldenström Macroglobulinemia. *Mayo Clin Proc.* 2019 Mar;94(3):394-396.
971. Trakada G, Kastiris E, Gavriatopoulou M, Velentza L, Fotiou D, Ziogas DC, Panagiotidis I, Eleutherakis-Papaiakovou E, Roussou M, Migkou M, Kanellias N, Ntanasis-Stathopoulos I,

- Kallianos A, Terpos E, **Dimopoulos MA**. Pulmonary function abnormalities are common in patients with multiple myeloma and are independently associated with worse outcome. *Ann Hematol*. 2019 Jun;98(6):1427-1434.
972. Kyriazoglou A, Zagouri F, Fotiou D, Dimitrakakis C, Marinopoulos S, Zakopoulou R, Kaparelou M, Zygogianni A, **Dimopoulos MA**. Discrepancies of current recommendations in breast cancer follow-up: a systematic review. *Breast Cancer*. 2019 Sep;26(5):681-686.
973. Sergentanis TN, Ntanasis-Stathopoulos I, Tzanninis IG, Gavriatopoulou M, Sergentanis IN, **Dimopoulos MA**, Psaltopoulou T. Meat, fish, dairy products and risk of hematological malignancies in adults - a systematic review and meta-analysis of prospective studies. *Leuk Lymphoma*. 2019 Aug;60(8):1978-1990.
974. **Dimopoulos MA**, Laubach JP, Echeveste Gutierrez MA, Grzasko N, Hofmeister CC, San-Miguel JF, Kumar S, Labotka R, Lu V, Berg D, Byrne C, Teng Z, Liu G, van de Velde H, Richardson PG. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. *Eur J Haematol*. 2019 Jun;102(6):494-503.
975. Fotiou D, Gavriatopoulou M, Ntanasis-Stathopoulos I, Migkou M, **Dimopoulos MA**, Terpos E. Updates on thrombotic events associated with multiple myeloma. *Expert Rev Hematol*. 2019 May;12(5):355-365.
976. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, Liu CJ, Kastritis E, Zanwar S, Fell G, Abeykoon JP, Hornburg K, Neuse CJ, Marinac CR, Liu D, Soiffer J, Gavriatopoulou M, Boehner C, Cappuccio JM, Dumke H, Reyes K, Soiffer RJ, Kyle RA, Treon SP, Castillo JJ, **Dimopoulos MA**, Ansell SM, Trippa L, Ghobrial IM. Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. *J Clin Oncol*. 2019 Jun 1;37(16):1403-1411.
977. Lontos M, Kyriazoglou A, Dimitriadis I, **Dimopoulos MA**, Bamias A. Systemic therapy in cervical cancer: 30 years in review. *Crit Rev Oncol Hematol*. 2019 May;137:9-17.
978. Moreau P, Kumar S, Boccia R, Iida S, Goldschmidt H, Cocks K, Trigg A, Zahlten-Kumeli A, Yucel E, Panjabi SS, **Dimopoulos M**. Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m² vs. twice-weekly 27 mg/m² carfilzomib (randomized A.R.R.O.W. study). [Leukemia](#). 2019 Dec;33(12):2934-2946.
979. Kastritis E, Morel P, Duhamel A, Gavriatopoulou M, Kyrtsolis MC, Durot E, Symeonidis A, Laribi K, Hatjiharissi E, Ysebaert L, Vassou A, Giannakoulas N, Merlini G, Repousis P, Varettoni M, Michalis E, Hivert B, Michail M, Katodritou E, Terpos E, Leblond V, **Dimopoulos MA**. A revised international prognostic score system for Waldenström's macroglobulinemia. *Leukemia*. 2019 Nov;33(11):2654-2661.
980. Kalapanida D, Zagouri F, Gazouli M, Tsiakou A, Zografos E, Dimitrakakis C, Marinopoulos S, Giannos A, Sergentanis TN, Kastritis E, Terpos E, **Dimopoulos MA**. Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case-control study. *Onco Targets Ther*. 2019 May 28;12:4195-4202.
981. Facon T, Lee JH, Moreau P, Niesvizky R, **Dimopoulos M**, Hajek R, Pour L, Jurczynszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. *Blood*. 2019 May 2;133(18):1953-1963.

982. Mateos MV, Spencer A, Nooka AK, Pour L, Weisel K, Cavo M, Laubach JP, Cook G, Iida S, Benboubker L, Usmani SZ, Yoon SS, Bahlis NJ, Chiu C, Ukropec J, Schechter JM, Qin X, O'Rourke L, **Dimopoulos MA**. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. [Haematologica](#). 2020 Jan 31;105(2):468-477
983. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, **Dimopoulos M**; OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019 Jun;20(6):781-794
984. Spicka I, Ocio EM, Oakervee HE, Greil R, Banh RH, Huang SY, D'Rozario JM, **Dimopoulos MA**, Martínez S, Extremera S, Kahatt C, Alfaro V, Carella AM, Meuleman N, Hájek R, Symeonidis A, Min CK, Cannell P, Ludwig H, Sonneveld P, Mateos MV. Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma. *Ann Hematol*. 2019 Sep;98(9):2139-2150.
985. Kleber M, Ntanasis-Stathopoulos I, **Dimopoulos MA**, Terpos E. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care? *Expert Rev Hematol*. 2019 Aug;12(8):651-663.
986. Beksac M, Cengiz Seval G, Kanellias N, Coriu D, Rosiñol L, Ozet G, Goranova-Marinova V, Unal A, Bila J, Ozsan H, Ivanaj A, Balić LI, Kastritis E, Bladé J, **Dimopoulos MA**. A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome. [Haematologica](#). 2020 Jan;105(1):201-208
987. Kyriazoglou A, Zagouri F, **Dimopoulos MA**. Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning? *ESMO Open*. 2019 Jun 25;4(3):e000479.
988. **Dimopoulos MA**, Moreau P, Iida S, Huang SY, Takezako N, Chng WJ, Zahlten-Kumeli A, Sersch MA, Li J, Huang M, Lee JH. Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. *Trials*. *Int J Hematol*. 2019 Oct;110(4):466-473.
989. Stamatelopoulos K, Georgiopoulos G, Athanasouli F, Nikolaou PE, Lykka M, Roussou M, Gavriatopoulou M, Laina A, Trakada G, Charakida M, Delialis D, Petropoulos I, Pamboukas C, Manios E, Karakitsou M, Papamichael C, Gatsiou A, Lambrinouadaki I, Terpos E, Stellos K, Andreadou I, **Dimopoulos MA**, Kastritis E. Reactive Vasodilation Predicts Mortality in Primary Systemic Light-Chain Amyloidosis. *Circ Res*. 2019 Sep 27;125(8):744-758.
990. Facon T, **Dimopoulos MA**, Meuleman N, Belch A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick W, Rose C, Tempescul A, Boyle E, Manier S, Attal M, Moreau P, Macro M, Leleu X, Lorraine Chretien M, Ludwig H, Guo S, Sturniolo M, Tinel A, Silvia Monzini M, Costa B, Houck V, Hulin C, Yves Mary J. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. [Leukemia](#). 2020 Jan;34(1):224-233

991. Moreau P, Sonneveld P, Boccadoro M, Cook G, Mateos MV, Nahi H, Goldschmidt H, **Dimopoulos MA**, Lucio P, Bladé J, Delforge M, Hajek R, Ludwig H, Facon T, San Miguel JF, Einsele H. CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. [Haematologica](#). 2019 Dec;104(12):2358-2360.
992. Zagouri F, Korakiti AM, Zakopoulou R, Kyriazoglou A, Zografos E, Haidopoulos D, Apostolidou K, Papatheodoridi MA, **Dimopoulos MA**. Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis. *Cancer Treat Rev*. 2019 Sep;79:101885.
993. **Dimopoulos MA**, Kastritis E. How I treat Waldenström's Macroglobulinemia. [Blood](#). 2019 Dec 5;134(23):2022-2035
994. Ntanasis-Stathopoulos I, Gavriatopoulou M, Fotiou D, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Kastritis E, **Dimopoulos MA**, Terpos E. Screening for Gaucher disease among patients with plasma cell dyscrasias. *Leuk Lymphoma*. 2019 Sep 30:1-3. doi: 10.1080/10428194.2019.1672059. [Epub ahead of print]
995. Skorda A, Sklirou AD, Sakellaropoulos T, Gianniu DD, Kastritis E, Terpos E, Tsitsilonis OE, Florea BI, Overkleeft HS, **Dimopoulos MA**, Alexopoulos LG, Trougakos IP. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells. [J Cell Mol Med](#). 2019 Dec;23(12):8010-8018.
996. Kastritis E, Dialoupi I, Gavriatopoulou M, Roussou M, Kanellias N, Fotiou D, Ntanasis-Stathopoulos I, Papadopoulou E, Ziogas DC, Stamatelopoulos K, Manios E, Ntalianis A, Eleutherakis-Papaiakovou E, Papanikolaou A, Migkou M, Papanota AM, Gakiopoulou H, Psimenou E, Tselegkidi MI, Tsitsilonis O, Kostopoulos I, Terpos E, **Dimopoulos MA**. Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. *Blood Adv*. 2019 Oct 22;3(20):3002-3009.
997. Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Kastritis E, Terpos E, **Dimopoulos MA**. Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma. [Expert Rev Anticancer Ther](#). 2019 Nov;19(11):921-928.
998. **Dimopoulos MA**, Cavo M, Mateos MV, Facon T, Heeg B, van Beekhuizen S, Gebregergish SB, Nair S, Pisini M, Lam A, Slavcev M. A matching-adjusted indirect treatment comparison (MAIC) of daratumumab-bortezomib-melphalan-prednisone (D-VMP) versus lenalidomide-dexamethasone continuous (Rd continuous), lenalidomide-dexamethasone 18 months (Rd 18), and melphalan-prednisone-thalidomide (MPT). *Leuk Lymphoma*. 2019 Nov 5:1-7. doi: 10.1080/10428194.2019.1682571. [Epub ahead of print]
999. Mateos MV, San-Miguel J, Goldschmidt H, Sonneveld P, **Dimopoulos MA**, Heeg B, Hashim M, Deraedt W, Hu P, Lam A, He J. The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison. *Leuk Lymphoma*. 2019 Nov 5:1-11. doi: 10.1080/10428194.2019.1675881. [Epub ahead of print]
1000. Gavriatopoulou M, Ntanasis-Stathopoulos I, Mouloupoulos LA, Manaios A, Fotiou D, Eleutherakis-Papaiakovou E, Migkou M, Bourgioti C, Terpos E, Kastritis E, **Dimopoulos MA**. Treatment of Bing-Neel syndrome with first line sequential chemoimmunotherapy: A case report. *Medicine (Baltimore)*. 2019 Nov;98(44):e17794.

1001. Papageorgiou L, Alhaj Hussien K, Thouroude S, Mbemba E, Cost H, Garderet L, Elalamy I, Larsen A, Van Dreden P, **Dimopoulos MA**, Mohty M, Gerotziapas GT. Modelization of Blood-Borne Hypercoagulability in Myeloma: A Tissue-Factor-Bearing Microparticle-Driven Process. *TH Open*. 2019 Nov 4;3(4):e340-e347.
1002. Papanota AM, Ntanasis-Stathopoulos I, Kastritis E, **Dimopoulos MA**, Gavriatopoulou M. Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia. *J Blood Med*. 2019 Aug 27;10:291-300.
1003. Weisel K, Majer I, DeCosta L, Oriol A, Goldschmidt H, Ludwig H, Campioni M, Szabo Z, **Dimopoulos M**. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. [Leuk Lymphoma](#). 2020 Jan;61(1):37-46.
1004. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, **Dimopoulos M**, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kamnietzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. *N Engl J Med*. 2019 Aug 22;381(8):727-738.
1005. Orlowski RZ, Moreau P, Niesvizky R, Ludwig H, Oriol A, Chng WJ, Goldschmidt H, Yang Z, Kimball AS, **Dimopoulos M**. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups. *Clin Lymphoma Myeloma Leuk*. 2019 Aug;19(8):522-530.e1.
1006. Birmpilis AI, Karachaliou CE, Samara P, Ioannou K, Selemenakis P, Kostopoulos IV, Kavrochorianou N, Kalbacher H, Livaniou E, Haralambous S, Kotsinas A, Farzaneh F, Trougakos IP, Voelter W, **Dimopoulos MA**, Bamias A, Tsitsilonis O. Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. *Cancers (Basel)*. 2019 Nov 9;11(11).
1007. Mateos MV, Ludwig H, Bazarbachi A, Beksac M, Bladé J, Boccadoro M, Cavo M, Delforge M, **Dimopoulos MA**, Facon T, Gheraldes C, Goldschmidt H, Hájek R, Hansson M, Jamroziak K, Leiba M, Masszi T, Mendeleeva L, O'Dwyer M, Plesner T, San-Miguel JF, Straka C, van de Donk NWCJ, Yong K, Zver S, Moreau P, Sonneveld P. Insights on Multiple Myeloma Treatment Strategies. *Hemasphere*. 2018 Dec 27;3(1):e163.
1008. Kyriazoglou A, Ntanasis-Stathopoulos I, Terpos E, Fotiou D, Kastritis E, **Dimopoulos MA**, Gavriatopoulou M. Emerging Insights Into the Role of the Hippo Pathway in Multiple Myeloma and Associated Bone Disease. *Clin Lymphoma Myeloma Leuk*. 2019 Oct 9. pii: S2152-2650(19)32007-5. doi: 10.1016/j.clml.2019.09.620. [Epub ahead of print]
1009. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, **Dimopoulos MA**, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guenec S, Dubin F, Anderson KC; ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-

- dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. *Lancet*. 2019 Dec 7;394(10214):2072.
1010. Ntanasis-Stathopoulos I, Gavriatopoulou M, Kastritis E, Terpos E, **Dimopoulos MA**. Multiple myeloma: Role of autologous transplantation. *Cancer Treat Rev*. 2020 Jan;82:101929.
1011. Kastritis E, Roussou M, Gavriatopoulou M, Kanellias N, Migkou M, Eleutherakis-Papaiakovou E, Ziogas DC, Fotiou D, Ntanasis-Stathopoulos I, Dialoupi I, Giannouli S, Tsigiotis P, Delimpasi S, Mparmparousi D, Spyropoulou-Vlachou M, Xirokosta A, Terpos E, **Dimopoulos MA**. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone. *Blood Adv*. 2019 Dec 10;3(23):4095-4103.
1012. Moreau P, **Dimopoulos MA**, Yong K, Mikhael J, Risse ML, Asset G, Martin T. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. *Future Oncol*. 2020 Jan;16(2):4347-4358.
1013. Mateos MV, Cavo M, Blade J, **Dimopoulos MA**, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. *Lancet*. 2020 Jan 11;395(10218):132-141.
1014. Zografos E, Zagouri F, Kalapanida D, Zakopoulou R, Kyriazoglou A, Apostolidou K, Gazouli M, **Dimopoulos MA**. Prognostic role of microRNAs in breast cancer: A systematic review. *Oncotarget*. 2019 Dec 24;10(67):7156-7178.
1015. Bagratuni T, Mavrianou N, Gavalas NG, Tzannis K, Arapinis C, Liontos M, Christodoulou MI, Thomakos N, Haidopoulos D, Rodolakis A, Kastritis E, Scorilas A, **Dimopoulos MA**, Bamias A. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. *Eur J Cancer*. 2020 Feb;126:125-135.
1016. Kokotis P, Manios E, Schmelz M, Fotiou D, Dialoupi I, Gavriatopoulou M, Roussou M, Lykka A, **Dimopoulos MA**, Kastritis E. Involvement of small nerve fibres and autonomic nervous system in AL amyloidosis: comprehensive characteristics and clinical implications. *Amyloid*. 2020 Jan 23:1-8. doi: 10.1080/13506129.2020.1713081. [Epub ahead of print]
1017. Terpos E, Kostopoulos IV, Kastritis E, Ntanasis-Stathopoulos I, Migkou M, Rousakis P, Argyriou AT, Kanellias N, Fotiou D, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Ziogas DC, Papanota AM, Spyropoulou-Vlachou M, Trougakos IP, Tsitsilonis OE, Paiva B, **Dimopoulos MA**. Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy. *Hemasphere*. 2019 Oct 1;3(6):e300.
1018. Anargyrou K, Fotiou D, Vassilakopoulos TP, Christoulas D, Makras P, Dimou M, Ntanasis-Stathopoulos I, Masouridou S, Angelopoulou MK, Papatheodorou A, Tsionos K, Panayiotidis P, **Dimopoulos MA**, Terpos E. Low Bone Mineral Density and High Bone Turnover in Patients With Non-Hodgkin's Lymphoma (NHL) Who Receive Frontline Therapy: Results of a Multicenter Prospective Study. *Hemasphere*. 2019 Sep 24;3(6):e303.

1019. Kastritis E, Leblond V, **Dimopoulos MA**, Kimby E, Staber P, Kersten MJ, Tedeschi A, Buske C. Correction to: "Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". *Ann Oncol*. 2019 May;30(5):860-862.
1020. Bahlis NJ, **Dimopoulos MA**, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. *Leukemia*. 2020 Jan 30. doi: 10.1038/s41375-020-0711-6. [Epub ahead of print]
1021. Bamias A, Tzannis K, Dimitriadis I, Tsironis G, Papatheorodidi AM, Tsiara A, Fragkoulis C, Xirokosta A, Barbarousi D, Papadopoulos G, Zakopoulou R, Varkarakis I, Mitsogiannis I, Adamakis I, Alamanis C, Stravodimos K, Papatsoris AG, Dellis AE, Drivalos A, Ntoumas K, Matsouka H, Halvatsiotis P, Raptis A, Gerotziafas GT, **Dimopoulos MA**. Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy. *Clin Genitourin Cancer*. 2020 Jan 8. pii: S1558-7673(19)30394-5. doi: 10.1016/j.clgc.2019.12.021. [Epub ahead of print]

